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ABSTRACT 
 
This project sets out to create a reference laboratory service capable of detecting platelet 
function disorders using the latest techniques and based on the most current research. 
Platelet function disorders are difficult to diagnose due to differing phenotypic 
presentation and multiple causative agents. Platelet research has moved rapidly over the 
past decade and has included new reagents, analysers and techniques in the way platelet 
function disorders are diagnosed. A forward-looking diagnostic laboratory needs 
translate this ongoing research into routine laboratory practice, whilst ensuring that 
techniques used in the laboratory comply with the current guidelines and performed in a 
standardised and scientifically rigorous way. 
 
Literature searches where used to develop a pre-analytical questionnaire and this has 
been adopted. It has proved to be an important tool for standardisation of the pre-
analytical procedure which is now in use at other diagnostic centres.  New light 
transmission aggregation equipment and agonists have been introduced, standardised 
and reference ranges generated, driven by evidence based practice. Reagent comparison 
studies have been undertaken to asses’ cost-effectiveness of the assays in the laboratory.  
Platelet nucleotide reference ranges have been generated and are in use. The flow 
cytometric analysis of glycoproteins has been brought ‘in-house’, has been 
standardised, and is now being offered as a routine assay to specialist haematology 
clinical staff, improving the service the laboratory offers.  
 
 This work has enabled an extended range of assays available to the laboratory and now 
has capacity for specialist testing of inherited platelet disorders. This together with 
expert clinical staff creates the scientific and technical environment required for the 
establishment of a specialist regional referral centre.  The reputation of the laboratory 
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has been additionally enhanced, through presentations and collaborations with 
manufacturers, other healthcare scientists and professional bodies. 
All these improvements based on strong scientific research and rigorous application 
have enabled the patient to undergo a thorough investigation with the minimum of 
inconvenience and enabled the health care provider to utilise resources more effectively.  
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Blood is a complex fluid composed of many constituent parts. The components of this 
system are leukocytes, erythrocytes, platelets and plasma. The areas on which this thesis 
will concentrate on are the platelets and plasma constituents (e.g. blood clotting 
proteins). Platelets have always played a crucial role in health and disease. Formed from 
the megakaryocyte in the bone marrow and circulating for ten days in the blood stream 
before removal by the spleen, they are sensitive to their local physical and chemical 
environment. 
Platelets are principally involved in physiological haemostatic interactions, including 
those taking place between platelets and the blood vessels. Critical to these processes 
(which include adhesion aggregation and content release) are the platelet membrane and 
various organelles, including alpha granules, delta granules and lysozymes. The 
platelets also play a role in the localisation and control of many biochemical processes, 
such as prostaglandin production and the coagulation cascade. The latter process is 
particularly important for haemostasis and involves zymogens (enzyme precursors) and 
co-factors from the plasma. Various products, such as Factor V (FV) and von 
Willebrand factor (VWF) are also delivered from within the platelet, to the outer 
membrane and on to the local plasma environment. This creates a micro-environment 
allowing optimal zymogen interaction, as well as a level of protection from inhibitory 
processes where further clotting factors are activated driving the cascade forward. 
These processes, as well as the dysfunction of platelets and laboratory investigation of 
platelet disorders will be the focus of this chapter. 
 
1.1 Normal platelet function 
1.1.1 Historical overview 
Investigations into thrombus formation began in the mid 19
th
 century (reviewed in 
(Gazzaniga & Ottini, 2001); (Mustard, J. F. Kinlough-Rathbone R.L., 2002) when both 
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Wharton-Jones (1852) and Zhan (1875) independently observed white thrombi in frogs. 
However as frog platelets have nuclei, they incorrectly stated that these were leukocyte 
fragments. Shultz (1865) observed platelets independently calling them 'clumps of 
irregular shape' and by 1873 Ranvier had described fibrin clots. In 1882, Hayem 
described the platelets ability to change shape and noted their 'spiney' nature. However 
it was the Italian Bizzozzero in 1882 who is credited with describing platelets as is 
understood today. In Bizzozzeros text he named them 'piasthne', which translated as 
'petite plaques' or 'plaquettes' when the text was translated to French. The anglicising of 
the word plaquettes gives us platelet. In 1885 Lubnitsky described these new blood 
components as being part of the haemostatic plug. Platelet research then lulled until the 
late 1950s when Bournameaux described platelets ability to adhere to vascular 
subendothelium. Hovig advanced this research in 1963 to describe platelets ability to 
interact with collagen. Hellem and Owen postulated that erythrocytes released a 
substance that was able to aggregate platelets and in 1961 Gaarder proved that this was 
adenine diphosphate (ADP). The big leap in platelet research was facilitated by Gustav 
Born in 1962 and his invention of the platelet aggregometer (considered in more detail 
in section 1.3.3) (Born et al., 1963; Born, 1962). 
This led to an acceleration in research in the mid 1960s; Born went on to show that 
platelet aggregation adopted Michelis-Menton like kinetics and second phase 
aggregation was described. Platelet ultra-structure was demonstrated by electron 
microscopy, Ardlie (1966) showed adrenaline to be a platelet aggregator and Kloeze 
(1966) described prostaglandin interaction. The prostaglandin interaction work led to 
aspirin being described as a potent cyclo-oxygenase inhibitor; work for which John 
Vane was awarded the Nobel Prize in 1970. 
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1.1.2 Platelets in primary haemostasis 
 The haemostatic process is nominally broken down into two distinct phases, primary 
haemostasis and secondary haemostasis. 
Primary haemostasis are the actions leading to the initial plugging of the breached 
vessel. This involves platelets, the vessel wall and von Willebrand factor (VWF). 
Normal flow (or shear rate) is maintained by the vessel releasing nitric oxide (NO) and 
prostaglandin I2
 
(PGI2). When there is a break in the vessel, sub-endothelial collagen is 
exposed and the concentration of PGI2
 
and NO decreases and the vessel constricts in 
response. This slows the blood flow which minimises blood loss and increases the time 
in which thrombotic components are in contact with the vessel wall.   
Blood vessels contain collagen types I – IV and VI however it is types I and III that are 
involved in adhesion. In vessels such as veins and the large arteries, with a low flow 
rate, and therefore a low shear stress, the exposed sub-endothelial collagen binds 
directly to the glycoprotein Ia/IIa (GPIa/IIa) located on the platelet membrane to tether 
it then Glycoprotein VI (GPVI) (Varga-Szabo, Pleines, & Nieswandt, 2008) activates 
receptors on the platelets membrane surface.  In vessels with a higher shear rate, such as 
the arterioles the von Willebrand factor (VWF) is needed to anchor the platelets. VWF 
interacts with the type I collagen, which causes a conformation change that causes 
adhesion to the platelet GPIa, then as in low shear environments GPVI activates the 
platelet.  
As the platelet activates and shape change is initiated glycoprotein Ib (GPIb) binds to 
VWF and anchors the platelets to the endothelial surface. When there is a break in the 
integrity of the endothelium, VWF is released from storage in the endothelial Weibel-
Palade bodies into the circulation. This activates the GPIb component of the GPIb-V-IX 
complex, and VWF is immobilised on exposed collagen fibrils,  facilitating the 
activation of receptors GPIa/IIa and GPVI on the platelet surface(Gardiner et al., 2010). 
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GPIb activates phospholipase C (PLC) which in turn catalyses phosphatidylinositol 
bisphosphate (PIP2). This produces diacylglycerol (DAG) and phospholipase A2 
(PLA2). DAG is the substrate for protein kinase C (PKC) and the product of this 
reaction interacts with the tail portion of GPIIbIIIa and the receptor change enhances the 
binding of fibrinogen to GPIIbIIIa. Cross linking of GPIIbIIIa on other platelets by 
fibrinogen causes irreversible aggregation to proceed. PLA2 catalyses membrane 
phospholipid to arachidonic acid, which itself is catalysed by cyclo-oxygenase to 
become prostaglandin G2 (PG2). PG2 is catalysed by thromboxane synthase to 
thromboxane A2
 
(TXA2). This is released and reacts with the thromboxane receptor 
amplifying the cascade mechanism.  
The collagen-activated GPVI catalyses a different isomer of PLC (PLCγ2) to achieve 
the amplification of the release cascade. As these reactions take place calcium ions are 
mobilised through the platelet via the dense tubular system. These calcium ions 
contribute to the release of thromboxane and to the fusion of granules with the external 
membrane. 
Alpha granules, following fusion with the main platelet membrane (Gurney, Lip, & 
Blann, 2002), expose P-selectin on the outer surface of the platelet. The P-selectin was 
previously contained in an inactive form on the internal surface of the granules. P-
selectin facilitates the adhesion of platelets to leukocytes and vessel surfaces. The 
granule contents are also released into the micro-environment. These contents include 
fibrinogen and GPIIbIIIa, (which enhances further GPIIbIIIa coverage and consequently 
additional binding) and VWF (which will amplify tethering and platelet/platelet 
binding) and a number of growth factors (platelet derived growth factor (PDGF), 
endothelium derived growth factor (EDGF), and vascular endothelial growth factor 
(VEGF) required for repair to the damaged vasculature.  During this period, dense 
granules are also released. These contain secondary amplification products such as 
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calcium ions, serotonin (5HT), ADP and adenosine triphosphate (ATP). Calcium ions 
increase the external concentration increase the flux across the platelet membrane to 
drive thromboxane generation. Serotonin constricts the vessel wall to decrease blood 
loss from the damaged vessel and ADP activates the P2Y1 and P2Y12 receptors on the 
platelet. These receptors are Gq- and Gi- coupled receptor respectively, which feed into 
the PKC pathway detailed above. They also release more P-selectin and GPIb onto the 
platelet membrane surface. 
Due to forward flow the platelet continues to roll along the surface causing more 
collagen adhesion and VWF binding. The platelet also changes shape, rearranging its 
actin-myosin skeleton from discoid to spherical and finally extending filopodia, to 
facilitate attachment to the damaged endothelium. Eventually the platelet is tightly 
bound to the surface of the break in the vessel. These events do not continue in 
isolation; the platelet has released molecules from cellular granules into the localised 
micro-environment.  
This serves to recruit additional platelets to plug the break in the vessel and stem the 
loss of further blood.  These additional platelets are bound to the original activating 
platelet, as activation of GPIa increases the affinity of glycoprotein IIb/IIIa (GPIIb/IIIa) 
for fibrinogen, allowing the rapid cross linking of platelets to form the characteristic 
fibrin mesh. This mesh eventually involves other blood cells captured within the fibrous 
structure to give the recognisable ‘blood clot’ (Figure 1.1). 
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1.1.3 Platelets and the coagulation cascade (Secondary haemostasis) 
Simultaneously to the platelets being activated, the clotting mechanism is initiated. This 
process of secondary haemostasis involves the action of a series of enzymes, aided by 
co-factors such as FVIII, in the fluid component of the blood - converting it from a 
liquid form into a solid localised clot.  This is partially achieved by the release of tissue 
factor (TF) from the platelet membrane and further tissue factor exposure from the 
adventitia (outer) layer of the blood vessel. The released tissue factor binds with Factor 
VII (FVII) and to its activated form FVIIa. The FVII remains inactive until activated by 
the FVIIa-TF complex. This complex can reside on the platelet surface, where it will 
bind Factor X (FX) to form the extrinsic tenase complex.  
Simultaneous to the extrinsic tenase complex formation, there is intrinsic tenase 
Figure 1.1 Overview of platelet biochemistry Used with permission.  See reference for 
legend (Broos et al., 2012) 
 (Broos et al., 2012) 
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complex production, it is comprised of activated Factor IX (FIXa), activated Factor VIII 
(FVIIIa), Factor X (FX) and calcium ion (Ca
2+
). The FVIII has been made available by 
the platelet alpha granules and plasma, and the Ca
2+
 provided by the delta (dense) 
storage granules.  However FX is activated, it - together with activated Factor V (FVa)  - 
complexes with Factor II (prothrombin) converting the inactive zymogen into the active 
enzyme thrombin (FIIa). This converts soluble fibrinogen to insoluble fibrin causing the 
haemostatic mesh to form. The thrombin also activates the protease activated receptors 
(PARs) on the platelet surface. This is the final stage in creating the ‘plug’. Both 
‘tenase’ and ‘prothrombinase’ complexes need a phospholipid surface and this is 
provided by the platelet membrane, facilitated by the exposure of phosphatidylserine 
within discrete vesicles (Lentz, 2003). The platelet provides the delivery system, the 
scaffold system and much of the bulk for the coagulation cascade.  
These processes have been studied in great detail, initially to understand the cause of 
bleeding disorders but also to seek methods for reducing the incidence of cardiovascular 
disease and prevent inappropriate thrombus formation. 
Vascular damage/disruption also initiates the process of contact activation. High 
molecular weight kininogen (HMWK) and pre-Kallikrein (PK) are present in plasma 
and activated by activated Factor XII (FXIIa).  This activation is in response to an 
external activator such as change in the vessel surface or change of pH. The activated 
HMWK and Kallikrein bind to platelets via the GPIb complex. Concurrently platelet 
dense granules release inorganic polyphosphate (Ruiz, Lea, Oldfield, & Docampo, 
2004) which has been shown to accelerate the activation of FXI by thrombin and FXIa 
(Choi, Smith, & Morrissey, 2011)   This shows that platelets are involved at the very 
fulcrum of the coagulation mechanism. Understanding the function of platelets can lead 
the understanding of other coagulation disorders further down the cascade. 
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1.1.4 Other roles for platelets 
By virtue of the platelets’ involvement with delivery of prostaglandins and interactions 
with the vasculature; researchers questioned whether the platelet was involved in other 
physiological processes. It has been found that platelets do play an integral role in the 
immune response, including interactions with leukocytes. It has been shown that the 
platelet contains over three hundred unique proteins (Coppinger et al., 2004), with most 
being contained within the alpha granules. 
When the platelet is activated and the alpha granules fuse with the platelet membrane 
and these bioactive molecules are released into the local microenvironment.  There are 
molecules involved in vascular remodelling, such as histidine rich glycoprotein and α-2-
antiplasmin. There are those that are involved in angiogenesis such as C1-inhibitor and 
α-1-antitrypsin. Vascular endothelial growth factor (VEGF) and Platelet derived growth 
factor (PDGF) are involved in cell proliferation.  
The platelet specific receptor P-selectin is exposed from the inner membrane of the 
alpha granule to the outer membrane of the platelet as the granule fuses with the outer 
envelope of the platelet. One of the many ligands for this is the P-selectin glycoprotein 
ligand 1 (PSGL1) which is expressed exclusively on leukocyte membranes. Once 
tethered to platelets, these neutrophils bind via tightly via GPIIIa, and cause production 
of thromboxane and prostaglandins (Weyrich, Lindemann, & Zimmerman, 2003). 
In addition, they are also involved in the initial mechanical phase when encountering 
foreign bacteria and viruses. They have been shown to engulf them, producing viricidal 
and fungicidal chemicals called platelet microbial proteins (PMPs) predominantly 
containing two groups of  thrombocidins (induced by thrombin)  and kinocindins (a dual 
chemokine and microbiological entity), and reactive oxygen species (Yeaman, 2010). 
The alpha granules also contain the serine protease plasmin and its zymogen precursor 
plasminogen, antithrombin and C1-inhibitor. Plasmin breaks down fibrin, antithrombin 
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binds to thrombin, and C1-inhibitor reduces the efficacy of the contact activation 
system. The platelet does not actively contribute to the fibrinolytic process;  however it 
does release products that arrest the procedure and keep balance (Blair & Flaumenhaft, 
2009).  
Dense granules contain calcium ions, which apart from being essential to the 
coagulation cascade are also required for would healing and fibrin formation and 
serotonin a potent vasoconstrictor which will modulate blood flow through the damaged 
vessel and increase capillary permeability. This increase in permeability allows cellular 
components to pass through to the lymph. Platelets also have receptors that induce B-
cells to produce antibodies and enhance T-cell responses (Elzey et al., 2003) 
 
 
1.2 Platelet dysfunction in bleeding disorders 
1.2.1 Platelet quantitative disorders 
Platelets contribute to a wide variety of processes as shown previously.  Therefore a 
reduction in platelets in diseases such as idiopathic thrombocytopaenic purpura (ITP) 
and thrombotic thrombocytopaenic purpura (TTP) gives bleeding symptoms as there are 
insufficient platelets to perform the functions required.  TTP can be genetic, where there 
is an absence of  a disintegrin and metalloproteinase with a thrombospondin type 1 
motif, member 13(ADAMTS13) and acquired, where an event has instigated a blocking 
of ADAMTS13 function.  These events can range from pregnancy, cancer, systemic 
lupus erythematosus and organ transplantation. 
There are a numbers of disorders that are functional defects, such as Bernard Soulier 
syndrome and Myosin Heavy chain gene 9 (MYH9) disorders, which presents with a 
low platelet count, but characteristically large platelets (macrothrombocytopaenia). As 
described above platelets use many receptors and release many bioactive components to 
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provide optimal function. Disorders can include reduction or absence in any of these. 
MYH9 disorders (Althaus & Greinacher, 2009), such as May-Hegglin, Fechtner and 
Sebastian syndromes are multi-factorial disorders including symptoms such as nephritis, 
cataracts, deafness, leukocyte inclusions and macrothrombocytopaenia. The defect is 
within the actin myosin skeleton of the platelets outer envelope. The platelets are 
released from the megakaryocyte prematurely and have poor structural integrity. 
1.2.2 Acquired platelet function disorders 
There are various disorders that influence function as well as the quantity of platelets. 
These include genetic and acquired causes.  
The largest acquired cause is drug-related, such as thrombocytopaenia caused by 
heparin. Heparin induced thrombocytopaenia (HIT) is an difficult disorder to diagnose 
and manage (Cuker et al., 2010; T. Warkentin, 2006).   Abciximab (Aster, 2005) also 
causes thrombocytopaenia, this is characterised (compared to HIT) by its rapid onset 
and markedly low platelet count. Some systemic disorders affect platelet function, such 
as renal failure (Remuzzi et al., 1978), liver disease (Witters et al., 2008) and sepsis 
(Yaguchi et al., 2004). 
Disseminated intravascular coagulopathy (DIC) -via fibrin/fibrinogen degradation 
products can down regulate platelet function (Yaguchi et al., 2004), this is due to both 
activation and consumption.  Abnormal platelet function, as well as thrombocytopaenia, 
is sometimes seen associated with the chronic myeloproliferative disorders, acute 
myeloid leukaemia and myelodysplastic syndromes. Significant numbers of patients 
with myeloma and Waldenströms macroglobulinaemia have impaired platelet function 
due to the interference of function by paraproteins (Zangari et al., 2007). This is thought 
to be mediated by interference with fibrinogen polymerisation (Cohen et al., 1970) 
Drugs are the most common cause of platelet dysfunction. Aspirin irreversibly 
inactivates the platelet cyclo-oxygenase pathway, thereby blocking aggregation and it 
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can therefore be used as an effective anticoagulant drug. Many other drugs are known to 
affect platelet function to varying degrees, as shown in Table 1.1: 
 
Drug Type Example Action Reference 
NSAID Aspirin, Ibuprofen Inhibition of COX (Gurbel et al., 
2007) 
Beta Lactam 
Antibiotics 
Penicillin Irreversible binding to the 
membrane, disruption of 
calcium flux. 
(Cazenave, et al., 
1973) 
Cardiovascular 
drugs 
Thienopyridines e.g. 
clopidogrel and prasgrul, 
RheoPro and 
Competitive binding to 
membrane receptors 
(Ben-Dor, Kleiman, 
& Lev, 2009) 
Psychotropics SSRIs, Competitive binding to 
adreno-receptors and 
reduction in serotonin 
pool 
(Dietrich-
Muszalska et al., 
2010) 
Anaesthetics Halothane Reduction in Ca
2+
 flux (Kohro & 
Yamakage, 1996) 
Chemotherapeutic 
agents 
Thalidomide for myeloma Thrombotoxicity (Kwaan & Vicuna, 
2007) 
Anticoagulants Heparin Binding to FC-receptor 
via PF4, leading to 
sequestration and 
thrombocytopaenia. (HIT) 
(T. E. Warkentin & 
Greinacher, 2004) 
Table 1.1: Drugs that interfere with platelet aggregation studies 
 
Not every drug within each category will affect platelet function and their effects tend to 
be concentration-dependent. 
Some foods and food additives can also affect platelet function if ingested in sufficient 
amounts. Examples include fish oils (Din et al., 2008), green tea (Son et al., 2004), 
garlic (Iciek, Kwiecień, & Włodek, 2009), cumin (Srivastava, 1989), turmeric (Cordier 
& Steenkamp, 2012), chocolate (Khawaja, Gaziano, & Djoussé, 2011), excessive use of 
vitamin supplements (Kobzar et al., 2009; Violi, Pignatelli, & Basili, 2010), and the 
black tree fungus (Kim et al., 2011) used in Chinese cuisine. In sufficient amounts, 
these foodstuffs can generate abnormal results in platelet function testing that can 
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complicate diagnostic interpretation. However, abnormal results due to foodstuffs alone 
are unlikely to translate into a genuine acquired bleeding disorder. 
1.2.3 Genetic Platelet disorders 
As presented above there are a number of ways the haemostatic mechanism involving 
platelets can break down. Genetic disorders of platelet function are characterized by the 
area of function affected, as follows. 
1.2.3.1  Major deficiencies of surface adhesion receptors 
The two most common receptor disorders are Glanzmann’s thrombasthenia and 
Bernard–Soulier syndrome, which are amongst the most clinically severe of the 
hereditary platelet function defects. 
First described by Swiss paediatrician Eduard Glanzmann (Glanzmann, 1918) 
 Glanzmann’s thrombasthenia is characterized by a deficiency or functional defect of the 
GPIIb/IIIa complex first elucidated independently by Nurden and Phillips (Nurden & 
Caen, 1974; Phillips et al., 1975).  This complex is the product of proteins from two 
genes ITGA2B (GPIIb) and ITGB3 (GPIIIa), these genes are located on chromosome 
17. There have been 82 mutations characterised in ITGA2B and 51 in ITGB3 
(Franchini, Favaloro, & Lippi, 2010), the discrepancy due to the ITGA2B gene being 
larger (65kbp compared to 17kbp). These are registered on the Glanzmanns 
Thrombasthenia database 
(http://sinaicentral.mssm.edu/intranet/research/glanzmann/menu).  
 Flow cytometric analysis of the glycoproteins was first described almost 30 years ago 
(Jennings et al, 1986) 
It is classified into three subtypes (George, Caen, & Nurden, 1990): 
• Type I has 0–5% of normal levels of GPIIb/IIIa receptor numbers on the platelet 
surface 
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• Type II has 6–20% GPIIb/IIIa of normal levels of GPIIb/IIIa receptor numbers on the 
platelet surface 
• ‘Variant’ has 50–100% GPIIb/IIIa receptor numbers on the platelet surface but with 
reduced fibrinogen binding. 
The most common clinical features are typical of a primary haemostatic disorder, such 
as epistaxis, purpura, petechiae, excessive bruising, gum bleeding and menorrhagia. 
Platelet counts are normal. Bleeding after trauma/surgery can be severe and 
pregnancy/delivery markedly increase the risk of bleeding (Siddiq, Clark, & Mumford, 
2011). 
Two French haematologists Jean Bernard and Jean-Pierre Soulier described this disease 
in 1948 (Bernard & Soulier, 1948) Bernard–Soulier syndrome results from the absence 
or decreased expression of the GPIb–V–IX complex on the platelet surface. Patients 
present with mild to moderate thrombocytopaenia and enlarged or giant platelets. 
Bleeding symptoms are also typical of a primary haemostatic disorder, but are more 
severe than expected for the degree of thrombocytopaenia due to the concomitant 
functional defect. Bernard-Soulier syndrome is a result of a mutation in one of three 
genes. Gene GP1BA encodes the proteins for the alpha sub-unit of GPIb, GP1BB 
encodes for the beta sub-unit and GP9 for the GPIX. 
1.2.3.2 Other receptor defects 
 Defects in the coupled ADP receptor P2Y12 is an autosomal recessive disorder first 
described by Cattaneo in 1992 (Cattaneo et al., 1992). These patients have defective 
ADP binding to the receptor due to defective receptor synthesis(Marco Cattaneo, 2005) 
Laboratory presentation includes reduced aggregation responses to ADP even at high 
doses such as 100µM, reversible aggregation to weak agonists and failure of nucleotide 
secretion (Podda, Femia, Pugliano, & Cattaneo, 2012)  
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There are two thromboxane receptors in human tissue, differing only in carboxy-
terminus.  This is caused by a differential splicing of the TxA2R products and these are 
called TxA2Rα and TxA2Rβ respectively. Only TxA2Rα appears on platelet surfaces. 
These receptors play a critical role in up-regulation of the platelet aggregation cascade, 
responding to the liberation of arachidonate from the platelet membrane and its 
subsequent conversion to thromboxane A2. Defects have been demonstrated in this 
receptor (Mumford et al., 2010) giving a reduced response to both arachidonate and 
U46619. 
Of the collagen receptor defects only GPVI has been described. This is  normally 
caused by either  autoimmune antibodies causing internalisation or shedding of the 
receptor (Bender et al., 2010), or mutations in the GP6 gene (Dumont et al., 2009) of 
unknown inheritance. Distinguishing GPVI defects in the laboratory is relatively easy 
using the agonist selective for the GPVI receptor, Convulxin. This is derived from the 
venom of the tropical rattlesnake crotalus durissus terrificus (Polgár et al., 1997).  An 
Arg60 to Leu substitution has been found in the thromboxane A2 receptor (Hirata et al., 
1994). With new agonists such as the thromboxane mimetic U46619 this is a relatively 
easy laboratory phenotypic diagnosis. Defects in the epinephrine receptor have been 
described (Kambayashi et al., 1996; Rao et al., 1988). 
 1.2.3.3 Platelet granule disorders 
Platelet granule disorders are defined as a group of disorders where by platelet function 
is defective if granule numbers are reduced, granule contents are deficient, or if release 
mechanisms fail (Nurden, Freson, & Seligsohn, 2012). Most of these disorders affect 
dense (or δ)  granules or α-granules, but rarely affect both. Since the dense and α-
granules are storage sites, their defects are also referred to as storage pool disease. 
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Dense body disorders 
Disorders of dense bodies are often part of a more complex congenital disorder, 
although isolated dense body defects are known. The bleeding phenotype associated 
with dense body disorders is usually of mild–moderate severity, with significant 
bleeding associated with trauma/surgery. Platelet counts and size are normal. There are 
three main disorders: 
Hermansky–Pudlak (Walker et al., 2007) syndrome is a diverse autosomal-recessive 
disorder affecting a number of organelles, in particular, melanosomes and platelet dense 
bodies. There are nine identified variations of HPS, mutations in the genes coding for 
Hermansky Pudlak protein 1 and 4 being the most common and most severe (Masliah-
Planchon et al., 2012). Hermansky Pudlak proteins cluster to form ‘biogenesis of 
lysosome related organelle complex’ (BLOC). These complexes HPS proteins 7, 8 and 9 
cluster to form BLOC1. Proteins 3, 5 and 6 form BLOC2 and 1 and 4 for BLOC3. HPS 
protein 2 is part of the adapter protein 3 (AP3) complex, this complex is responsible for 
mediating recognition and protein sorting. The defect has been shown to cause 
lysosomal membrane proteins such as LAMP3 to be routed to the platelet outer 
envelope rather than into the dense body. A mutation in HPS2 gene leads to 
immunodeficiency along with the other associated pathologies such as albinism and 
dense body deficiency. These proteins are ubiquitous amongst cells but seem only to 
cause a defective phenotype in melanocytes (melanosomes) and platelets (dense 
bodies).  
Chediak–Higashi (Buchanan & Handin, 1976) syndrome is an autosomal-recessive 
disorder also associated with albinism and dense body deficiency. It is caused by a 
mutation in LYST (CHS1) gene. This gene codes for a cytosolic protein thought to be 
involved in granule size and movement (Kaplan, De Domenico, & Ward, 2008). 
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Phenotypically the immune system is affected and large inclusion bodies are seen in 
white cell precursors in the bone marrow. 
Primary dense body deficiency is a clinically heterogeneous disorder with an uncertain 
genetic basis that is not associated with other abnormalities. Within this group are the 
rare Rab27 disorders such as Griscelli syndrome. The Rab27a gene encodes for a 
protein involved in melanocyte and cytotoxic T-cell production. The mouse model has 
been found to have a reduced number of granules per platelet and an increased bleeding 
time, but no symptomatic bleeding diathesis. In human cases the T-cell mutation 
engenders a life threatening immunodeficiency. Recently a further subset has been 
described (Jedlitschky et al., 2010) with a mutation in the ABCC4 genes, the 
corresponding protein thought to mediate nucleotide trafficking into the granules. 
Alpha-granule disorders 
Defects of α-granules (Harrison & Martin Cramer, 1993) are extremely rare and so it is 
difficult to generalize about clinical features. 
There are three main disorders: 
Grey platelet syndrome is an autosomal recessive disorder linked with a complete 
absence of α-granules and thus the levels of their contents are reduced or absent. There 
are a number of genetic causes such as a mutation in the x-linked GATA1 gene (Paola, 
Johnson et al 2011; Tubman et al., 2007) and NBEAL2 (Albers et al., 2011). The 
resulting defective protein is unable to import proteins into the granule. This results in 
the characteristic appearance of platelets on Romanowksy stained blood films as 
agranular, misshapen grey ‘ghost’ platelets. The platelet count is often reduced and 
platelets can be slightly larger than normal (Bain & Bhavnani, 2011). Mass 
spectrometric analysis has shown that grey platelet syndrome platelets contain almost 
no PF4, βTG, Multimerin and fibronectin, but only a reduced amount of albumin and 
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fibrinogen. Some proteins that should be in the α-granule appear on the granule surface 
giving the possibility of mis-targeted  protein production (Maynard et al., 2010). 
Paris-Trousseau syndrome (Favier et al., 2003) is characterized by thrombocytopaenia 
together with other congenital abnormalities, such as immune deficiency, neurological 
dysfunction and variable albinism. There are giant α-granules in a percentage of the 
circulating platelet population that cannot release their contents, and a sub-population of 
abnormally matured micro-megakaryocytes that lyse upon maturation. It is caused by a 
11q chromosome deletion. Chromosome 11q contains the genes for ETS1 and FLI1, 
both of which have been demonstrated in megakaryocyte maturation. FLI1 especially 
activates genes encoding for GPIb, and this has been shown to relate to the pathology of 
the disease. 
Quebec platelet disorder (Hayward & Rivard, 2011) previously known as Quebec factor 
V is characterized by increased levels of platelet urinary plasminogen activator (u-PA). 
This can be up to a one hundred fold increase. This increase in uPA, which activates 
platelet plasminogen, proteolysis platelet factor V along with other α-granule proteins 
and subsequently degrades α-granules content. It is an autosomal dominant disorder 
caused by the tandem deletion of PLAU on chromosome 10 (Blavignac et al., 2011). 
PLAU encodes for uPA and its regulatory proteins. Its laboratory profile is difficult to 
elucidate as plasma uPA is normal compared to platelet uPA, patients have a reduction 
in platelet count, compared to their unaffected kindred of about 50%. The platelet 
aggregation can show first phase only with epinephrine. The phenotypic bleeding can be 
attributed to reduced platelet proteins coupled with a reduced platelet count, but 
consensus is that it is due to increased fibrinolysis. 
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1.2.3.4 Disorders of platelet biochemistry 
Abnormalities in platelet biochemistry inevitably impair platelet function. Wiskott–
Aldrich syndrome (WAS) (Notarangelo, Miao, & Ochs, 2008) is a rare X-linked 
disorder resulting from defects in the WAS gene that encodes for the WAS protein 
(WASp). WASp is a regulator of actin polymerisation that has five defined domains. It 
has been shown to take part in biochemical signalling, synapse formation, cell 
locomotion and cytoskeleton maintenance. Children born with WAS present with 
bruising, small platelets and purpura resulting from thrombocytopaenia and abnormal 
platelet function. WAS is a complex disorder with features including eczema and 
immune deficiencies, which can be severe (Ochs & Thrasher, 2006). 
Deficiencies of platelet enzymes such as cyclo-oxygenase have also been described (A. 
Nurden, Fiore, Pillois, & Nurden, 2009). 
1.2.3.5 Disorders of phospholipid exposure 
Scott syndrome is an extremely rare bleeding disorder characterized by the reduced 
exposure of negatively charged phospholipids to facilitate tenase and prothrombinase 
formation. Consequently the coagulation cascade cannot proceed to completion (Satta et 
al., 1997). Stormorken syndrome is also rare and is almost the reverse of Scott 
syndrome in that non-activated platelets express full procoagulant activity but a reduced 
response to collagen. Paradoxically this does not lead to a prothrombotic stage, but a 
mild bleeding disorder. This appears to stem from the inability to bind to collagen upon 
activation. Also there is increased clearance of the affected platelets, leading to mild 
thrombocytopaenia (Solum, 1999). 
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1.3 Overview of laboratory tests for platelet function disorders 
1.3.1 Pre analytical factors 
Before proceeding to laboratory investigation it is essential that the physician should 
examine the patient and take a detailed bleeding history (including type, location and 
frequency) and family history.  As with any test, pre-analytical variables need 
consideration, such as the quality of the venepuncture. Ultimately such variables can 
distort the results and hinder interpretation. A clean draw using a wide bore needle 
(minimum 21G), giving minimal stasis and therefore minimal activation, is optimum.  
The blood should be collected into plastic or siliconised glass containers to minimise the 
activation by the charged surfaces (Vasin et al., 2003), a discard tube used to minimise 
inclusion of cellular activators such as tissue factor (Harrison et al., 2011),and 
consideration should be given to the anticoagulant. Sodium citrate has been 
demonstrated to enhance the effects of ADP and reduce the efficacy of GPIIb/IIIa 
(Kaiser et al., 2011)Other alternatives such as heparin, hirudin (Wallen et al., 1997) and 
D-Phenylalanyl-L-Prolyl-L-Arginine Chloromethyl Ketone (PPACK) are available. 
Steps must therefore be taken to minimise the effects of confounding factors, including 
those indicated above (see Table 1.1). This extends to other lifestyle factors such as: 
exercise before analysis (Vucinic et al., 2010), smoking (Pamukcu et al., 2011) and 
family history (Borhany et al., 2010). Medical procedures performed in the recent past 
also need careful consideration, as products such as X-Ray contrast media (Heptinstall 
et al., 1998) will affect platelet function. 
1.3.2 Point of care devices 
The physiology of the blood and the vessel wall and the relationship between them was 
studied by Virchow in 1845 (Dickson, 2009). He proposed the association between the 
blood, the vessel wall, and the flow of the blood over the endothelium.  
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An overall measure of the mechanisms of the triad of in vivo vascular integrity is the 
bleeding time. This previously popular screening test for primary haemostatic disorders 
entails - when using the Ivy Method - the applying of a standardised pressure with a 
sphygmomanometer to the patient’s upper arm and making a standardised cut in the 
inside of the forearm. Blood is removed from the wound site with a filter paper, so that a 
clot does not form, and the time for the bleeding to stop is measured.  However the 
method has disadvantages, such as operator variability, dependence on fibrinogen 
levels, incision size, skin quality and skin temperature giving the assay poor 
reproducibility (Lehman et al., 2001; Rodgers & Levin, 1990). In diseases such as 
hereditary telangiectasia, the bleeding time is of diagnostic significance as the disease 
involves the breakdown in vascular integrity.  
In relation to its haemostasis role, some centres have proposed the discontinuation of 
the bleeding time completely, in favour of a more reproducible mechanical method 
using whole blood. The Platelet Function Analyser (PFA-100, Dade Behring, Illinois, 
USA) (Kundu et al., 1995) analyses the platelets under stress of movement, passing a 
whole blood sample under negative pressure up a tube to an aperture, which is coated 
with either collagen and epinephrine, or collagen and ADP.  The time taken for the 
platelets to plug this aperture is the ‘closure time’ and is measured in seconds. This 
assay cannot function with low platelet or packed cell volume (PCV) values.  The assay, 
performed by using cartridges that are impregnated with either collagen and epinephrine 
or collagen and ADP, puts the blood under a pneumatic pressure. However, although 
this method satisfies two of Virchows’ criteria, it provides no indication of vascular 
integrity (Li et al, 1998). 
The VerifyNow (Accumetrics, California, USA) (Smith et al., 1999) is a system based 
on polymeric beads that are coated with either fibrinogen for testing  GPIIb/IIIa 
inhibitors or arachidonate for the aspirin responder assay. It was designed to function as 
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a point-of-care (POCT) analyser and therefore requires minimal training. The analyser 
provides very specific information and is only approved for aspirin resistance screening 
and anti-glycoprotein therapy monitoring.  
Cone and plate(let) analysis (Varon et al., 1997) also involves the use of applied 
pressure. The blood sample is placed in the analyser in which it is subjected to the 
equivalent of arterial sheer flow. Under the pressure applied, the blood sample passes 
across a plastic matrix, and after two minutes the matrix is stained and analysed by an 
image scanner. The size distribution, surface coverage, and average size is calculated 
and represented in numerical form. This has been commercialised and is the basis of the 
Diamed Impact analyser (Diamed, Cressier sur Morat, Switzerland). 
At the 2004 International Society of Thrombosis and Haemostasis Scientific 
Standardisation Committee meeting, Diamed (Diamed, Cressier sur Morat, Switzerland) 
released the Impact R analyser (Shenkman et al, 2008) which gives researchers the 
ability to change the pressure characteristics, so that the effect of different shear rates 
are investigated. 
Both the VerifyNow and the Impact analysers are reliant upon the respective agonists 
and the quality of the samples. Both the analysers suffer from the inherent limitation of 
other stand-alone platelet function analysers, such as the PFA-100, in that they are not 
able to measure vascular involvement. The clot signature analyser (Xylum, USA) (Li et 
al., 1998) based on work by Gőrőg (Görög & Ahmed, 1984) attempts to overcome this 
by using a method whereby the whole blood sample is passed through a vessel in the 
analyser that is subsequently punctured. The flow of the blood through the vessel and 
out of the puncture site is measured together with the thrombi build-up. This produces a 
characteristic plot or ‘signature’. This has the advantage that the measurement is taken 
over a period of time, not just a ‘snapshot’, as in the tests mentioned earlier  
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1.3.3 Light Transmission Aggregometry (LTA) 
Based on the method developed by Born in 1962 (Born, 1962), platelet aggregation 
employs a light path through platelet rich plasma (PRP) and records the increase in 
transmission as the platelets are removed from suspension, as agglutination and 
aggregation take place. Agonists such as ADP, epinephrine and collagen are added to the 
PRP, and then the response of the platelets is monitored graphically. 
This technique has its advantages and limitations. Although this process includes no 
vascular or other cellular involvement, it has value in demonstrating platelet disorders 
and diagnosing von Willebrand disease (VWD).  Limitations include a lack of 
sensitivity to platelet aggregates, and the process is affected by stir speed, temperature, 
plasma lipids, pH changes, and processing time. Whole blood aggregation (Matsuno, 
Furukawa, & Terada, 1984) tests the platelet in a more physiological cellular 
environment, so that leukocyte and erythrocyte interactions are monitored; however it 
still does not show the effect of endothelial dysfunction or micro-aggregate formation 
and few centres use this method.  Laser aggregometry (Toshima et al., 2008) was 
developed (PA-200, Kowa, Japan; 230ELA-2, Biola, Russia) that can detect aggregates 
much smaller than those detected by conventional light transmission aggregometers; 
however only one specialist research centre in the UK (Queens Medical Centre, 
Nottingham) has access to this equipment. 
Routine agonists used are ADP, collagen, arachidonate, epinephrine and ristocetin, two 
further agonists TRAP and U46619  have recently been advocated for inclusion in the 
testing repertoire (Harrison et al., 2011). A standard trace detailing the phases seen in 
LTA is shown in figure 1.2 
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Fig 1.2: Stages of platelet agglutination and aggregation.  
Aggregation trace showing the distinct phases of platelet aggregation and how these 
phases relate to platelet physiology 
Used with permission from (Moore & Gurney, 2010) 
 
1.3.3.1 Current agonists 
Adenosine diphosphate: 
ADP is a weak agonist at low concentrations. It therefore stimulates platelets to release 
other substances to continue to full aggregation. At higher concentrations these 
secondary releases are not required and aggregation proceeds fully. Using ADP as an 
agonist evaluates the platelets P2Y1 and P2Y12 receptors. These receptors induce the 
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release of further ADP from dense granules in the platelet and the formation of 
thromboxane A2. 
Arachidonate: 
Arachidonate is released from the platelet membrane by phospholipase A2.  It is then 
converted to ProstaglandinG2 and ProstaglandinH2 by COX.  It is central to 
prostaglandin synthesis and is dependent as an agonist on its conversion, via 
thromboxane synthase to thromboxane A2. Thromboxane receptors on the platelet are 
activated; shape change occurs and release granular products. The COX reaction is the 
target for aspirin and therefore arachidonate as an agonist is susceptible to analgesic 
ingestion by the patient. 
Epinephrine: 
Epinephrine interacts with 2- adrenergic receptors on the platelet, and only reacts in 
citrated PRP or in the presence of other agonists. Again, it is inhibited by the ingestion 
of COX inhibitors.  
Collagen: 
Collagen is a strong agonist. Fibrils of collagen in suspension adhering to the platelet 
via glycoprotein (GP) Ia and GPVI cause immediate activation, which initiates release 
of granule contents and causes a subsequent single-phase pattern. GPIa receptor signals 
via the phospholipase A2 pathway, which is inhibited by aspirin, where as GPVI signals 
via phospholipase C and is not affected. Stimulation of GPIa will also initiate the 
release of arachidonate with the activation of the phospholipase A2 
Ristocetin: 
Ristocetin (Coller & Gralnick, 1977) is product of antibiotic research that was 
discontinued after thrombocytopaenia was observed in recipients. Ristocetin 
agglutinates platelets by inducing the binding of von Willebrand Factor (VWF) rather 
than activating them. This is achieved by phenolic groups on the ristocetin having a 
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positive charge, causing both a reduction in the overall charge between VWF and GPIb 
which are both negatively charged. It also causes a structural change in the GPIb to 
facilitate binding. 
1.3.3.2 New Agonists 
9, 11 dideoxy-9-methanoepoxyprostaglandin F2U46619): 
This stable Thromboxane Mimetic (U46619) (Paul, Jin, & Kunapuli, 1999)  9, 11 
dideoxy-9-methanoepoxyprostaglandin F2 is a thromboxane receptor agonist. It is an 
analogue of prostaglandin H2, a prostaglandin that shares a platelet receptor with 
thromboxane A2. As has been previously stated, prostaglandins are produced in 
conjunction with the ADP release from the delta granules. This agonist is useful in 
determining where a breakdown has occurred. If arachidonate and U46619 fail to 
aggregate platelets then it is possible that the thromboxane receptor is at fault. If the 
arachidonate fails, but U46619 activates the PRP then the COX1 conversion of 
arachidonate to thromboxane mechanism should be under investigation. If the patient 
has taken COX1 inhibitors then the arachidonate, collagen and epinephrine will be poor 
agonists, but the mimetic will work.  
Calcimycin (A23187): 
The calcium ionophore Calcimycin (A23187) or Ionomycin is used in calcium 
membrane interaction studies. The agonist increases the internal calcium concentration 
and so activates the platelet. As a large number of the platelet processes are dependent 
on calcium flux, this is a good method for determining this process rather than detecting 
it as a secondary affect. 
Thrombin Receptor Agonist Peptide (TRAP): 
TRAP is used as an alternative to thrombin. A peptide sequence is exposed when 
thrombin is activated, and this sequence has been synthesised. This compound is used to 
activate the platelet via the protease-activated receptor 1(PAR-1) without the 
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interference of other coagulation processes such as the conversion of fibrinogen to fibrin 
– thus preventing thrombus formation. As it is an artificial specific peptide it gives no 
information on the interaction of thrombin with the PAR-4 or GPIb receptor. 
 
1.3.4 Secretion assays 
Platelet nucleotides, consisting of the adenosine diphosphate and adenosine triphosphate 
stored in the dense granules, are a useful marker for differentiating and diagnosing 
dense storage pool disorders. 
Initial investigation by platelet aggregation may indicate a storage pool disorder, but is 
not specific enough to indicate whether alpha granules or dense granules are reduced or 
absent. Quantification of the contents of the granules, such as ADP and ATP, provides a 
more diagnostic approach and a relatively simple way of distinguishing the disorders. 
Those storage pool disorders that involve the dense granules, such as Hermansky-
Pudlak and Chediak-Higashi syndromes, have a reduction, or even absence, of their ATP 
and ADP stores. 
Platelet nucleotides were first measured using firefly (Photinus pyralis) preparations, 
which produce luminescence in proportion to the ATP concentration. More recently the 
active ingredient, luciferase, has been produced artificially and therefore is readily 
available in kit form.  
The luminescence is measured in a luminometer and related to that produced by a 
standard ATP solution. Phosphoenol pyruvate is added to the reaction to convert the ATP 
into a measurable stable form in the ATP tube. To measure ADP, pyruvate kinase is 
added in excess to the reaction causing all of the ADP to be converted into ATP. This 
reaction is shown in Figure 1.3. This ATP tube is then measured and referred to as ‘total’ 
and subtracted from the ATP only. 
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Figure 1.3: Processes used in platelet nucleotide assay 
 
ATP Luciferin-luciferase reagent is a stable light emission (decay rate of ATP and light 
emission around 0.5%/min). This stability of emission makes it possible to use simple 
tube luminometers. It is also suitable for ATP measurements down to 10-15mol. 
There are alternative analysers using similar methodology to that described above. The 
Chronolog 700 series whole blood analysers (LabMedics, Stockport, Cheshire) are able 
to measure platelet aggregation and luminescence on a combined platform. However the 
Chronolog system only confirms the lack of release. If the Chronolog system and the 
analysis technique described above are combined then enzymatic disturbances within 
the platelet can be diagnosed. An example would be a protein kinase defect in which the 
patients’ platelets have normal nucleotide levels however internal enzymatic signalling 
is defective. The granules are present; they are not being activated and moving to the 
surface to release their contents. 
 
1.3.5 Flow cytometric assays 
Flow cytometers were developed from the automated cell counter which was patented in 
1953 by Wallace Coulter. These cell counters used a stream of fluid passing through a 
charged gate. Each time a cell passed within the gate an electrical impulse would be 
Phosphoenol-pyruvate Pyruvate 
ADP + Mg
2+ 
Pyruvate Kinase 
Adenyl Luciferin + Light 
Luciferase 
ATP + Luciferin 
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created. The size of the impulse denoted the size of the cell. Using size-based guidance, 
leukocytes being the largest, then erythrocytes, and finally platelets, the smallest these 
cells could be classed into groups and automated blood cell count could be performed. 
Using this fine control of particles through a fluid (hydrodynamic focusing) and instead 
of using charged gates as the detection system, lasers are used. As technology 
developed the fluid dynamics of the system became more controlled and the underlying 
electronics improved with micro-circuitry, and this allowed for advanced analysers to be 
built. A further development was the use of lasers to interrogate cells passing through 
the gate. The laser was used to evaluate the transparency and shape of the cell, but 
became further involved after the development of cheaper monoclonal antibodies. These 
antibodies would attach to receptors of interest and be conjugated with fluorescent dye 
markers. Depending on the return fluorescence the presence of these specific cell 
receptors could be evaluated. This has lead to advances in determining different types of 
leukaemia and increased disease monitoring capability.  
This gave rise to the flow cytometer, a phrase that was ratified at 5th American 
Engineering Foundation Conference on Automated Cytology in Pensacola (Florida) in 
1976, just eight years after its invention. 
As some platelet disorders are caused by the reduction or mutation in receptors on the 
platelet surface, these assays methodologies can be used in the diagnosis of these 
disorders (Michelson, 1996). Receptors such as the GPIIb/IIIa and GPIb on the platelet 
surface can have monoclonal antibodies raised against them. When these antibodies are 
conjugated with a fluorescent molecule, it allows rapid diagnosis of Glanzmanns 
thrombasthenia and Bernard Soulier respectively. Further targets have been sought for 
platelet analysis (van Velzen et al, 2012) P-selectin (CD62P) and the commercial 
antibody PAC-1 are only expressed on activated platelets and are used  markers for this. 
Thienopyridine activity can measured using the vasodilator-stimulated phosphoprotein 
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(VASP) assay (Jakubowski et al., 2008). VASP is an intracellular platelet protein that is 
non-phosphorylated at rest. Its phosphorylation state is regulated by the cAMP pathway, 
activated by PGE1 and deactivated by ADP. The ADP inhibition is mediated by the 
P2Y12 receptor. The assay involves adding platelets, PGE1 and ADP and using an 
antibody against the phosphorylation site of VASP. When the ADP binding to P2Y12 is 
inhibited by prasgrul or clopidogrel, VASP phosphorylation decreases. Therefore VASP 
phosphorylation is proportional to P2Y12 inhibition. Expression of Annexin V on the 
platelet surface is being developed as a diagnostic parameter for Scott syndrome 
(Flores-Nascimento et al., 2012) and flow methods are also being developed for 
microparticle analysis (Orozco & Lewis, 2010) and Heparin induced thrombocytopaenia 
(www.iqproducts.nl/products/specialties/hitalert-kit). 
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 Table 1.2:   Describing major platelet function disorders and their manifestation in aggregation 
studies with additional laboratory follow up. Modified from Moore & Gurney, 2010 
Key: N=normal, 0=absent, 1=primary wave only, R=reduced, Coll=collagen, Ri=ristocetin, AA=arachidonic acid, Epi=epinephrine, 
COX=cyclo-oxygenase, TRAP=thrombin receptor agonist peptide 
 
Condition Platelets Agonist Further 
investigation 
 Count Size ADP Coll Ri AA Epi TRAP U46619  
Glanzmanns 
thrombasthenia 
N N 0 0 1 0 0 R/0 R/0 Flow cytometry 
for GPIIb/IIIa 
Bernard-Soulier 
syndrome 
Low Large N N 0 N N N N Flow cytometry 
for GPIb 
COX Deficiency N N 1/R R N R R N N COX Analysis 
Drug induced 
 (aspirin shown) 
N N 1/R R N R/0 R N N Stop aspirin 
(use of 
questionnaire) 
Thromboxane 
receptor defects 
N N 1/N R N R N N R Platelet 
nucleotide/ 
biochemistry 
analysis 
P2Y12 receptor 
defects 
N N R/0 N N N N N N Receptor 
analysis/ 
biochemistry 
analysis 
Ehlers Danlo 
 syndrome 
N N N N N N N N N Genetic testing 
Other physical 
manifestations 
VWD N N N N 0/R/N N N N N VWF screening  
Storage Pool defects 
Grey platelet  
syndrome 
Low N R/1 N/R N N N R N Electron 
microscopy 
Quebec platelet 
syndrome 
N N N N N 0 N N N Multimerin 
analysis 
Chediak-Higashi 
syndrome 
N N R/1 R N N R N N Dense 
granule/nucleot
ide analysis 
Hermansky 
Pudlak syndrome 
N N R/1 R N N R N N Dense 
granule/nucleot
ide analysis 
Other physical 
manifestations 
Membrane anomalies 
Scott syndrome N N N N N N N N N Flow 
cytometric 
Annexin V 
analysis 
Genetic testing 
Paris-trousseau  
syndrome 
Low Large N/R N N N N R/1 N Electron 
microscopy for 
large alpha-
granules. Other 
physical 
manifestations 
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1.4 Diagnostic pathways  
Bristol is at the junction of three main areas of the UK: the south west peninsula 
(Dorset, Devon and Cornwall), Wales (Vale of Glamorgan and surrounds), and western 
counties (Wiltshire and Oxfordshire), and is positioned to provide a significant region 
with specialist services. There are also strong collaborative ties with the University of 
Bristol's departments of pharmacology and biochemistry. 
Platelets function disorders are a heterogeneous group of common bleeding disorders 
that require specialist technical and clinical expertise. The fact that there are many 
disorders with differing treatment protocols depending on the diagnosis gives rise to the 
need for a specialist laboratory.  
Prior to 2006 at Bristol platelet testing procedures were lacking in three main areas:  
 Systematic and comprehensive testing repertoire driven by evidence based practice 
 Specialist techniques to support routine testing 
 The skills and experience in reporting specialist tests 
 
Recently a number of diagnostic algorithms have become available-most notably the 
UK review of Bolton Maggs et al (Bolton-Maggs et al., 2006) that highlighted 
deficiencies in the diagnostic pathway(s) 
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Figure 1.4: Diagnostic algorithm from Bolton Maggs et al 
 
It  was felt that as a regional centre Bristol could not fulfil all the diagnostic areas 
required of a comprehensive laboratory service. Platelet aggregation was not developed 
and therefore there could be a delay in diagnosis of 43% of the disorders listed in the 
figure above.  Furthermore, platelet nucleotide and glycoprotein analysis were out 
sourced to other specialist laboratories, leading to a delay for a 36% of diagnoses. This 
led to unacceptable turnaround times for results to be available to the treating clinician; 
on occasion the return of results could take three months. This was deemed 
unacceptable and there was therefore a need for testing to be brought in house. 
Particularly important was glycoprotein analysis, as it could be performed on small 
samples. This would form part of the urgent paediatric platelet screen. In bringing the 
platelet aggregation to a first line test and the glycoproteins and release assays in-house 
there is now the facility to increase diagnostic work (according to the figure above) by 
over 50%.  
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No test is ever foolproof and a skilled specialist scientist is needed to assist in selection, 
performing and interpretation of results to support the clinical team in obtaining the 
correct diagnosis for the patient. 
 
1.5 Aims and Objectives 
The active involvement of platelets in the haemostatic process demands that platelet 
analysis is an integral part of patient investigation methodologies in the haemostasis 
laboratory’s repertoire. It has been shown above that the methods for assessing platelet 
numbers, function and contents are numerous and are not without their limitations. 
Those methods that the laboratory chooses to employ should be `fit for purpose'. This 
can only be achieved by thorough method assessment, complemented by knowledge of 
the strengths and weaknesses of each assay. 
Therefore the overall objectives of this project are to develop platelet laboratory 
protocols that will enhance the assessment of platelet function and improve diagnostic 
accuracy in a cost-effective manner.  To support this main objective it is intended that 
the following developments, procedures and evaluations will be incorporated: 
 
1. Minimisation of pre-analytical variability in platelet function testing, using 
questionnaires, standardised sample collection  and clinical interview. 
2. Improvement in standardisation of light transmission platelet aggregometry (LTA) by  
     generating new reference ranges for the common agonists ADP, Ristocetin, Collagen,    
      Epinephrine and Arachidonate. 
3. Addition to the LTA repertoire of – and generation of reference ranges for – two new 
agonists:   a thrombin receptor agonist peptide (TRAP) and a stable thromboxane 
mimetic U46619. 
4. Comparison of two sources of equine tendon collagen in order to determine whether 
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a more cost-effective preparation is comparable to that recommended in the 
guidelines as the ‘gold standard’ (i.e.: with the aim to reduce the cost of the assay 
without sacrificing quality). 
5. Standardisation of platelet nucleotide reference ranges. 
6. Implementation of a flow cytometric assay for platelet glycoprotein analysis, to 
include selection of antibodies and construction of reference intervals. 
 
In the general discussion I will provide evidence of: 
7. Integrating all of the above into a specialist laboratory environment encompassing a 
comprehensive, streamlined process for the diagnosis of platelet function disorder. 
8. Achieving recognition of this specialist service, not only locally and regionally, but 
 ultimately nationally and internationally. 
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Chapter 2: Materials and Methods 
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2.1 Standardisation and minimisation of pre-analytical variables 
Standardisation of the pre-analytical variables is a complex task to achieve. By its very 
definition it happens before the sample is analysed and therefore part of it does not 
come under the auspices of the trained laboratory personnel. Therefore, to standardise 
the procedures one has to engage many staff groups.  
The medical staff at Bristol Royal Infirmary are aware of standardised questionnaires 
for interviewing patients with more common bleeding disorders such as haemophilia 
(Rodeghiero et al., 2010; Rydz & James, 2012) and there have been moves to modify 
this for inherited platelet disorders (Marcus et al, 2010). Clinical consultations involve 
detailed questioning regarding drugs and diet as mentioned above.  
2.1.1 Pre-analytical Questionnaire 
To reinforce the clinical consultation and assist the nursing staff, and to make available 
a laboratory document, a pre-analytical questionnaire was devised (Gurney, 2004). The 
questionnaire was initially devised by interrogating the papers referenced earlier with 
respect to diet, lifestyle and pharmaceutical intake. 
Discussion took place between the haemophilia centre nursing staff, haemophilia 
clinical team, and relevant laboratory personnel to ensure that the questionnaire was 
fully understood and therefore able to be used to maximum effect. Nursing staff were 
made aware that a questionnaire was required to be completed with every request for 
platelet aggregation testing. The questionnaire was also used to inform the scientist 
writing the final report. 
This questionnaire has been through various versions depending on needs of the 
particular laboratory operating it. The original version was initially devised at Guys and 
St. Thomas hospitals, and revisions were subsequently made for its use at BRI           
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2.1.2 Sample collection standardisation 
Additional information was included with the questionnaire, in order to standardise 
sample collection, based on recent International Society for Thrombosis and 
Haemostasis guidelines (Harrison et al., 2011). This procedural advice included: veni-
puncture procedure; use of a ‘discard’ tube (to minimise the amount of tissue fluid in 
the resulting sample); anticoagulant choice; and time limits on collection to testing 
period. To facilitate the latter a member of the laboratory staff collects the samples from 
the clinic. This not only speeds up transport of samples, it ensures the time of sampling 
is known and prevents the samples being transported via a pneumatic delivery system 
(Glas et al,, 2012) 
2.2 Generation of reference ranges for Light Transmission Aggregation 
To achieve standardisation of LTA in our laboratory more efficiently and cost-
effectively the decision was taken to upgrade the current platelet aggregometer from the 
current Biodata PAP-4D to the Biodata PAP-8E (AlphaLabs, Eastleigh, Hants).   
The introduction of the ISTH recommended panel (Harrison et al., 2011) has also 
necessitated generating new reference ranges for the common agonists: ADP, ristocetin, 
collagen, epinephrine and arachidonate. These recent ISTH guidelines also 
recommended the addition of two new agonists: TRAP and a stable thromboxane 
mimetic U46619. These have been also been introduced to the laboratories’ testing 
repertoire. Therefore this section details the procedures for generating reference ranges 
for the expanded range of agonists. 
2.2.1 Subjects 
 Reference controls used to produce reference ranges were volunteers from within the 
laboratory and associated staff.  The reference ranges were developed by collating the 
data produced from thirty four references samples (16 males, 18 females; mean age 38) 
during routine platelet aggregation studies. 
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 All individuals were initially screened using the pre-analytical questionnaire. 
2.2.2 Sample collection and Preparation 
Samples were taken and transported to the laboratory as described above (see 2.1). They 
were then centrifuged at 200g for 10 minutes with no brake applied at the end of 
centrifugation. The resulting platelet-rich plasma (PRP) was transferred from the sample 
to a plastic tube using a plastic pasteur pipette, taking care to avoid the buffy coat. The 
PRP samples were then capped and stored at 20-25
0
C whilst the original samples were 
re-centrifuged at 3000g for ten minutes to produce platelet-poor plasma (PPP).  
2.2.3 Materials 
All agonists (identified above) were supplied by Hart Biologicals (Hart Biologicals, 
Hartlepool, County Durham). Dilutions of each agonist were prepared as shown in table 
2.1 below and stored at 20-25 degrees until added.   
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Agonist Reconstitution 
Fluid 
Stock 
Solution 
Working Solution Final concentration in PRP. 
ADP 
 
 
Reagent grade water 200M  
1) 150L stock + 150L Saline 
(100M) 
2) 50L (1) + 50L Saline 
3) 50L (1) + 200L Saline 
4) 50L (3) +100L Saline  
25L agonist + 225L PRP 
1) 10 M 
2) 5 M 
3) 2 M 
4) 1 M 
Collagen  
(Nycomed) 
Buffer supplied in kit 
pH 2.8 
1 mg/mL  
1)50L stock +950L kit buffer 
2)50L (1) +200 L kit buffer 
 
L agonist + 225L PRP 
1) 10g/mL 
2) 2g /mL 
 
Ristocetin Physiological saline 20 g/L  
1) Neat stock 
 50L (1) + 50L Saline
l agonist + 225l PRP 
1.25 g/L 
0.6 g/L 
Arachidonate Reagent grade water 5mg/mL Use neat (50L) 1mM 
25L agonist + 225l PRP 
Epinephrine Reagent grade water 1 mM 1) 50L stock +200L Saline 
2) 50L (1) + 450L Saline 
25l agonist + 225l PRP 
1) 20  M 
2) 2  M 
Thrombin Receptor 
Agonist Peptide 
(TRAP) 
Reagent grade water 568µL in vial 
1.73mg/mL 
1mM 
 
 
1) 150L (2) + 150L Saline 
2) 100L  (3) + 900L Saline 
25L agonist + 225L PRP 
3) 10M 
4) 1M 
U-46619 Physiological saline 500M 1) Neat  
2) 100L(3) + 900L Saline 
 
25l agonist + 225l PRP 
3) 5M 
4) 1M 
Table 2.1: Details of the dilutions and final concentrations of the agonists used in the platelet aggregation assays 
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2.2.4 Method  
Light transmission was measured through a stirred sample, taking the PPP as the 
100% reference and the PRP as 0%. The agonist was added directly to the PRP, 
the analyser determined the increase in light transmission caused by platelets 
aggregating and produced a trace. The reaction was allowed to continue for at 
least five minutes. In order to assess the distribution of normal aggregation 
procedure, traces were run using the highest dose of each agonist and preparing a 
trace graph with eight different controls. 
  
 
2.3 Comparison of two collagen sources for light 
transmission aggregometry 
2.3.1 Subjects 
25 subjects (13 Males 12 Females with an average age 38 years) were assayed. 
This was a sub population of the group in 2.2.1. 
2.3.2 Sample collection and preparation 
Samples were collected as described and prepared as described in 2.2.2. 
2.3.3 Materials 
Horm collagen preparation has been the gold standard preparation for a number 
of years (Yardumian, Mackie, & Machin, 1986). It is manufactured by Nycomed 
and prepared from equine tendon collagen particles derived from collagen sponge 
strips. The method consists of several grinding and mixing procedures finally 
resulting in a suspension that contains 1 mg/ml of native collagen fibrils in pH 2.7 
– 2.9 glucose buffer solution, with parahydroxibenzoicacid –methylester and 
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parahydroxibenzoicacid –propylylester preservatives. Most of the alternative 
collagen preparations on the market are of bovine origin and would therefore not 
be suitable as a direct comparison. Hart Biologicals were the first reagent 
company to supply an alternative equine tendon preparation. The reagent supplied 
by Hart was produced in a very similar way but the suspension medium had less 
biocides. The lack of biocides gives it a shorter shelf life, but should not interfere 
with the assay.  
 Horm collagen and the alternative source were supplied by ABP pharmaceuticals 
(ABP, New Jersey, USA). 
2.3.4 Method 
Each subject had platelet aggregation performed on a PAP-8E analyser as 
described in 2.2. For this study both collagen preparations were run in parallel, 
using 10µg/mL and 2 µg/mL dilutions. Maximum aggregation, initial slope and 
lag phase data points were recorded from the analyser. 
 
2.4 Generation of a Platelet nucleotide assay reference range 
Platelet nucleotides, consisting of the ADP and ATP stored in the dense granules, 
are a useful marker for differentiating and diagnosing dense storage pool 
disorders.  Assays used to assess nucleotide levels can be broadly separated into 
two groups; release during aggregation, and absolute quantification. 
Quantification of nucleotides enables diagnosis of delta storage pool disorders 
(SPD) and distinguishing from synthetic defect in release cycle. More recently the 
active ingredient, luciferase, has been produced artificially and therefore is 
readily available in kit form.  
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2.4.1 Subjects 
Data was collected from 31 control subjects (21 female and 10 male, average age 
32 range 18-52)  
2.4.2 Sample collection 
Platelet nucleotide analysis was performed on PRP, collected and prepared as 
described above (see 2.2.2). A platelet count was performed on an automated cell 
counter and the PRP adjusted to 300 x 10
9
/L with hard spun platelet poor plasma 
(PPP).  Once the PRP was prepared 500L was aliquoted into a small container.  
To this was added 50L 0.134M EDTA to chelate the calcium. The mixture was 
then vigorously mixed. Into this mixture 50L 20% Triton X-100 was added. This 
breaks down the platelet membrane and releases the cytosol. After further 
vigorous mixing and 500L Absolute Ethanol was added which precipitates out 
the membrane solids and leaves the cellular fluid for analysis. The sample was 
mixed again and left to stand at 4C for 15-30 minutes; after this the samples 
were stored at -70C, (where they are stable for up to 6 months). 
2.4.3 Materials 
The luminometer used in the laboratory was in need of replacing. Luminometers 
were therefore selected for comparison based on their capacity to perform to the 
criteria of our assay. These criteria included the ability to output raw data in both 
printed form and to a computer  in a recognised format. The ability to construct 
the standard curves and then relate subsequent samples and controls to the curve 
was considered desirable, but not essential as the necessary spreadsheets for 
calculating values from raw data were already in use in the laboratory.  
Luminometers that were requested for in-house evaluation were the Berthold 
LB9507 (Jencons) and the Luminoskan (Thermo). Both instruments met the brief, 
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but it was decided on a cost basis that only the Berthold LB9507 would be 
evaluated against the current method. 
Luminescent reagents (ATP standard and ATP monitoring reagent) were all 
manufactured by Biotherma (Biotherma, Handen, Sweden) and supplied by 
LabTech International (LabTech International, East Sussex, UK) 
2.4.4 Method 
An ATP standard curve was generated using a known ATP standard. An ADP 
control was incubated with pyruvate kinase and incubated for 15 minutes. The 
control was analysed on the luminometer to confirm the ADP to ATP reaction had 
taken place. Once completed the confirmation was checked using the following 
equation; luminescence of the ADP control divided by the luminescence top point 
on the standard curve multiplied by one hundred (to give a percentage 
conversion).  
If the percentage conversion was less that 80% then the assay was restarted. Once 
the conversion was confirmed the samples were defrosted, centrifuged and the 
supernatant aliquoted into testing vials. The supernatant phosphoenol pyruvate 
was added in excess and assayed to determine the ATP concentration. An 
additional aliquot of the original supernatant/mixture was then mixed with 
pyruvate kinase. The reaction of phosphoenol pyruvate to pyruvate, catalysed by 
pyruvate kinase, is driven by ADP and ATP. The ATP value of the original sample 
is referred to as initial ATP and the pyruvate catalysed ATP as total ATP. To 
calculate the ADP, initial ATP is subtracted from the total ATP.  
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2.5 Generation of a flow cytometric glycoprotein reference 
range 
2.5.1 Subjects 
Data was collected from 32 adult control subjects (26 female and 6 male, average 
age 40 range 16-72) and 11 paediatric control subjects (6 male and 5 female, 
average age 1.5years range, 1day -2years). 
2.5.2 Sample collection 
The adult samples were taken using the same phlebotomy procedure as for 
platelet aggregation (see 2.2.2). The platelet aggregation control sample was used 
for data acquisition and if the aggregation on the patient was normal that was 
used also. 
Of the paediatric samples, seven were collected as samples coming to the 
laboratory for routine analysis of glycoproteins, and when no abnormality was 
found they were included in the reference pool. Three samples were collected 
after verbal consent was obtained, as umbilical cord samples, in collaboration 
with midwives at St Michaels Hospital, Bristol. 
2.5.3 Materials 
2.5.3.1 Antibody selection 
To establish an enumeration technique for these important receptors, the 
appropriate antibodies were first selected. To select the antibodies a number of 
manufacturers were approached, who produced the antibodies of interest (in this 
case anti GP IIb/IIIa), and asked to participate in the trial.  Three manufacturers 
participated: AbD Serotec (Endeavour House, Langford Lane, Kidlington, OX5 
1GE, UK);Beckman Coulter (Oakley Court, Kingsmead Business Park, London 
Road, High Wycombe, HP11 1JU); and R&D Systems ( Abingdon, Oxford UK). 
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Company Clone Isotype Conjugate PE/ 
Ig ratio 
Catalogue 
Number 
Lot  
Number 
Recommended 
Concentration 
Serotec Y2/ 
51 
IgG1 PE not stated MCA2588PE 0307 Not stated. Lyophilised. 
Recommend add 1ml, use 10ul 
per test. Probably 100ug/ml 
 
Serotec PM6/13 IgG1 PE not stated MCA728PE 0304 Not stated. Lyophilized. 
Recommend add 1ml, use 10ul 
per test. Probably 100ug/ml 
 
Coulter SZ21 IgG1 PE 0.5-1.5 PN IM3605 16 Not stated.  
20ul per test of 500,000 cells 
 
R&D 
Systems 
256809 IgG2a PE not stated FAB2266P LNP 
0209101 
10ug/ml 
 
Table 2.2: Characteristics and sources of antibodies considered. 
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2.5.3.2 Optimisation of antibody 
The analyser was set up and checked for noise and background fluorescence.  The 
antibodies were then diluted to ascertain their optimal dilution and fluorescence 
stability. The graphs below illustrate this data for the R&D and Beckman Coulter 
antibodies. The Coulter antibody maintained fluorescence at increased dilutions. It is 
also demonstrated more linear fluorescence. This antibody was therefore selected for 
further study. 
 
 
Figure 2.1: Dilution and stability graphs 
Graphs showing the dilution and stability of two manufacturers antibodies.  The 
Coulter antibody is represented in the graph on the right, the R&D antibody in the 
graph on the left. The Coulter antibody has a more stable fluorescence at a higher 
dilution. 
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Figure 2.2: Mean fluorescence vs. dilution for all antibodies demonstrating the 
additional range of the Coulter antibody 
2.5.4 Methods 
The samples were diluted one in twenty with Becton Dickinson FACSFlow
© 
(Becton 
Dickinson, Oxford, UK) reagent, a saline based transport fluid for Becton Dickinson 
flow cytometers. The antibody was diluted one in ten with FACSFlow
©. 80μL of 
antibody solution and 10μL of the diluted blood were then incubated, at room 
temperature, for 15 minutes in the dark. After incubation 200μL of FACSFlow© was 
added to stop the reaction. These samples were then processed using a Becton 
Dickinson LSR
©
 flow cytometer (Becton Dickinson, Oxford, UK), reading at least 
5000 events (Schmitz et al., 1998) which had been calibrated previously using 
rainbow and cytometer setup and tracking (CST) beads. 
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3.0 Results 
3.1 Pre-analytical questionnaire 
The variability in presentation of platelet function disorder requires a standard 
procedure followed to minimise interfering factors. To do this a pre-analytical 
questionnaire was implemented at Bristol in July 2010 (See table 3.3 St Thomas’ and 
3.4a-c Bristol). Since 2010, when the new questionnaire became part of the testing 
process, there have been 85 platelet aggregation assays performed. Of these there 
were 22 (26%) patients identified that had ingested substances that could affect the 
results of the assay.  Sixteen (19%) were taking prescription medication and six (7%) 
taking over the counter (OTC) or herbal preparations. Six (27%) affected patients 
assays needed repeating after the subjects had abstained from the `identified 
substances' for at least fortnight. The other 16 were reported as having no 
abnormality observed, with the caveat that it had been noted the patient had been 
taking drugs known to interfere with platelet function. The two case studies 
described below are used as illustrations:  
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Questionnaire for all platelet aggregation patients & controls 
 
Question Response 
Are you taking?  
 Aspirin (within the last 14 days 
MINIMUM) 
 
 OTC Cold Relief Medication e.g. Lemsip  
 Ibuprofen  
On Any of the Prescription Medication 
below?  
COX1 inhibitors (indomethicin, 
sulfinpyrazone, naproxen) ADP receptor 
agonists,(ticlopidine, clopidogrel) GPIIb/IIIa 
agonists, (Rheopro, tirofiban, eptitifabatide, 
Intelligrin) Prostaglandins (Cliostazol), Tri-
cyclic antidepressants (Imipramine, 
amitripyline) 
 
 
 
 
If the PATIENT has answered YES to the above please reschedule. 
If the CONTROL has answered YES please find another volunteer. 
 
On any other current prescription medication? 
Please circle relevant drugs. 
 Penicillin, ampicillin, propranolol, atenolol, 
captopril, perindopril, anaesthesia,  
 
 
Are you currently taking vitamin 
supplements? If yes tick or circle if listed 
below 
Vitamins B6, C, E all affect platelets 
 
 
 
Are you taking dietary supplements or herbal 
remedies? If yes please tick or circle if listed 
below: 
Starflower oil, Fish oil, Ginko Biloba and 
Green Tea all have platelet antagonistic 
ingredients  
 
 
 
 
 
Have you had a take-away within the last 48 
hours? 
Elements in Turmeric, Cumin, Onion, Garlic, 
Ginger, Clove, black tree fungus & mono 
sodium glutamate all affect platelets. 
 
Do you drink or smoke? 
Alcohol, Caffeine & Smoking have been 
known to affect platelets 
 
Was this a clean Draw?  
 
 Figure 3.1: Initial questionnaire developed at St Thomas hospital 
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LTA PLATELET STUDY 
For first-line investigation of platelet bleeding disorders  
 
Surname  
Forename  
UH Bristol  or NHS No  
Date of birth  
 
First Line investigation?  
Follow Up investigation?  
Family study? (please identify proband)  
 
Document exposure to any of the following in the last 2 weeks  
 
D
a
t
e
? 
 Aspirin   
 ‘Over the counter’  cold relief medication   
 Ibuprofen   
 Any of the Prescription Medication below?  
   NSAIDs:                           Indomethicin, Sulfinpyrazone, Naproxen  
   ADP blocker:                   Ticlopidine, Clopidogrel, Prasugel  
   GPIIb/IIIa agonists:          Reopro, Tirofiban, Epitifibatide, 
Intelligrin 
   Prostaglandins:                Cliostazol 
   Antidepressants:              Citalopram, seroxat imipramine, 
amitripyline 
 
 
 
 
 
List all prescription drugs below 
 
List all vitamin or dietary supplements and herbal remedies in last 10 
days 
e.g. Starflower oil, Fish oil, Ginko Biloba and Green Tea Vitamins B6, C, E 
Alcohol, caffeine or tobacco in last 24 hours?          
 
 
 
 
Figure 3.2a: Current extended questionnaire used at  
Bristol Royal Infirmary Part a 
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Control   
Initials  
Gender  
Age  
Expose to anti-platelet agents in last 10 days  (y/n)  
 
  Please contact Mr David Gurney, Senior BMS (or designee) on ext 22598 before 
blood sample is taken. Please report exposure to anti-platelet drugs - inpatient or 
control. 
 
 Collect one ‘purple top’ EDTA sample, followed by 6-8 4.5ml ‘blue top’ citrate 
samples, using a needle gauge between 19 and 21 if appropriate. Use minimal 
venous stasis. Please discard tubes that are incompletely filled or in which the blood 
draw has been difficult.  
 
 The specimens may also be suitable for factor and VWF assays. Please indicate 
on separate request form/ICE request. Please enclose ICE request stickers or 
paper form with this request. 
 
 
Specimen collection 
Collection date  
Collection time  
Traumatic venepuncture?  
 
 
 
 
 
 
 
 
 
Figure 3.2b: Current extended questionnaire used at  
Bristol Royal Infirmary Part b 
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 Prepare PRP from citrate samples 15 min at 170g followed by PPP  
 Process EDTA sample for blood count, mean platelet volume and film. 
 
Time of sample receipt  
Platelet count on EDTA 
sample 
 
Platelet count on PRP 
preparation 
 
Appearance of PPP Clear / Lipaemic / Haemolysed 
 
 Only if PRP count  >  600×109 per litre, dilute down to 600 using PPP 
 
 
Count on PRP after 
adjustment 
 
 
Start time of aggregation 
study 
 
End time of aggregation 
study 
 
 
Report: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report compiled by: 
Date: 
 
Figure 3.2c: Current extended questionnaire used at Bristol Royal Infirmary Part c 
To be completed by the laboratory: 
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Case Study One:  A subject with unexplained peri-operative bleeding was referred to 
the haematology clinic for investigation. Standard haemostasis testing (coagulation 
screen, factor VIII, factor IX and von Willebrand screening) was performed and 
these were all normal.  At this point in the diagnostic process the clinician requested 
a platelet aggregation analysis. Upon filling in the questionnaire the patient informed 
the nurse that they were taking multivitamins. When subject to further questioning 
the patient admitted to taking allium (garlic) capsules, calcium citrate with vitamin 
D, quercetin with bromelain, cod liver oil, co-codamol, fluconazole, cetirizine, and 
high dose vitamin C.  None of these were listed in his pre-operative clinical history. 
As noted in section 1.2.2 many of these items may interfere with platelet 
aggregation. A reduced ADP response (shown as lines 1-4 in Figure 3.3), compared 
to the control was observed, and it was decided to repeat the assay after stopping 
these products. Repeat testing demonstrated no untoward results (shown as lines 5-8 
in Figure 3.3). Without the questionnaire and the nursing staff diligence this patient 
could have been diagnosed as mild platelet function defect of unknown 
determination.  
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Figure 3.3: ADP aggregometer  traces on patient SL:  
Pre: Line 1 10μM ADP,  Line 2 5μM ADP,  Line 3 2μM ADP, Line 4 1μM ADP  
Post: Line 5 10μM ADP,  Line 6 5μM ADP,  Line 7 2μM ADP, Line 8 1μM ADP 
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Case Study Two:  On completing the pre-analytical questionnaire a second patient, 
BF, was found to have been prescribed propantheline bromide for excessive 
sweating. On further investigation it was discovered that this patient had also been 
investigated by the paediatric team some 18 months previously. This meant we had 
access to pre drug, on drug and off drug data.  
Propantheline belongs to the anti-muscarinics which down regulates acetylcholine 
receptors. As these receptors are G-coupled receptors there was concern that they 
also down regulate ADP receptors as these are also G-coupled. In Figure 3.4 lines 1 
and 2 show the patients’ response to low dose ADP before the patient was prescribed 
the drug, lines 3 and 4 show the patients’ response whilst on the drug and lines 5 and 
6 when the patient was retested after abstaining from the drug for a month.  It was 
demonstrated that this patient had a mild bleeding defect as yet uncharacterised that 
seem to be up-regulated whilst on the medication. 
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Figure 3.4: ADP aggregometer traces for BF:  
March 2011 Line 1 2μM ADP, Line 2 1μM ADP,   
July 2012 Line 3 2μM ADP, Line 4 1μM ADP 
        August 2012 Line 5 2μM ADP, Line 6 1μM ADP 
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 3.2 Generation of reference range data for light 
transmission aggregation 
A series of graphs giving a visual representation of the data obtained for the 
platelet agonist references ranges is shown. The scatter plots in Figure 3.5 
illustrate that there is minimal lag in the ADP at 10μM and 5 μM and the initial 
slope values are more spread as the concentrations decrease. This is most 
noticeable in the 2 plots, as it is at this point that the platelets can be induced to 
produce a biphasic response. This concludes with either a second phase 
(release) or a full reversal (disaggregation) of the agglutination process. On the 
scatter plot below (Figure 3.6), detailing the results for collagen, ristocetin and 
epinephrine, it is demonstrated that the collagen reaction happens in uniform 
groups were the epinephrine has a wide range of results at 20μM and two 
discrete groups at 2μM. Variation in response of normal controls to epinephrine 
is well known (Harrison et al., 2011)where the epinephrine has a wide range of 
results at 20μM and two discrete groups at 2μM. In the reference group for low 
dose ristocetin (0.6m/L) there are some noticeable responders which could be 
mild hyper-responders. This is normally indicative of Type 2B VWD or 
pseudo/platelet type VWD and should be investigated further. There are two 
subjects who respond to low dose ristocetin ~100%. As indicated this is 
indicative of Type 2B VWD or pseudo/platelet type VWD and these candidates 
should have ristocetin induced mixing studies or genetic analysis to determine 
if there is a disorder present.  There is a group of six subjects whose 
aggregation with low dose ristocetin ~75%. This is increased and there is an 
argument for removing these patients from the reference range as they are not 
considered ‘normal’. However this then becomes an artificial construct, if 
Figure 3.4: ADP aggregometer traces for BF:  
March 2011 Line 1 2μM ADP, Line 2 1μM ADP,   
July 2012 Line 3 2μM ADP, Line 4 1μM ADP 
       August 2012 Line 5 2μM ADP, Line 6 1μM ADP 
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these patients are exhibiting no symptoms, should not the definition of 
‘normal’ be altered? The answer to this theoretical argument is to increase the 
sample population to establish the percentage of these outliers.  
 
 
 
 
 
 
 
Figure 3.5: Scatter plots for ADP reference range 
(A) shows maximum aggregation, slope and lag for 10µM ADP, (B) shows maximum 
aggregation, slope and lag for 5µM ADP, (C) shows maximum aggregation, slope and 
lag for 2µM ADP, and (D) shows maximum aggregation, slope and lag for 1µM ADP, 
 
A
 
 A
 A   A 
B 
C
  A 
D 
  A 
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Figure 3.6:  Scatter plots detailing range for final aggregation, primary slope, 
and lag data for all concentrations of collagen (top), ristocetin (middle) and 
epinephrine (bottom) 
(A) Shows final aggregation, primary slope and lag for 10g/mL collagen (B) Shows final aggregation, primary 
slope and lag for 2g/mL collagen  (C) Shows final aggregation, primary slope and lag for 1.2mg/mL ristocetin  
(D) Shows final aggregation, primary slope and lag for 0.6 mg/mL ristocetin (E) Shows final aggregation, 
primary slope and lag for 20M epinephrine  (F) Shows final aggregation, primary slope and lag for 20M 
epinephrine   
 
 
C 
A 
F 
D 
B 
E 
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Figure 3.7: Scatter plots for TRAP and U46619 reference range 
(A) shows maximum aggregation, slope and lag at 10µM TRAP, (B) shows maximum 
aggregation, slope and lag at 2µM TRAP, (C) shows maximum aggregation, slope and lag at 
5µM U46619, and (D) shows maximum aggregation, slope and lag at 1µM U46619 
 
E 
A
  A 
B 
C
  A 
D
  A 
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Agonist Concentration Slope Maximum aggregation Lag phase 
  Mean (Median) 2SD Mean (Median) 2SD Mean (Median) 2SD 
ADP 10μM 60 (61) 30 88 (84) 28 0 (0) 4 
5μM 57 (65) 36 87 (84) 38 1 (0) 16 
2μM 38 (35) 28 50 (53) 68 3 (0) 14 
1μM 16 (15) 24 14 (13) 22 2 (0) 16 
Collagen 10μg/mL 65 (66) 32 91 (88) 24 2 (0) 16 
2μg/mL 58 (62) 42 82 (84) 52 3 (0) 24 
Ristocetin 1.2g/L 51 (53) 38 89 (91) 34 8 (0) 32 
0.6gL 7 (0) 34 20 (4) 66 1 (0) 8 
Epinephrine 20μM 18 (13) 24 71 (79) 58 4 (0) 22 
2μM 8 (5) 20 36 (20) 66 1 (0) 12 
TRAP 10μM 69 (71) 32 88 (84) 26 0 (0) 2 
1μM 15 (12) 30 16 (10) 38 0 (0) 0 
U46619 5μM 67 (66) 118 86 (83) 22 0 (0) 0 
1μM 35 (45) 62 52 (75) 88 3 (0) 34 
Arachidonate 1.6mM 54(57) 40 84(83) 42 7(0) 22 
 
Table 3.1: Details of the mean (median) and twice standard deviation (SD) for all agonists at working dilutions. 
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dilutions for major platelet aggregation parameters giving the reference range 
(Mean +/- 2SD) 
It has been assumed that the data is parametric; this is supported by the fact that 
the mean and median are similar for most data points. It is noticeable (highlighted 
points on table 3.1) that where there is variation between the mean and median 
these are at low concentrations of agonists and there is no uniform skew. 
(ristocetin being skewed to the right and U46619 being skewed to the left). The 
reference range is calculated as mean +/- 2 standard deviations from the mean. 
This takes in 95% of the data population.. The scatter plots in Figure 3.7 illustrate 
the dose response nature of the agonist TRAP. However the scatter plots for 
U46619 demonstrate that at lower doses the populations are split into two discrete 
groups. Both final aggregation responses and primary slope have separated into 
groups. There are no documented receptor polymorphisms which would explain 
this result. However the concentration of the agonist is at a critical threshold and 
the data demonstrates that a small shift to the right on a steep dose response curve 
has a dramatic response. 
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Figure 3.8: Showing PAP-8E traces for multiple control subjects at 10μM ADP 
 66 
 
 
Figure 3.8 on the previous page illustrates the wide ranges noted in the table on 
the previous page. As a qualitative assay the reference intervals are wide. The 
different lag phases (especially in line 4 Figure 3.8) and the slope and maximal 
aggregation (Lines 1 & 7 Figure 3.8) of all with the same dose ADP.  
 
 
3.3 Results for collagen reagent comparison.  
Collagen is a key agonist in the platelet aggregation stimulating the GPVI 
receptor. However the current reagent is expensive. It was proposed to compare 
the current reagent with a reagent new to the market but with a substantially lower 
price. The object was to critically compare the preparations in healthy control 
population. Maximum aggregation, slope and lag phase data points, were taken 
from the PAP-8E analyser and statistically analysed using GraphPad Prism (La 
Jolla, California, USA). Scatter plots, correlation curves, and Bland Altman plots 
shown below were produced (Figures 3.9–3.11). These show that using a high 
dose (10µg/mL) agonist there is little difference in results for maximum 
aggregation between the two preparations of collagen. Horm collagen has a mean 
of 90% with a median of 87% compared to Hart 87% and 82% respectively. The 
absolute ranges (that is minimum value to the maximum value) is 72-116% for 
Horm and 70-116% for Hart. This pattern is repeated with the slope and lag 
values. With the slope data Horm mean is 69’, median 68’ (absolute range 49’-
93’), with the Hart reagent it is 67, 66 (51-91) respectively and lag data Horm 
mean 22s, median 19s (0-34s) compared to the Hart reagent mean 22s, median 
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21s (0-51s). This data is shown on the two left hand data clusters on the scatter 
graphs in Figure 3.9. On the right hand side of these cluster graphs is 
demonstrated the wider variation at the lower doses of collagen.    
 
 
 
 
 
Linear regression analysis was performed and the graphs can be seen below in 
figure 3.10. Figure 3.10a is maximum aggregation with high dose collagen on the 
Figure 3.9: Scatter graphs of comparison data 
Maximum aggregation (A), slope (B) and lag (C) using 10µg/mL and 2µg/mL Horm 
and Hart collagen 
A B 
C 
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left and low dose on the right. As observed with the scatter there is good 
agreement for maximum aggregation with high dose collagen (r
2 
0.92, p<0.001), 
however it is much poorer for low dose collagen (r
2 
0.77, p<0.001) At 2mg/mL 
collagen the Hart reagent produces lower values for both maximum aggregation 
and slope, as is demonstrated by the two points parallel with the X axis on the 
maximum aggregation graph and three points on the slope graph. For the lag 
phase and the slope correlation was poor at both collagen concentrations (lag 
phase 10µg/mL r
2 
0.36, p<0.001 and slope 10µg/mL r
2 
0.41, p<0.001). This data is 
summarised in table 3.2. 
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Figure 3.10: Linear regression analysis of comparison data  
Maximum aggregation (A and B) slope (C and D) and lag phase (E and F). 
10µg/mL collagen is depicted in the left hand column and 2mg/mL in the right 
hand column 
A B 
C D 
E F 
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The Bland Altman plots below for the maximum aggregation at high dose 
collagen (Figure 3.11 top left) show good agreement with minimal bias. At low 
agonist dose, reflecting the outliers on linear regression curve the maximum 
aggregation, there is a  positive bias and broader spread (with one point above the 
upper limit of agreement) on the Bland Altman plot (Figure 3.11 top right). 
However for slope (Figure 3.11 middle plots) and lag phase (Figure 3.11 bottom) 
there is wide variation at both concentrations of agonists with little correlation on 
the regression curves. The Bland Altman plots show a wide spread with the slope 
having a positive bias and the lag phase has negative bias.  
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Figure 3.11: Bland Altman analysis of comparison data 
Maximum aggregation (A and B) slope (C and D) and lag phase (E and F). 
10µg/mL collagen is depicted in the left hand column and 2µg/mL in the 
right hand column 
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B 
D 
E F 
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 Collagen 
concentration 
(µg/mL) 
r
2
 p Confidence 
Interval (95%) 
Maximum 
Aggregation 
10 0.92 <0.001 0.9 – 1.1 
 2 0.77 <0.001 0.8 – 1.2 
Lag Phase 10 0.36 0.006 0.5 – 1.7 
 2 0.58 <0.001 0.6 – 1.2 
Slope 10 0.41 <0.001 0.4 – 0.9 
 2 0.43 <0.001 0.4 – 0.9 
 
Table 3.2: Table showing statistical values for comparison between Horm and 
Hart collagen preparations 
 
In summary at 10µg/mL final concentration of collagen there is good grouping 
with little significant difference between the reagents. By contrast at 2µg/mL there 
is a significant difference.  When plotted, the regression for the maximum 
aggregation is good, but less so for slope and lag phase. At 2mg/mL there is poor 
correlation overall all parameters. When the maximum aggregation was plotted 
the Bland Altman show good agreement at 10mg/mL Agreement was poorer with 
slope and lag phase. At 2µg/mL there is poor agreement across all parameters. 
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  3.4 Generation of a platelet nucleotide reference range g
Platelet nucleotide analysis is essential for establishing the diagnosis of a delta storage 
pool (dense granule) disorder. New equipment had been purchased to improve 
reliability. This necessitated the establishment of a new reference range for the new 
equipment and that data is presented below. In figure 3.12 the measured values of ATP 
and total ATP, and calculated values of ADP, adjusted ATP and adjusted totals a are 
given with mean and ranges. Where the PRP count was less than the required 300 or 
could not be adjusted physically with PPP a mathematical adjustment was made to 
ensure correlation. Adjustment was made by dividing the desired platelet count by the 
actual platelet count of the PRP.  In figure 3.12 below the mean adjusted ATP is 17, 
with a range of 7-43. This range is higher than the unadjusted ATP 15 (7-27). This is 
due to a low platelet count causing an outlier to be amplified. (e.g. PRP count of 100 x 
10
9
/L would cause a multiplication  adjustment factor of 3) This adjustment factor and 
resulting high value for ATP would also explain the negative value for ADP on the 
scatter plot. If both the total adjusted ATP and the adjusted residual ATP are artificially 
raised by a lower platelet count, then a low or negative value would be the result. This 
then becomes the lower limit of the assays sensitivity. In addition low platelet counts 
will amplify analytical error. In a normal platelet dense granule there is twice the ADP 
than ATP (Mills & Thomas, 1969) the mean on the scatter plot is 2.8, the  reported 
median is 1.3. Dividing the amount of nucleotide by the platelet count in the PRP 
(Figure 3.12 right hand side )  The data is summarised in table 3.3 
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Figure 3.12: Scatter plots showing data for platelet nucleotide reference 
ranges  
Plot A shows ranges for platelet nucleotides and the plot B nucleotide/platelet ratio 
 
 
 
 
 
 
Table 3.3: Reference range values for platelet nucleotide analysis. 
The data in this table shows the ranges when constructed using mean +/- 2SD 
 
The given reference range for platelet counts on automated analysers is normally 
given in the range of 150 - 400 x 10
9
/L. In our study the range is 180 - 400 x 10
9
/L 
which is comparable and indicates that a representative sample of the 'normal' 
population has been sampled. The mean and the median results show good 
agreement and so the data is assumed to be parametric. Therefore the reference 
 Mean (Median) SD CI (95%) 
Platelet Count 290 (300)     55 271-309 
ATP 17 (15) 7.1 14-19 
ADP 11 (10) 7.1 8-13 
Total 27 (25) 7.7 24-30 
Ratio 2.8 4.7 1.1-4.4 
A B 
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range for this data was calculated as mean +/- 2SD. Using this calculation the 
ADP reference interval is 0-26 fluorescent light units (FLU). However the 
confidence interval indicates that 95% limits are 8-13 FLU. This is more plausible 
as a patient with no ADP in the dense granules would not be considered ‘normal’. 
The confidence interval assumes knowledge of a value for the wider population 
being calculated, where as the calculated reference interval is based only on the 
sample population. An alternative is to use the median +/- 2SEM. Standard error 
of the mean (SEM) involves the mean in the calculation so the true value is 
known, where as standard deviation is just scatter from the mean. Using SEM 
includes the mean in the calculation; the spread is smaller for small populations 
and becomes larger in larger populations. Larger populations assume that you are 
nearer to the ‘actual’ mean. Given this the nucleotide reference intervals would be 
calculated as shown in table 3.4 below. 
 
 Median 2SEM CI (95%) 
Platelet Count 300 19 271-309 
ATP 15 2.4 14-19 
ADP 10 2.6 8-13 
Total 25 2.8 24-30 
Ratio 2.8 4.7 1.1-4.4 
 
Table 3.4: Showing reference intervals for platelet nucleotides  
The reference range is calculated as Median +/- 2SEM 
 
Using median +/- 2SEM, the reference range for the platelet count becomes of 
281-319 x 10
9
/L, which is a smaller give range than the 95% confidence interval. 
This would be unusable in a modern haematology laboratory as it is too 
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constrictive. However the nucleotide reference intervals now compare well with 
the 95% confidence intervals and are more realistic.  
 
 3.5   Generation of a platelet glycoprotein reference range 
Bringing an assay in-house requires the same reference range work up as 
establishing a new assay. Control samples for platelet aggregation and patients 
that exhibited no abnormal reaction in the platelet aggregation assay were enrolled 
into the glycoprotein reference range study. This data, from 32 adult and 11 
paediatric cases is shown below. The scatter graphs are depicted with mean lines 
As the GPIIb/IIIa molecule is known to exist as a dimer (Wagner et al., 1996) on 
the surface of the platelet it helps to confirm our reference interval as both CD41 
and CD61 give similar ranges for all calculated parameters. As both mean +/- 2SD 
(23091 +/- 8296), median +/- 2SEM  (22474 +/- 1250)  and 95% confidence 
interval (21829-24352) are similar for CD61 and (25256+/- 8890, 25506 +/-1340, 
23095-26608) for CD61 this can be accepted as a true reference range. Visually 
this can beeb seen in the left hand scatter plot of figure 3.13.  However, the mean 
+/- 2SD for CD42b (7270 +/- 13230) allows for a patient with no CD42b (-5960 
as bottom of range) to fall within the range. This is not correct and would not 
distinguish control patients to those with Bernard Soulier syndrome. The median 
+/- 2 SEM is comparable to the 95% confidence interval and is therefore a more 
realistic range. As this range is selected for CD42b, the median +/- 2SEM will be 
used for the other glycoproteins.  
As can be seen in table 3.6, and visually in figure 3.13, the paediatric reference 
ranges are similar to those of the adults. The statistical power is limited due to the 
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small sample population. Further data needs to be tested to confirm this 
hypothesis. 
However none of these assays are infallible. Many manufacturers use different 
clones to raise their monoclonal antibodies. It has been suggested that the 
specificity of these antibodies may affect the results obtained (Curvers et al., 
2008) Results must always be considered within the limitations of each assay. The 
case study below illustrates this. 
 
 
 
 
 
 
 
Figure 3.13: Scatter plots showing ranges for platelet glycoproteins 
The plot on the left shows adult data with (from left to right) CD61, CD42b, 
CD41, FSC and SSC (FSC and SSC: Forward and side scatter denote the size 
and granularity of the platelet). The plot on the right is the paediatric data, with 
the same x axis 
 
 78 
 Mean 2SD Median 2SEM 95%CI 
CD61 23091 8296 22474 1250 21829-24352 
CD41 25256 8890 25506 1340 23095-26608 
CD42b 7270 13230 7244 642 6615-7925 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5: Reference range for adult glycoprotein analysis 
Data in the table shows the glycoprotein reference range for the adult 
population  
 
 Mean 2SD Median 2SEM 95% CI 
CD61 19025 8868 17773 2956 15617-22433 
CD41 20221 5474 20238 1824 18117-22325 
CD42b 7240 5928 6034 2240 4498-9981 
 
Table 3.6: Reference range for paediatric glycoprotein analysis 
Data in the table shows the glycoprotein reference range for the paediatric 
population 
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Case study One:  
It has been reported (Weiss et al., 1995) that the antibody (Coulter SZ21 IgG1 PE) 
chosen for analysis of Glanzmanns Thrombasthenia, can provide false positives. A 
case referred to the Bristol laboratory had been diagnosed with a 50% reduction in 
GPIIbIIIa in both parents and no GPIIbIIIa in the offspring. However it was 
established that an incorrect diagnosis of Glanzmanns Thrombasthenia had been 
made at the referring location. There are two variants of GPIIIa nominally called 
Human Platelet Antigen1 (HPA1) and HPA2 the difference being a leucine/proline 
switch at position thirty three.   The antibody used by the referring hospital, (as 
well as the Bristol laboratory), only detects HPA1. This is present in 99% of the 
population. However it was subsequently determined that the parents of this child 
were phenotypically HPA1/ HPA2 and this is what gave the apparent reduction in 
glycoprotein numbers. The phenotype of the child was HPA2/HPA2 and therefore 
the antibody used in the two laboratories didn’t recognise any of their GPIIIa 
receptors. 
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Figure 3.14: Flow cytometry data from control and family members 
Top: Histogram with normal control platelets,  
Middle parent 50% identification of GPIIIa  
Bottom patient with no bound GPIIIa (red line shows median fluorescence peak 
for reference range) 
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Chapter 4: Discussion 
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4.1 Introduction 
St Thomas’ hospital and Bristol Royal Infirmary are both large regional 
comprehensive care centres for patients with bleeding disorders. At the outset of 
this project these centres did not have the laboratory support for dealing with 
platelet function disorders.  To give these centres the services that were needed a 
review of all documented guidance was initially performed (Bolton-Maggs et al., 
2006; Christie et al., 2008; Davidson et al., 1988; Harrison et al., 2011). When the 
project was initially undertaken, most of the guidelines were yet to be written, so 
reliance was placed on the British Committee for Standards in Haematology 
(BCSH) document of 1988 (Davidson et al., 1988). Whilst waiting for subsequent 
affiliated guidance to be published, autonomous laboratory research groups were 
publishing their own recommendations (Harrison, 2009; Hayward, 2008; 
Hayward & Eikelboom, 2007; Moffat et al, 2005) It should be noted that the 
authors on the autonomous guidance tended to be those that subsequently 
published similar guidance affiliated to a national or international standards body.   
Several surveys from the UK (Jennings et al., 2008), Canada (Price et al., 2007) 
and the ISTH (Cattaneo et al., 2009)  had indicated guidance was urgently needed.  
Also apparent from these published surveys, especially the international 
community survey ( Cattaneo et al., 2009) was that some guidance (Bolton-Maggs 
et al., 2006; Christie et al., 2008; Davidson et al., 1988) was not being adhered to. 
This non-uniform testing led to ISTH scientific sub-committee investigation and 
the results of this formed  Paolo Greseles’ presentation in Liverpool at ISTH SSC 
2012, which is discussed in section 4.2 (http://www.isth.org/default/index.cfm 
/ssc1/2012-ssc-subcommittee-minutes/2012-platelet-physiology-minutes) 
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With the rapid publishing of guidance over the last ten years, the current 
document may not remain the remain the de-facto standard (Harrison et al., 2011) 
for long.  This requires a robust evidence based practice protocol. Furthermore 
evidence based practice is recommended as a key performance indicator (KPI) in 
a recent report published by the Royal College of Pathologists (RCPath)(Furness, 
2011). 
Implementation of the evidenced based (Baum, 2012; Mickenautsch, 2010) 
review methodology involved searching for  primary evidence from published 
trials and meta-analyses that are readily available on the internet (Gurney, 2006) 
and a search stratagem was devised. This included an automated PubMed
© 
(http://www.ncbi.nlm.nih.gov/pubmed) search for the phrase 'platelets' and the 
results delivered by email every day (See Figure 4.1 for full search details). In a 
personal conversation with Paul Harrison, he advised on the time limit, as large 
amounts of papers are constantly being generated and therefore assessing daily 
gives manageable results. This is augmented by an electronic table of contents 
search for all coagulation based journals. 
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Figure 4.1 PubMed search request for literature involving platelets as part of the 
laboratorys’ evidence based practice methodology. 
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Figure 4.2: Screenshot of St Thomas Hospital Intranet page for the haemostasis 
laboratory showing author as point of contact for platelet work. 
 
A single scientist responsible for the specialist platelet function testing has provided both 
clinical staff and scientific colleagues with a single contact point. This ensures that the 
process of platelet function testing (see Figure 4.3) from booking the patient to sending out 
the report is monitored to meet the quality standards required. Administrative staff  now liaise 
with the nominated laboratory scientist to ensure that, as the tests involve time and technical 
skill, there are the staff available to analyse the samples. The nursing staff liaise with the 
nominated laboratory scientist to ensure the information is correct, the samples reach the 
laboratory without delay and the clinicians interact when requesting tests and receiving 
reports. This ensures continuity for the patients sample throughout the process. 
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Organising Platelet FunctionTesting 
 
1. New Patients requiring combined clinic appointment/medical review and platelet 
function testing 
 
Clinician categorises as urgent or non-urgent and states whether ‘standard’ or ‘extended’ 
testing is required: 
 
Non Urgent Platelet Function testing: 
 
1) Haemophilia Centre Coordinator emails David Gurney david.gurney@uhbristol.nhs.uk 
if extended testing required copy in Matt Jones matthew.jones@bristol.ac.uk: 
Give patient details, specify standard or extended platelet function testing, advise that a 
Tues am slot is needed 
2) David (and Matt) agree a date (minimum of 2 weeks notice) and advise Haemophilia 
Centre Coordinator by email antony.woolcomb@uhbristol.nhs.uk 
3) Haemophilia Centre Coordinator will provisionally book clinic appointment (1
st
 slot), 
phone patient to confirm availability and send appointment with the explanatory letter and 
patient information leaflet to patient via standard post. (If clinic is overbooked to discuss 
with medic and move another patient out). Also the patient is to be entered in the 
Haemophilia Centre Diary for the nurses to take the blood. 
4) In the week prior to appointment Haemophilia Centre Coordinator will phone patient to 
confirm. 
 
Urgent Platelet Function Testing: 
  
As above however does not need to be a Tuesday, but does need to coincide with a 
medic available to review.  
When date confirmed by lab Haemophilia Centre coordinator will hand this over to a 
medic to phone the patient to explain the procedure and ensure no incompatible meds 
etc 
 
2. Known Patient having ongoing investigations for bleeding: 
 
The expectation is that the patient will have been seen in clinic and discussed need for 
platelet function testing.  
After clinic medic refers case to Haemophilia Centre Coordinator who: 
 
1) Will arrange time and date for platelet function testing (does not need to be a Tues and 
does not need medic review) 
 
2) Send date and info leaflet to patient 
Figure 4.3 Protocol for booking in platelet function tests at Bristol 
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4.2 Pre-analytical variability 
Pre-analytical variability was an initial focus of this project. It has been 
successfully minimised by involving all staff groups in developing the 
questionnaire which now includes details of over the counter drugs, herbal 
preparations and guidance on correct phlebotomy. The results above (Section 3.2) 
demonstrate that the pre-analytical questionnaire has not reduced the number of 
platelet aggregation assays performed. The assays that are performed are able to 
have this information included in the report leading to more informed diagnostic 
decisions by the clinical team. At the 2012 ISTH meeting Paolo Gresele presented 
data of a survey of over two hundred laboratories, ninety two of which were 
clinical laboratories from thirty seven countries. In this survey 36% of laboratories 
gave no clinical interview, 70% performed no pre-analytical questionnaire, and 
36% did not perform a normal control with each assay. There was an increased 
reporting of ADP defects and 34% of cases were undefined as to the cause of the 
patients original bleeding. The data supports the concept that ‘undefined cases’ 
could be attributed to one or more of the following: no clinical input, no pre-
analytical checking or control run. Greater focus on these three items may have 
presented the testing laboratory with reasons for these symptoms, such as aspirin 
ingestion or thienopyridine prescriptions. 
In light of the 2008 NEQAS report (I. Jennings et al., 2008) contact was made 
with distributor  (Alpha Labs Eastleigh, Hants) with the suggestion that to help to 
rectify some of the concerns of the authors a 'user group' meeting should be 
convened.  As the Biodata PAP-4D and PAP-8E are one of the most common 
platelet aggregometers available it was hoped to reach a large number of scientists 
active in platelet function analysis. This took place in London in October 2008 
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(see appendices 1-3 for agenda, presentation and report). The speakers also 
included Ian Jennings, author of the report (I. Jennings et al., 2008) who spoke 
about current practice and gave an insight into further data from the study and 
Paul Harrison who spoke about the then, upcoming guidelines as he was a panel 
member. Work on the pre-analytical questionnaire was presented and delegates 
present were offered it for use in their laboratories. After the meeting contact was 
made with eleven representatives of laboratories (see table below) and followed 
this up with an email 6 months later enquiring into the value and usage of the 
questionnaire (see appendix 4 for text).  
 
Laboratory Follow up 
Sheffield No reply 
Abergavenny No reply 
Swansea No reply 
Ashford Being discussed 
Manchester No reply 
Bournemouth No reply 
Edinburgh Used, locally modified 
London (Royal 
Free) 
No reply 
London 
(Imperial) 
Used in Haemophilia centre 
with nurses 
London (UCL) Used in SOP but not in 
practice 
Hull Used, locally modified 
 
Figure 4.1: Correspondence regarding use of questionnaire 
 
This small sample bears out the data that was being described by Gresele at the ISTH 
SSC 2012, detailed above. There has to be an assumption that those laboratories that did 
not reply to the follow up email are not using the questionnaire. It was assumed then 
that these places are still performing platelet function tests. This would be simple 
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conjecture, these laboratories may already be using questionnaires and noted there was 
little difference from those presented, or where at the user group to assess the suitability 
of setting up the assay and decided against setting up a complex assay. It is a concern 
however that these laboratories may be performing this test.  If a pre-analytical 
questionnaire was to be used, rather than go through the review process prudence would 
dictate using an example provided? One laboratory has implemented it completely, and 
a further two laboratories have modified it for local use. As a standardisation tool 
viewing the modification would have been a useful exercise to confirm that the core 
questions had not been removed from the document. The final two answers are cause 
for concern. If the document is under discussion, but not been implemented it means 
that those people discussing it are unaware of guidance on the use of a pre-analytical 
questionnaire. If they are unaware regarding this portion of the guidance, one has to be 
concerned about the performance of the whole assay in that particular laboratory. 
Finally, a laboratory has included the document as part of their standard operating 
procedure (SOP) but does not use it to screen patients. This is a concern on a number of 
levels; firstly an SOP is a monitored document which can be audited by Clinical 
Pathology Accreditation (www.cpa-uk.co.uk) and if the document is included ‘as is’ 
during an audit the assessor is within their powers to ask to see examples of the 
completed questionnaire. Secondly the questionnaire is not being used clinically and 
therefore this calls into question the knowledge of the current guidelines. All the non-
user laboratories are within the catchment of laboratories that are using the 
questionnaire and this confirms that these specialist assays should be done by specialist 
centres that understand the assay to the fullest extent. 
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Patient Questionnaire - PLATELET AGGREGATION 
 
For first-line investigation of platelet bleeding disorders.  This form must be 
completed by the requesting clinician and/or a member of the 
Haemophilia nursing team prior to platelet aggregation testing. 
 
Surname  
Forename  
NHS  Number / Hospital Number  
Date of Birth  
Telephone Number  
 
First Line Investigation?  
Follow Up Investigation?  
Family study? (please identify affected individual 
and relationship) 
 
Previous Platelet Aggregation Results?  
 
The following drugs are contraindicative to platelet aggregation testing and 
must be avoided for 14 days prior to date of test. 
 
 
 Aspirin and Ibuprofen 
 ‘Over the counter’  cold relief medication  
 Homeopathic remedies 
 Prescription medication  
   NSAIDs:                          Indomethicin, Sulfinpyrazone, Naproxen   
   ADP blocker:                  Ticlopidine, Clopidogrel, Prasugel  
   GPIIb/IIIa agonists:         Reopro, Tirofiban, Epitifibatide, Intelligrin 
   Prostaglandins:               Cliostazol 
   Antidepressants:             Citalopram, seroxat imipramine, amitripyline 
   Antimicrobials:                Penicillins, Cephalosporins 
   Anticoagulants:               Warfarin, heparinoids, direct thrombin inhibitors 
 
List all current medication, including any not listed above, and provide date 
taken 
 
 
List all vitamin or dietary supplements and herbal remedies in last 10 days 
eg Fish oil, Ginko Biloba and Green Tea  Vitamins B6, C, E 
 
 
Figure 4.4a: Questionnaire as modified and used at Hull and East Yorkshire Hospital 
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NHS Trust (see table 4.1) 
 
 
Actions to be completed by health care 
professional when booking platelet aggregation 
test 
 
Signature  
Identify any current medication listed above that is 
contraindicative for platelet aggregation – check BCSH 
guidelines and/or haemophilia nursing team database 
 
 
REQUESTING CLINICIAN: Advise patient to discontinue 
medication identified that is contraindicated  
 
 
Advise patient to avoid alcohol, caffeine and tobacco 24 
hours prior to test 
 
 
Advise patient to avoid high concentrations of garlic, 
onion, ginger, ginseng, fish oil, tamarind, turmeric, 
vitamins C and E prior to test  
 
 
Provide patient with platelet aggregation information 
sheet 
 
 
Advise patient to contact Haemophilia nursing team if 
unwell or if contraindicative medication has been taken 
two weeks prior to the date of the test 
 
 
 Details of test 
 
Date, time and location for patient to attend         
 
 
 
                                                                                    
Details confirmed with:                                                LAB 
                                                                            PATIENT  
                                                                         LOCATION  
 
Date 
Time 
Location 
 
 
  
  
  
 
Figure 4.4b: Questionnaire as modified and used at Hull and East Yorkshire Hospital NHS Trust (see table 4.1) 
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  4.3 Platelet aggregation: instrument introduction and 
reference ranges 
With regard to the instrumentation used to assess platelet aggregation in this 
study, the PAP-8E has a number of advantages compared with its predecessor the 
PAP-4D. It has eight channels, each taking 250μL of sample, whereas the earlier 
model had only four channels each taking 500μL of sample. This is advantageous 
for a number of reasons: double the number of reaction channels means that the 
assaying the samples takes less time, the assay is able to be performed within the 
recommended time-frame set in the guidelines. Doubling the channels has 
decreased the size of the reaction cuvettes and with this less PRP being used. This 
has a direct result on the amount of sample required and less sample volume being 
taken. The reduced sample volume is advantageous when dealing with minimal 
volumes required by the paediatric patients.   Advances in the controlling software 
means that data manipulation is also easier with the newer machine.  With the 
PAP-4D operator experience determined where the agonist was added. This led to 
agonists running down the side of the reaction cuvette before entering the PRP, 
giving a falsely elevated lag phase value. An advantage with the PAP-8E is that 
the sample cuvette cover is shaped to allow a pipette tip to be positioned directly 
above the centre of the sample, allowing the agonist to drop straight into the PRP 
minimising any lag phase errors.  
As a new analyser and a new reagent supplier was being used, new references 
ranges were established for the current agonists being used in the department. The 
new agonists as advised by the current guidelines have been established and are 
now in use. On the Gaussian curve used to calculate reference ranges, there will 
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be 2.5% of the population at either end of the curve which, although the sampling 
suggests is 'normal', will be outside the reference range. For this reason, it should 
not be referred to as a 'normal range' but a reference range or reference interval. 
The most recent platelet aggregation agonist reference data to be published 
(Dawood, Wilde, & Watson, 2007; Hayward et al., 2008) shows similarity to our 
data; however Dawood et al only observed the traces for a maximum of three 
minutes, whereas the current guideline recommends five minutes. Agonists such 
as epinephrine and collagen can have extended lag phases in some disease states, 
by not observing for a full five minutes there may be some late changes that 
would have been unaccounted. Hayward et al show a similar but tighter range for 
arachidonate and 5µM ADP (they don’t give further dilution ranges) and for 
collagen, epinephrine, U46619 and ristocetin the reagent concentrations differ 
from those used in this study. . Other researchers found discrete populations in 
other agonists, also at specific dilutions.(Hayward et al., 2009) 
Some variation might be expected as the data from the Birmingham group was 
prepared with Chronolog (LabMedics, Stockport, Cheshire) equipment and 
reagents, where as this data was prepared on a Biodata PAP-8E with hart 
Biologicals reagents. The Dawood et al paper only shows example traces rather 
than reference ranges.  
The aggregometer trace was then followed for at least five minutes and the trace 
visually interpreted and a report written. Some of the  recent guidance  advocates 
starting with a 'screening' set of agonist dilutions (Moffat et al., 2005), and then 
once an anomaly is observed, to proceed to further dilutions. However as the 
preparation of the platelet rich plasma and the dilutions of the agonist are the time 
limiting stages of the assay, all dilutions of each agonist were run each time in this 
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study. 
Another procedural discussion is on the dilution of the PRP to standardise the 
platelet count. Mani and Cattaneo (Cattaneo et al., 2007; Mani et al., 2005) stated 
that the process of adding hard spun plasma to ‘normalise’ the PRP was 
introducing factors that were interfering with the assay. This has been disputed 
(Castilloux et al., 2011) however the current guidance (Harrison et al., 2011) is 
only to dilute PRP when the platelet count in excess of 600 x 10
9
/L 
With low dose U46619 the final aggregation and slope are split into two distinct 
populations this can also be observed with final aggregation at low dose 
epinephrine. This low dilution is due to the agonist concentration being on the 
threshold of the activation limit for the platelet receptors. 
In-vitro testing however, presents its own problems. Preparation of PRP removes 
erythrocytes and leukocytes, removing with them any part they may play in the 
aggregation process. It also involves centrifuging the blood sample and this 
activates platelets to a small degree. There are many in-vitro methods for 
analysing platelets, most of these are only of any worth when analysed with a 
control. This way you are distinguishing between how the platelets react ‘in this 
test environment’ compared to a control. This will give an indication, but no more, 
on how they operate within the body.  
 
4.4 Collagen reagent comparison  
The collagen comparison produced data that showed that the ABP 
pharmaceuticals (ABP, New Jersey, USA) collagen had a greater degree of 
variation in normal controls (Figure 3.9-3.11, Table 3.2) which was more 
pronounced at lower concentrations. This will only be of significance if the lower 
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limits of the range give rise to no distinguishable difference between non-
responding diseased patients. Analysis of known diseased controls will be used to 
confirm the new agonist is able to separate the normal and diseased control 
populations. It should be noted that Nycomed Horm collagen is six times more 
expensive than the comparative product supplied by ABP pharmaceuticals (ABP, 
New Jersey, USA). 
 If after completing the diseased control study and the data shows that the  broad 
nature of the Hart collagen reference interval means it cannot distinguish between 
normal and diseased patients then the laboratory will continue use the Horm 
product. The laboratory will inform Hart Biologicals of this finding and it is 
hoped that the product can be standardised to meet the Horm specifications and 
then the department can reduce its reagent budget. Until the diseased control study 
has been performed a decision to switch to the cheaper reagent cannot be made. 
The fact the Horm preparation is the ‘gold standard’ seems to be an historical 
accident and reliant on the fact that twenty years ago it was the only collagen 
preparation available (email conversation with Alby Patterson (CEO Hart 
Biologicals) and Richard Farndale (Professor of Biochemistry, University of 
Cambridge (Farndale, 2006)). 
 
4.5 Platelet nucleotides reference ranges 
Platelet nucleotide analysis is a useful adjunct to nucleotide release analysis as 
performed on the Chronolog analyser (LabMedics, Stockport, Cheshire). The 
Chronolog analyser measures luminescence as produced in a PRP sample after 
activation with an agonist, most commonly TRAP, this is a representation of the 
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granule release mechanism. If the granule release mechanism is defective, then 
the Chronolog analyser will product results indicative of delta storage pool 
disorder. Upon measuring platelet nucleotide content directly as described above 
in section 2.4, a normal result will be obtained. These results coupled together 
give the information that there is an enzymatic cascade problem in the release 
machinery, such defective PKC isomers. 
 With the an expert clinical team and technical proficient laboratory service, the 
Bristol Haemophilia centre has been selected as a quaternary referral centre for 
Hermansky Pudlak disorder and is recommended by Hermansky-Pudlak 
Syndrome Network UK (http://www.hpsnetwork.co.uk/) a support network for 
HPS patients. 
The nucleotide assay is a quantitative test; therefore the median +/- 2SEM is a 
sensible way to produce a reference interval; however it would not be useful to 
construct a range for the platelet aggregation in the same way. The small 
population size and the qualitative nature of the assay mean that the mean +/- 2SD 
is the correct way to calculate this. 
 
4.6 Flow cytometric glycoprotein reference ranges 
Flow cytometry for platelet glycoproteins is now offered as a routine test to all the 
specialist haematology clinical teams.  In this study patients who had normal 
aggregation results were included in the reference population for the glycoprotein 
reference interval. This practice increases the number of subjects in the reference 
pool more quickly than just using control subjects. However one has to consider 
that these patients have had other platelet function tests performed  as their 
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symptoms dictate a primary bleeding disorder. So, if the patient has a positive 
bleeding history, should they be used as a control? The data in the results section 
(Table 3.5) indicates that this was an acceptable practice as the reference interval 
is quite narrow with few outliers. If this data had presented with a large spread or 
a number of outlying results then this approach would have been re-considered. 
Published data on these reference ranges (Ozsavci et al., 2002) state that GPIIb 
was 43828+/- 7904, GPIIIa 42351+/- 1049 and GPIb 22166+/- 3847.  The data 
was constructed using an antibody conjugated to fluorescein isothiocyanate 
(FITC) fluorochrome. This fluorochrome does not have a one-to-one ratio with its 
epitope and therefore the count is unreliable, this paper based the reference range 
on five normal cases, this is not statistically satisfactory. 
 Further analysis is needed to establish the reference interval for the paediatric 
controls; the current group does not have sufficient power to create a range. There 
are however, obstacles in obtaining paediatric control samples; these include 
ethical issues of collecting blood from healthy paediatric patients and population 
size. Population size is directly related to the ethical issue. 
 
4.7 Integration into a specialist laboratory environment 
In 2000 during a conversation with the Clinical Director of the haemophilia centre 
at St Thomas’ Hospital it was mentioned that only 40% of patients who have a 
laboratory demonstrable  platelet function disorder receive a clinical diagnosis. In 
the work presented here, there has been development of  sufficient expertise  to 
increase that value. Platelet aggregation is now listed in the department’s first line 
screening protocol and is available as part of the laboratory’s routine repertoire. 
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Previous to 2010 in Bristol, platelet aggregation was considered a second or third 
line specialist screening assay. This assay is now available to a greater number of 
patients, allowing diagnoses to be made in a shorter timeframe, meaning fewer 
hospital attendances for the patient. This saves time for the patient, and time and 
resources for the hospital. 
 In a recent study (Hayward et al., 2012) it was reported that adding LTA and 
VWD screening to first line bleeding disorder investigations increased the 
sensitivity from 3.7%  to 30% (whilst maintaining specificity  i.e. slightly reduced  
96% to 88%), compared to using just a coagulation screen which included a 
prothrombin time (PT), activated partial thromboplastin time (APTT) and 
fibrinogen (by the Clauss method).  There study also found that 36% of the 
definite bleeding disorders had no demonstrable cause, showing that there is still 
work to be done twelve years after the conversation with the St Thomas’ Clinical 
director.  
Integration of the service can be demonstrated by the fact that there was a single 
point of contact for platelet work at St Thomas’ hospital (Figure 4.2). This model 
has been repeated for the integration of service at Bristol Royal Infirmary (See 
Figure 4.3). Pre-analytical variability has been reduced by collaborating with all 
staff groups, a process that was driven by and centred on the laboratory (Section 
4.2).  
New aggregation equipment and new reagents have been introduced, standardised 
and reference ranges generated as driven by evidence based practice (Section 4.3). 
Studies have been undertaken to decrease the cost of the assays in the laboratory. 
Dependant on the results of further testing the cost of the collagen reagent  could 
decrease significantly (Section 4.4).   
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The flow cytometric analysis of glycoproteins has been brought ‘in-house’, 
improved and standardised and is now offered as a routine assay to specialist 
haematology clinical staff. This ensures the turnaround time has reduced from a 
week, to 8 hours. 
 Point of care testing has not been integrated into the department; however 
rotational elastometric (ROTEM) assays are used in theatres for rapid assessment 
of the patient undergoing surgery but has not been added to the laboratory 
diagnostic repertoire. 
All of these components mean the laboratory can fulfil every stage of the 
algorithm (Figure 1.4) presented by UK Haemophilia Centre Directors 
Organisation (UKHCDO) paper  (Bolton-Maggs et al., 2006) for diagnosing 
platelet disorders meet all the recommendations for diagnosing platelet function 
disorders in the latest guidelines (Harrison et al., 2011). The department has a 
dedicated molecular genetics unit on site for genetic confirmatory diagnosis of 
diseases covered in section 1.2.3. Should the need arise expertise in the fields of 
electron microscopy, western blotting and plasmid manipulation are available 
through collaboration with the Bristol Platelet Group, a specialist research team at 
Bristol University (www.bristolplatelets.org). Genetic analysis is more frequently 
performed as confirmation of a phenotypic analysis such as platelet aggregation or 
platelet release. In the current economic climate, electron microscopy tends to be 
used for absolute confirmation of new or rare disorders. This interaction between 
the diagnostic hospital laboratory and the university research laboratory is aiding 
the development of translational medicine. That is techniques that were the 
preserve of research laboratories, being used in specialist hospital laboratories for 
advanced diagnostic purposes. Polymerase chain reaction (PCR) genetic analysis 
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is a recent example of this.(Jones et al., 2011) 
Coupled with all the above, working with an expert team of clinicians and other 
scientists, there is now co-ordination of an advanced laboratory service for the 
benefit of  haemophilia centre patients.  
 
4.8 Recognition as a specialist service 
The laboratory has been recognised as expert by a number of the external 
organisations. Biodata approached the laboratory when it was preparing its user 
group (see appendix 1-3 for agenda). Hart Biologicals approached the laboratory 
for advice on platelet function kits and its collagen reagent (section 4.4). The 
Hermansky Pudlak network (http://www.hpsnetwork.co.uk/)  a patient support 
group approached the clinical team to operate as a tertiary referral centre for their 
members to confirm previous diagnosis. The improved laboratory has enabled it 
to participate in national studies, such as genotyping and platelet phenotyping 
(GAPP) study (http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID= 
9858). This study is using phenotypic diagnosis to direct gene sequencing and 
analysis so that a genetic diagnostic portfolio can be developed.   The GAPP study 
is a UK collaborative effort between the laboratories in Bristol, Birmingham and 
Sheffield, and international studies, such as the Bridge 
(https://bridgestudy.medschl.cam.ac.uk/whatis.shtml) study. This an international 
collaboration between UK, European and US laboratories building on the work 
the GAPP study researching genetic causes of rare platelet disorders. The 
collaboration has already yielded results in locating the causative gene in gray 
platelet syndrome (Albers et al., 2011). 
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A number of the services’ staff are now representatives on national (David 
Gurney, IBMS Haematology Specialist Advisory Panel) and international 
(Andrew Mumford, Platelet physiology ISTH SSC) committees. In my  role as 
specialist scientist at Bristol and specialist advisor for the IBMS, invitations to 
speak have been offered at IBMS Biennial congresses, and accepted in 2005 
(appendix 7), 2009 (appendix 8) and 2011 (appendix 9). These presentations have 
led to an invitation of collaboration for a book chapter (Moore & Gurney, 2010) 
on laboratory diagnosis of platelet function disorders. 
 
In his review of pathology service Lord Carter of Coles (Carter, 2006) 
recommended that specialist services be consolidated in areas of expertise. The 
laboratory at Bristol is now well placed to be one of those specialist laboratories. 
It has a comprehensive care centre for bleeding disorders on site, staffed by expert 
clinicians (A. D. Mumford, 2009) and a scientifically accomplished laboratory 
service.  
In the future we will continue to offer the best evidence based analysis for platelet 
function disorders. Phenotypic testing is likely to reduce over this period as more 
is discovered about platelet genetics.  Just as genetic testing will increase, so will 
our knowledge of platelet structure (Zufferey et al, 2011) Bristol Royal Infirmary 
is well place to build on this with a dedicated genetic laboratory (Jones et al., 
2011). Furthermore assays for deficiencies in particular proteins (or even groups 
of proteins) will become common place. All the proteomic data (Di Michele, Van 
Geet, & Freson, 2012) and genetic information (Freson, Izzi, & Van Geet, 2012) 
will yield numerical and structural results which may infer functional abnormality. 
Platelet aggregation is still the gold standard method that shows how they 
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function. Borns’ (Born, 1962) invention is still relevant sixty years on.  Figure 4.5 
shows the departments ‘expert centre’ entry on Ophanet, a database of the rare 
diseases network collated by INSERM under the auspices’ of the European Union. 
 
 
Figure 4.5: Bristol Royal Infirmary listing as an expert centre entry on 
Orphanet. 
 103 
Chapter 5: Reflection and 
Dissemination 
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 5.1 Reflection 
The professional doctorate as offered by the University of Portsmouth is a two 
component course; the first part comprising of a set of taught modules with the 
final part consisting of the project. The taught modules are broadly divided into 
four units:  
 Professional review and development. This is a critical reflection on what has 
been achieved to date with a learning contract to build in what is needed for future 
learning 
 Advanced research techniques. This involved learning a broad range of 
quantitive and qualitive research techniques and included an intermediate 
statistical module. 
 Publication and dissemination. This involved a critical appraisal of previously 
published journal articles, preparing articles for submission and reviewing other 
candidates’ submissions in the role of journal editor.  
 Project proposal. To produce a research proposal for this thesis (included as 
appendix 11) 
 
There are a number of learning theories and associated styles. The first one 
encountered and  the one that seemed particularly relevant whilst undertaking the 
course was Kolbs’ theory (Kolb, 1984) This model of four points of learning and 
the relevance to my learning experience; 
 Unconscious incompetence. In this instance being unaware of the existence of 
the DBMS course 
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 Conscious incompetence: Being aware of the course at University of 
Portsmouth but unsure of the requisite requirements to start studying. 
 Conscious competence: Moving from conscious incompetence to conscious 
competence is the move that most people would equate to ‘learning’, the act of 
doing something to change the perception of a given topic. This equates to 
actively searching out and researching a topic. 
 Unconscious competence: The ability to informally learn, that is acquiring 
information on a topic from outside an official learning environment. 
This was summed up succinctly by Donald Rumsfeld in 2004, with his speech, 
‘we know what we know. We know what we don’t know. We don’t know what we 
don’t know’. 
Informal learning is fun; the process of formalisation of informal learning is an 
anathema.  Reflective practice is something that any good scientist does on a 
regular basis, analyses what is known and unknown and what the incident has 
taught and what has now become a known value. The movement towards 
providing evidence that this task has been done, providing written reports on what 
has been learned, seems to strangle the joy of learning from the process. This 
formalisation of learning could make the career path unattractive for some 
students.  
The professional review module and the publication and dissemination module 
were of particular interest. Working with a mentor who introduced me to the 
publication process and with an interest in IT, the open access debate is something 
that was followed closely. When it came to writing about impact factors and open 
access the submitted course work benefitted from an informal interest and was 
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reflected in the marking. 
Teaching forms a large part of an advanced biomedical scientists role, so the 
knowledge that different people teach and learn in distinctly different ways has 
helped to orientate the appropriate teaching and tutoring methods to the learning 
needs of the individual under instruction.  
Instruction at different levels requires different skills. Preparing a clinical colleague 
as a candidate for MRCPath examinations requires a different skill set and level of 
teaching compared to teaching medical laboratory assistants. Clinical colleagues 
require science based tutoring where as laboratory assistants need to be made aware 
of reagent detail, quality assurance and sample requirements.  Inclusion of 
demonstration of applications and then letting students try that for themselves. 
Being aware that other people need to make notes on a task or need to watch a task 
being performed many times to absorb the information. If this helps the student to 
learn then this is the way it will be demonstrated.  
Figure 5.1 below shows my learning style which is verbal, visual and logical with 
no physical or aural components. 
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Figure 5.1: Learning graph for David Gurney 
 
A PowerPoint exercise (See appendix 4) that enabled trainees to revise outside the 
laboratory environment, reaffirming the theoretical concepts after a practical 
demonstration.  Removing an experienced scientist from a laboratory leaves a 
large gap of knowledge.  An in-house training presentation (appendix 6) was 
given and a platelet interpretation manual (see appendix 10) was written in order 
to ease the transition of the staff taking on the role that had been vacated. 
Presentation skills can only be learned by actually doing them. Previously I have 
only presented once at the UK Platelet group meeting in Leicester in 1999, the 
course honed these skills by requiring regular presentations to the academic group 
as part of the learning experience. These presentations in a safe friendly 
environment increased confidence in the ability to perform these tasks.   That 
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increase in confidence has resulted in invitations to present at Institute of 
Biomedical Sciences (IBMS) biennial congress detailing both platelet diagnostic 
work (case presentation 2005, 2009; appendices 7 and 8) and platelet development 
work (platelet analysis; 2011; appendix 9). The data in these presentations is 
directly related to the work carried out in this thesis. 
In gaining the confidence to present to the wider  profession the data presented 
was advising the profession on laboratory policy. This transition to policy advice 
meant that when offered a seat on the IBMS Haematology specialist advisory 
panel, this was accepted.  Subsequently the chair of the IBMS advisory panel was 
offered and accepted. Special advisory panels are in place to advise both the IBMS 
executive committee and the membership on a range of topics such as quality, 
training, registration, safety and emerging technologies. It has the remit to 
organise and advise on conference content, Institute academic examinations and 
nominate individual for both internal and external committees.  
Learning new techniques, such as flow cytometric analysis of platelet markers, 
platelet nucleotide analysis and nucleotide release analysis, has provided a better 
understanding of both the diagnostic process and the functioning of the platelet. 
The construction of the questionnaire has meant having to communicate with 
many levels of staff (detailed in 3.1).For example this has involved explaining to 
phlebotomy staff why the samples for this assay have to be taken in a specific way 
and explaining to nurses the need for thorough completion of the questionnaire. I 
was also involved with consultant staff in the initial review of the questionnaire 
and its use.  
In this age of consolidation (Carter, 2006) the specialist laboratory will be subject 
to rigorous scrutiny. The expert scientists must deliver value for money, by 
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ensuring that only the correct tests are done, eliminating wasteful testing to reduce 
time and resources. Additionally co-ordinating these tests so that efficient use of 
samples, so as to minimise inconvenience to both patient and clinical team.   It 
must be cost effective, but deliver results in a timely manner. In conclusion, the 
laboratory at Bristol is now able to deliver by a specialist clinical and scientific 
team all on one site. 
5.2 Dissemination 
Dissemination of knowledge has been demonstrated previously in section 4.7, 
however to summarise: 
Training has been given at local levels in both Bristol. (Appendix 5) and St 
Thomas’ (Appendix 6 and 10) across a broad range of staff groups 
Presentations have been given at local level (Appendix 6) and national events 
(Appendix 7-9) 
Interaction with both national (IBMS Haematology advisory panel) and 
international (ISTH Platelet physiology SSC) policy making 
Published work in text book (Moore & Gurney, 2010) 
(http://www.amazon.co.uk/Haematology-Fundamentals-Biomedical-Science-
Moore/dp/0199568839) a book which has been purchased by the department for 
teaching and consequently by a number of the students. 
  
 110 
References
 
  
 111 
Albers, C. A., Cvejic, A., Favier, R., Bouwmans, E. E., Alessi, M.-C., Bertone, P., Jordan, G., 
et al. (2011). Exome sequencing identifies NBEAL2 as the causative gene for gray 
platelet syndrome. Nature genetics, 43(8), 735–7. doi:10.1038/ng.885 
Althaus, K., & Greinacher, A. (2009). MYH9-Related Platelet Disorders. Seminars in 
Thrombosis and Hemostasis, 35(2), 189–203. doi:10.1055/s-0029-1220327 
Aster, R. H. (2005). Drug-induced immune cytopenias. Toxicology, 209(2), 149–53. 
doi:10.1016/j.tox.2004.12.031 
Bain, B. J., & Bhavnani, M. (2011). Gray platelet syndrome. American journal of hematology, 
86(12), 1027. doi:10.1002/ajh.22055 
Baum, S. J. (2012). Evidence-Based Medicine: What’s the Evidence? Clinical cardiology, 
260, 259–260. doi:10.1002/clc.21968 
Bender, M., Hofmann, S., Stegner, D., Chalaris, A., Bösl, M., Braun, A., Scheller, J., et al. 
(2010). Differentially regulated GPVI ectodomain shedding by multiple platelet-
expressed proteinases. Blood, 116(17), 3347–55. doi:10.1182/blood-2010-06-289108 
Ben-Dor, I., Kleiman, N. S., & Lev, E. (2009). Assessment, mechanisms, and clinical 
implication of variability in platelet response to aspirin and clopidogrel therapy. The 
American journal of cardiology, 104(2), 227–33. doi:10.1016/j.amjcard.2009.03.022 
Bernard, J., & Soulier, J. (1948). Sur une nouvelle variété de dystrophie thrombocytaire 
hémorragipare congénitale. Semaine des Hôpitaux de Paris, 24, 3217–3223. 
Blair, P., & Flaumenhaft, R. (2009). Platelet alpha-granules: basic biology and clinical 
correlates. Blood reviews, 23(4), 177–89. doi:10.1016/j.blre.2009.04.001 
Blavignac, J., Bunimov, N., Rivard, G. E., & Hayward, C. P. M. (2011). Quebec platelet 
disorder: update on pathogenesis, diagnosis, and treatment. Seminars in thrombosis and 
hemostasis, 37(6), 713–20. doi:10.1055/s-0031-1291382 
Bolton-Maggs, P. H. B., Chalmers, E. A., Collins, P. W., Harrison, P., Kitchen, S., Liesner, R. 
J., Minford, A., et al. (2006). A review of inherited platelet disorders with guidelines for 
their management on behalf of the UKHCDO. British journal of haematology, 135(5), 
603–33. doi:10.1111/j.1365-2141.2006.06343.x 
Borhany, M., Pahore, Z., Qadr, Z., Rehan, M., Naz, A., Khan, A., & Ansari, S. (2010). 
Bleeding disorders in the tribe : result of consanguineous in breeding. Orphanet Journal 
of Rare Diseases, 1–7. 
Born, G., Cross, M. J., & Fields, I. (1963). The Aggregation of Blood Platelets. J Physiol, 
168, 178–195. 
Born, G. V. R. (1962). Aggregation of Blood Platelets by Adenosine Diphosphate and its 
Reversal. Nature, 194(4832), 927–929. doi:10.1038/194927b0 
 112 
Broos, K., De Meyer, S. F., Feys, H. B., Vanhoorelbeke, K., & Deckmyn, H. (2012). Blood 
platelet biochemistry. Thrombosis research, 129(3), 245–9. 
doi:10.1016/j.thromres.2011.11.002 
Buchanan, G., & Handin, R. (1976). Platelet function in the Chediak-Higashi syndrome. 
Blood, 47(6), 941–948. Retrieved from 
http://bloodjournal.hematologylibrary.org/cgi/content/abstract/47/6/941 
Carter. (2006). Report of the Review of NHS Pathology Services in England (p. 94). Retrieved 
from 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndG
uidance/DH_4137606 
Castilloux, J. F., Moffat, K. A., Liu, Y., Seecharan, J., Pai, M., & Hayward, C. P. M. (2011). 
A prospective cohort study of light transmission platelet aggregometry for bleeding 
disorders: is testing native platelet-rich plasma non-inferior to testing platelet count 
adjusted samples? Thrombosis and haemostasis, 106(4), 675–82. doi:10.1160/TH11-06-
0378 
Cattaneo, Lecchi, A., Randi, a M., McGregor, J. L., & Mannucci, P. M. (1992). Identification 
of a new congenital defect of platelet function characterized by severe impairment of 
platelet responses to adenosine diphosphate. Blood, 80(11), 2787–96. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/1333302 
Cattaneo, M, Hayward, C., Moffat, K., Pugliano, M., Liu, Y., & Michelson, A. (2009). 
Results of a worldwide survey on the assessment of platelet function by light 
transmission aggregometry: a report from the platelet physiology subcommittee of the 
SSC of the ISTH. Journal of thrombosis and haemostasis : JTH, 7(6), 1029. 
doi:10.1111/j.1538-7836.2009.03458.x 
Cattaneo, Marco. (2005). The P2 receptors and congenital platelet function defects. Seminars 
in thrombosis and hemostasis, 31(2), 168–73. doi:10.1055/s-2005-869522 
Cattaneo, Marco, Lecchi, A., Zighetti, M. L., & Lussana, F. (2007). Platelet aggregation 
studies: autologous platelet-poor plasma inhibits platelet aggregation when added to 
platelet-rich plasma to normalize platelet count. Haematologica, 92(5), 694–697. 
doi:10.3324/haematol.10999 
Cazenave, J.-P., Packham, M. A., Guccione, M. A., & Mustard, J. F. (1973). Effects of 
Penicillin G on Platelet Aggregation, Release, and Adherence to Collagen. Proceedings 
of the Society for Experimental Biology and Medicine. Society for Experimental Biology 
and Medicine (New York, N.Y.), 142(1), 159–166. doi:10.3181/00379727-142-36980 
Choi, S. H., Smith, S. a, & Morrissey, J. H. (2011). Polyphosphate is a cofactor for the 
activation of factor XI by thrombin. Blood, 118(26), 6963–70. doi:10.1182/blood-2011-
07-368811 
Christie, J., Avari, T., Carrington, L., Cohen, E., DeBiase, B., Harrison, P., Kickler, T., et al. 
(2008). Platelet Function Testing by Aggregometry; Approved Guideline (Vol. 28). 
Pennsylvania: Clinical & Laboratory Standards Institute. Retrieved from 
 113 
http://www.clsi.org/source/orders/Product_Display.cfm?section=Hematology1&task=3&
CATEGORY=COAG&PRODUCT_TYPE=SALES&SKU=H58A&DESCRIPTION=<f
ont color=“0000a0”>Platelet Function Testing by Aggregometry; Approved 
Guideline</font><br><a  target=“_blank” 
href=“http://www.clsi.org/source/orders/free/h58-A.pdf”>Preview Sample 
Pages</a><br>  This document provides concrete, standard procedures for using 
aggregometry to assess platelet function in patient specimens with the intent to achieve  
Cohen, I., Amir, J., Ben-Shaul, Y., Pick, A., & De Vries, A. (1970). Plasma cell myeloma 
associated with an unusual myeloma protein causing impairment of fibrin aggregation 
and platelet function in a patient with multiple malignancy. The American Journal of 
Medicine, 48(6), 766–776. doi:10.1016/S0002-9343(70)80012-2 
Coller, B. S., & Gralnick, H. R. (1977). Studies on the mechanism of ristocetin-induced 
platelet agglutination. Effects of structural modification of ristocetin and vancomycin. 
The Journal of clinical investigation, 60(2), 302–12. doi:10.1172/JCI108778 
Coppinger, J. A., Cagney, G., Toomey, S., Kislinger, T., Belton, O., McRedmond, J. P., 
Cahill, D. J., et al. (2004). Characterization of the proteins released from activated 
platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. 
Blood, 103(6), 2096–104. doi:10.1182/blood-2003-08-2804 
Cordier, W., & Steenkamp, V. (2012). Herbal remedies affecting coagulation: a review. 
Pharmaceutical biology, 50(4), 443–52. doi:10.3109/13880209.2011.611145 
Cuker, A., Arepally, G., Crowther, M. A., Rice, L., Datko, F., Hook, K., Propert, K. J., et al. 
(2010). The HIT Expert Probability (HEP) Score: a novel pre-test probability model for 
heparin-induced thrombocytopenia based on broad expert opinion. Journal of thrombosis 
and haemostasis : JTH, 8(12), 2642–50. doi:10.1111/j.1538-7836.2010.04059.x 
Curvers, J., De Wildt-Eggen, J., Heeremans, J., Scharenberg, J., De Korte, D., & Van der 
Meer, P. F. (2008). Flow cytometric measurement of CD62P (P-selectin) expression on 
platelets: a multicenter optimization and standardization effort. Transfusion, 48(7), 
1439–46. doi:10.1111/j.1537-2995.2008.01738.x 
Davidson, C., Colvin, B., Barrowcliffe, T. W., Dawson, D., Machin, S., Poller, L., Preston, F., 
et al. (1988). Guidelines on platelet function testing. Journal of clinical pathology, 
41(12), 1322–30. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1141768&tool=pmcentrez&r
endertype=abstract 
Dawood, B. B., Wilde, J., & Watson, S. P. (2007). Reference curves for aggregation and ATP 
secretion to aid diagnose of platelet-based bleeding disorders: effect of inhibition of ADP 
and thromboxane A(2) pathways. Platelets, 18(5), 329–45. 
doi:10.1080/09537100601024111 
Di Michele, M., Van Geet, C., & Freson, K. (2012). Recent advances in platelet proteomics. 
Expert review of proteomics, 9(4), 451–66. doi:10.1586/epr.12.31 
 114 
Diamandis, M., Veljkovic, D., Maurer-Spurej, E., Rivard, G., & Hayward, C. (2008). Quebec 
platelet disorder: features, pathogenesis and treatment. Blood Coagulation & 
Fibrinolysis, 19(2), 109–119. doi:10.1097/MBC.0b013e3282f41e3e 
Dickson, B. C. (2009). Virchow’s triad. British journal of haematology, 145(3), 433. 
doi:10.1111/j.1365-2141.2009.07617.x 
Dietrich-Muszalska, A., Rabe-Jablonska, J., Nowak, P., & Kontek, B. (2010). The first- and 
second-generation antipsychotic drugs affect ADP-induced platelet aggregation. The 
world journal of biological psychiatry : the official journal of the World Federation of 
Societies of Biological Psychiatry, 11(2 Pt 2), 268–75. doi:10.3109/15622970802505792 
Din, J. N., Harding, S. A., Valerio, C. J., Sarma, J., Lyall, K., Riemersma, R. A., Newby, D. 
E., et al. (2008). Dietary intervention with oil rich fish reduces platelet-monocyte 
aggregation in man. Atherosclerosis, 197(1), 290–6. 
doi:10.1016/j.atherosclerosis.2007.04.047 
Dumont, B., Lasne, D., Rothschild, C., Bouabdelli, M., Ollivier, V., Oudin, C., Ajzenberg, N., 
et al. (2009). Absence of collagen-induced platelet activation caused by compound 
heterozygous GPVI mutations. Blood, 114(9), 1900–3. doi:10.1182/blood-2009-03-
213504 
Elzey, B. D., Tian, J., Jensen, R. J., Swanson, A. K., Lees, J. R., Lentz, S. R., Stein, C. S., et 
al. (2003). Platelet-mediated modulation of adaptive immunity. A communication link 
between innate and adaptive immune compartments. Immunity, 19(1), 9–19. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/12871635 
Farndale, R. W. (2006). Collagen-induced platelet activation. Blood cells, molecules & 
diseases, 36(2), 162–5. doi:10.1016/j.bcmd.2005.12.016 
Favier, R., Jondeau, K., Boutard, P., Grossfeld, P., Reinert, P., Jones, C. C., Bertoni, F., et al. 
(2003). Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new 
cases. Thrombosis and haemostasis, 90(5), 893–7. doi:10.1267/THRO03050893 
Flores-Nascimento, M., Orsi, F., Yokoyama, A., Pereira, F., Lorand-Metze, I., De Paula, E., 
Castro, V., et al. (2012). Diagnosis of Scott syndrome in patient with bleeding disorder 
of unknown cause. Blood coagulation & fibrinolysis : an international journal in 
haemostasis and thrombosis, 23(1), 75–7. doi:10.1097/MBC.0b013e32834d0c81 
Franchini, M., Favaloro, E. J., & Lippi, G. (2010). Glanzmann thrombasthenia: an update. 
Clinica chimica acta; international journal of clinical chemistry, 411(1-2), 1–6. 
doi:10.1016/j.cca.2009.10.016 
Freson, K., Izzi, B., & Van Geet, C. (2012). From genetics to epigenetics in platelet research. 
Thrombosis research, 129(3), 325–9. doi:10.1016/j.thromres.2011.11.050 
Furness, P. (2011). How to Assess the Quality of a Pathology Service (pp. 1–20). 
Gardiner, E. E., Arthur, J. F., Shen, Y., Karunakaran, D., Moore, L. A., Am Esch, J. S., 
Andrews, R. K., et al. (2010). GPIbalpha-selective activation of platelets induces platelet 
 115 
signaling events comparable to GPVI activation events. Platelets, 21(4), 244–52. 
doi:10.3109/09537101003695339 
Gazzaniga, V., & Ottini, L. (2001). The discovery of platelets and their function. History, (9), 
22–26. 
George, J. N., Caen, J. P., & Nurden, A. (1990). Glanzmann’s thrombasthenia: the spectrum 
of clinical disease. Blood, 75(7), 1383–1395. 
Glanzmann, E. (1918). Hereditäre hämorrhägische Thrombasthenie. Ein Beitrag zur 
Pathologie der Blutplättchen. Jahrbuch für Kinderheilkunde,, 88, 1–42. 
Glas, M., Mauer, D., Kassas, H., Volk, T., & Kreuer, S. (2012). Sample transport by 
pneumatic tube system alters results of multiple electrode aggregometry but not 
rotational thromboelastometry. Platelets, (July), 1–8. 
doi:10.3109/09537104.2012.718383 
Görög, P., & Ahmed, A. (1984). Haemostatometer: a new in vitro technique for assessing 
haemostatic activity of blood. Thrombosis research, 34(4), 341–57. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/6740567 
Gurbel, P. a, Bliden, K. P., DiChiara, J., Newcomer, J., Weng, W., Neerchal, N. K., Gesheff, 
T., et al. (2007). Evaluation of dose-related effects of aspirin on platelet function: results 
from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation, 115(25), 3156–
64. doi:10.1161/CIRCULATIONAHA.106.675587 
Gurney, D. (2004). Platelet controls: Food for thought. Biomedical Scientist, 48(3), 275–276. 
Gurney, D. A. (2006). Ask and you will find. Biomedical Scientist, 50(2), 157 – 159. 
Retrieved from http://www.ibms.org/go/media/the-biomedical-
scientist/archive,2006,02,70 
Gurney, D., Lip, G., & Blann, A. (2002). A reliable plasma marker of platelet activation: does 
it exist? American journal of hematology, 70(2), 139–44. doi:10.1002/ajh.10097 
Harrison, P. (2009). Assessment of platelet function in the laboratory Platelet aggregometry. 
Hämostaseologie, (37), 1–6. 
Harrison, P., Mackie, I., Mumford, A., Briggs, C., Liesner, R., Winter, M., & Machin, S. 
(2011). Guidelines for the laboratory investigation of heritable disorders of platelet 
function. British journal of haematology, 155(1), 30–44. doi:10.1111/j.1365-
2141.2011.08793.x 
Harrison, P., & Martin Cramer, E. (1993). Platelet α-granules. Blood Reviews, 7(1), 52–62. 
doi:10.1016/0268-960X(93)90024-X 
Hayward, C., Pai, M., Liu, Y., Moffat, K., Seecharan, J., Webert, K., Cook, R., et al. (2009). 
Diagnostic utility of light transmission platelet aggregometry: results from a prospective 
study of individuals referred for bleeding disorder assessments. Journal of thrombosis 
and haemostasis : JTH, 7(4), 676–84. doi:10.1111/j.1538-7836.2009.03273.x 
 116 
Hayward, C., Plumhoff, E., Timleck, M., Hoffman, S., Spitzer, E., Van Cott, E., & Meijer, P. 
(2012). External Quality Assessment of Platelet Disorder Investigations: Results of 
International Surveys on Diagnostic Tests for Dense Granule Deficiency and Platelet 
Aggregometry Interpretation. Seminars in thrombosis and hemostasis, (C). 
doi:10.1055/s-0032-1319767 
Hayward, C., & Rivard, G. (2011). Quebec platelet disorder. Expert review of hematology, 
4(2), 137–41. doi:10.1586/ehm.11.5 
Hayward, C.P.M. (2008). Diagnostic approach to platelet function disorders. Transfusion and 
Apheresis Science, 38(1), 65–76. doi:10.1016/j.transci.2007.12.009 
Hayward, Catherine P M, & Eikelboom, J. (2007). Platelet function testing: quality assurance. 
Seminars in thrombosis and hemostasis, 33(3), 273–82. doi:10.1055/s-2007-971814 
Heptinstall, S., White, a, Edwards, N., Pascoe, J., Sanderson, H. M., Fox, S. C., & Henderson, 
R. a. (1998). Differential effects of three radiographic contrast media on platelet 
aggregation and degranulation: implications for clinical practice? British journal of 
haematology, 103(4), 1023–30. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9886314 
Hirata, T., Kakizuka, A., Ushikubi, F., Fuse, I., Okuma, M., & Narumiya, S. (1994). Arg60 to 
Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding 
disorder. The Journal of clinical investigation, 94(4), 1662–7. doi:10.1172/JCI117510 
Iciek, M., Kwiecień, I., & Włodek, L. (2009). Biological properties of garlic and garlic-
derived organosulfur compounds. Environmental and molecular mutagenesis, 50(3), 
247–65. doi:10.1002/em.20474 
Jakubowski, J., Payne, C., Li, Y. G., Farid, N., Brandt, J., Small, D., Salazar, D., et al. (2008). 
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as 
assessed by VASP-phosphorylation and light transmission aggregometry. Thrombosis 
and haemostasis, 99(1), 215–22. doi:10.1160/TH07-09-0555 
Jedlitschky, G., Cattaneo, M., Lubenow, L. E., Rosskopf, D., Lecchi, A., Artoni, A., Motta, 
G., et al. (2010). Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: 
evidence from patients with delta-storage pool deficiencies. The American journal of 
pathology, 176(3), 1097–103. doi:10.2353/ajpath.2010.090425 
Jennings, I., Woods, T. a L., Kitchen, S., & Walker, I. D. (2008). Platelet function testing: 
practice among UK National External Quality Assessment Scheme for Blood 
Coagulation participants, 2006. Journal of clinical pathology, 61(8), 950–4. 
doi:10.1136/jcp.2008.057174 
Jennings, L., Ashmun, R., Wang, W., & Dockter, M. (1986). Analysis of human platelet 
glycoproteins IIb-IIIa and Glanzmann’s thrombasthenia in whole blood by flow 
cytometry, 68, 173–179. 
Jones, M. L., Murden, S. L., Bem, D., Mundell, S. J., Gissen, P., Daly, M. E., Watson, S. P., 
et al. (2011). Rapid Genetic Diagnosis of Heritable Platelet Function Disorders Using 
 117 
Next Generation Sequencing: Proof-of-Principle With Hermansky-Pudlak Syndrome. 
Journal of Thrombosis and Haemostasis, no–no. doi:10.1111/j.1538-7836.2011.04569.x 
Kaiser, A. F. C., Neubauer, H., Franken, C. C., Krüger, J.-C., Mügge, A., & Meves, S. H. 
(2011). Which is the best anticoagulant for whole blood aggregometry platelet function 
testing? Comparison of six anticoagulants and diverse storage conditions. Platelets, 
(July), 1–9. doi:10.3109/09537104.2011.624211 
Kambayashi, J., Shinoki, N., Nakamura, T., Ariyoshi, H., Kawasaki, T., Sakon, M., & 
Monden, M. (1996). Prevalence of impaired responsiveness to epinephrine in platelets 
among Japanese. Thrombosis research, 81(1), 85–90. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8747523 
Kaplan, J., De Domenico, I., & Ward, D. M. (2008). Chediak-Higashi syndrome. Current 
opinion in hematology, 15(1), 22–9. doi:10.1097/MOH.0b013e3282f2bcce 
Khawaja, O., Gaziano, J. M., & Djoussé, L. (2011). Chocolate and coronary heart disease: a 
systematic review. Current atherosclerosis reports, 13(6), 447–52. doi:10.1007/s11883-
011-0203-2 
Kim, K., Lim, K.-M., Kim, C.-W., Shin, H.-J., Seo, D.-B., Lee, S.-J., Noh, J.-Y., et al. (2011). 
Black soybean extract can attenuate thrombosis through inhibition of collagen-induced 
platelet activation. The Journal of nutritional biochemistry, 22(10), 964–70. 
doi:10.1016/j.jnutbio.2010.08.008 
Kobzar, G., Mardla, V., Rätsep, I., & Samel, N. (2009). Effect of vitamin B(6) vitamers on 
platelet aggregation. Platelets, 20(2), 120–4. doi:10.1080/09537100802687674 
Kohro, S., & Yamakage, M. (1996). Direct inhibitory mechanisms of halothane on human 
platelet aggregation. Anesthesiology. Retrieved from 
http://journals.lww.com/anesthesiology/Abstract/1996/07000/Direct_Inhibitory_Mechani
sms_of_Halothane_on_Human.14.aspx 
Kolb, D. (1984). Experiential learning: Experience as the source of learning and 
development.No Title. 
Kundu, S., Heilmann, E., Sio, R., Garcia, C., Davidson, R., & Ostgaard, R. (1995). 
Description of an in vitro platelet function analyzer--PFA-100. Seminars in thrombosis 
and hemostasis, 21 Suppl 2, 106–112. 
Kwaan, H. C., & Vicuna, B. (2007). Thrombosis and bleeding in cancer patients. Oncology 
Reviews, 1(1), 14–27. doi:10.1007/s12156-007-0003-7 
Lehman, C. M., Blaylock, R. C., Alexander, D. P., & Rodgers, G. M. (2001). Discontinuation 
of the bleeding time test without detectable adverse clinical impact. Clinical chemistry, 
47(7), 1204–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11427450 
Lentz, B. R. (2003). Exposure of platelet membrane phosphatidylserine regulates blood 
coagulation. Progress in Lipid Research, 42(5), 423–438. doi:10.1016/S0163-
7827(03)00025-0 
 118 
Li, C. K. N., Hoffmann, T. J., Hsieh, P. Y., Malik, S., & Watson, W. C. (1998). The Xylum 
clot signature analyzer®: A dynamic flow system that simulates vascular injury•. 
Thrombosis research, 92(6), S67–S77. Retrieved from 
http://www.sciencedirect.com/science/article/pii/S0049384898001637 
Mani, H., Luxembourg, B., Kläffling, C., Erbe, M., & Lindhoff-Last, E. (2005). Use of native 
or platelet count adjusted platelet rich plasma for platelet aggregation measurements. 
Journal of clinical pathology, 58(7), 747–50. doi:10.1136/jcp.2004.022129 
Marcus, P. D., Nire, K. G., Grooms, L., Klima, J., & O’Brien, S. H. (2010). The power of a 
standardized bleeding score in diagnosing paediatric type 1 von Willebrand’s disease and 
platelet function defects. Haemophilia, no–no. doi:10.1111/j.1365-2516.2010.02390.x 
Masliah-Planchon, J., Darnige, L., & Bellucci, S. (2012). Molecular determinants of platelet 
delta storage pool deficiencies: an update. British journal of haematology, 160(1), 5–11. 
doi:10.1111/bjh.12064 
Matsuno, K., Furukawa, M., & Terada, H. (1984). Electrical measurement of platelet 
aggregation using a whole-blood aggregometer. Rinsho byori The Japanese journal of 
clinical pathology, 32(9), 1029–1033. 
Maynard, D. M., Heijnen, H. F. G., Gahl, W. A., & Gunay-Aygun, M. (2010). The α-granule 
proteome: novel proteins in normal and ghost granules in gray platelet syndrome. 
Journal of thrombosis and haemostasis : JTH, 8(8), 1786–96. doi:10.1111/j.1538-
7836.2010.03932.x 
Michelson, A. D. (1996). Flow cytometry: A clinical test of platelet function. Blood, 87(12), 
4925–4935. 
Mickenautsch, S. (2010). Systematic reviews, systematic error and the acquisition of clinical 
knowledge. BMC Medical Research Methodology, 10(1), 53. doi:10.1186/1471-2288-10-
53 
Mills, D., & Thomas, D. (1969). Blood Platelet Nucleotides in Man and Other Species. 
Nature, 222(5197), 991–992. doi:10.1038/222991a0 
Moffat, K., Ledford-Kraemer, M., Nichols, W., & Hayward, C. (2005). Variability in clinical 
laboratory practice in testing for disorders of platelet function: results of two surveys of 
the North American Specialized Coagulation Laboratory Association. Thrombosis and 
haemostasis, 93(3), 549–53. doi:10.1267/THRO05030549 
Moore, G. W., & Gurney, D. A. (2010). Bleeding disorders and their laboratory investigation. 
In A. B. Gary Moore, Gavin Knight (Ed.), Haematology (Fundamentals in Biomedical 
Science) (1st ed., pp. 473–525). Oxford: OUP Oxford. Retrieved from 
http://www.amazon.co.uk/Haematology-Fundamentals-Biomedical-Science-
Moore/dp/0199568839 
Mumford, A. D. (2009). How useful is light transmission platelet aggregometry for the 
diagnosis of bleeding disorders? Journal of thrombosis and haemostasis : JTH, 7(4), 
673–5. doi:10.1111/j.1538-7836.2009.03276.x 
 119 
Mumford, A., Dawood, B., Daly, M., Murden, S., Williams, M., Protty, M., Spalton, J., et al. 
(2010). A novel thromboxane A2 receptor D304N variant that abrogates ligand binding 
in a patient with a bleeding diathesis. Blood, 115(2), 363–9. doi:10.1182/blood-2009-08-
236976 
Mustard, J. F. Kinlough-Rathbone R.L., P. M. . (2002). History of Platelets. Platelets in 
Thrombotic and Non-thrombotic Disorders (pp. 3–24). 
Notarangelo, L. D., Miao, C. H., & Ochs, H. D. (2008). Wiskott-Aldrich syndrome. Current 
opinion in hematology, 15(1), 30–6. doi:10.1097/MOH.0b013e3282f30448 
Nurden, A., & Caen, J. (1974). An Abnormal Platelet Glycoprotein Pattern in Three Cases of 
Glanzmann’s Thrombasthenia. British Journal of Haematology, 28(2), 253–260. 
doi:10.1111/j.1365-2141.1974.tb06660.x 
Nurden, A., Fiore, M., Pillois, X., & Nurden, P. (2009). Genetic testing in the diagnostic 
evaluation of inherited platelet disorders. Seminars in thrombosis and hemostasis, 35(2), 
204–212. doi:10.1055/s-0029-1220328 
Nurden, A. T., Freson, K., & Seligsohn, U. (2012). Inherited platelet disorders. Haemophilia : 
the official journal of the World Federation of Hemophilia, 18 Suppl 4, 154–60. 
doi:10.1111/j.1365-2516.2012.02856.x 
Ochs, H. D., & Thrasher, A. J. (2006). The Wiskott-Aldrich syndrome. The Journal of allergy 
and clinical immunology, 117(4), 725–38; quiz 739. doi:10.1016/j.jaci.2006.02.005 
Orozco, A., & Lewis, D. (2010). Flow cytometric analysis of circulating microparticles in 
plasma. Cytometry. Part A : the journal of the International Society for Analytical 
Cytology, 77(6), 502–14. doi:10.1002/cyto.a.20886 
Ozsavci, D., Yardimci, T., Demirel, G., Demiralp, E., Uras, F., & Onder, E. (2002). Flow 
cytometric assay of platelet glycoprotein receptor numbers in hypercholesterolemia. 
Platelets, 13(4), 223–229. doi:10.1080/09537100220146866 
Pamukcu, B., Oflaz, H., Onur, I., Cimen, A., & Nisanci, Y. (2011). Effect of cigarette 
smoking on platelet aggregation. Clinical and applied thrombosis/hemostasis : official 
journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 
17(6), E175–80. doi:10.1177/1076029610394440 
Paola, J. Di, Johnson, J., Ph, D., & Di Paola, J. (2011). Thrombocytopenias Due to Gray 
Platelet Syndrome or THC2 Mutations. Seminars In Thrombosis And Hemostasis, 37(6), 
690–7. doi:10.1055/s-0031-1291379 
Paul, B. Z., Jin, J., & Kunapuli, S. P. (1999). Molecular mechanism of thromboxane A(2)-
induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. The 
Journal of biological chemistry, 274(41), 29108–14. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10506165 
 120 
Phillips, D., Jenkins, C., Luscher, E., & Larriau, M. (1975). Molecular differences of exposed 
surface proteins on thrombasthenic platelet plasma membranes. Nature, 257(5527), 599–
600. doi:10.1038/257599a0 
Podda, G., Femia, E. A., Pugliano, M., & Cattaneo, M. (2012). Congenital defects of platelet 
function. Platelets, 23(7), 552–63. doi:10.3109/09537104.2012.724737 
Polgár, J., Clemetson, J. M., Kehrel, B. E., Wiedemann, M., Magnenat, E. M., Wells, T. N., & 
Clemetson, K. J. (1997). Platelet activation and signal transduction by convulxin, a C-
type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the 
p62/GPVI collagen receptor. The Journal of biological chemistry, 272(21), 13576–83. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9153205 
Price, E., Hayward, C., Moffat, K., Moore, J., Warkentin, T., & Zehnder, J. (2007). 
Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North 
America: A survey of North American specialized coagulation laboratories. Thrombosis 
and Haemostasis, 1357–1361. doi:10.1160/TH07-06-0401 
Rao, a K., Willis, J., Kowalska, M. a, Wachtfogel, Y. T., & Colman, R. W. (1988). 
Differential requirements for platelet aggregation and inhibition of adenylate cyclase by 
epinephrine. Studies of a familial platelet alpha 2-adrenergic receptor defect. Blood, 
71(2), 494–501. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2827817 
Remuzzi, G., Livio, M., Marchiaro, G., Mecca, G., & De Gaetano, G. (1978). Bleeding in 
Renal Failure: Altered Platelet Function in Chronic Uraemia only Partially Corrected by 
Haemodialysis. Nephron, 22(4-6), 347–353. doi:10.1159/000181474 
Rodeghiero, F., Tosetto, a, Abshire, T., Arnold, D. M., Coller, B., James, P., Neunert, C., et 
al. (2010). ISTH/SSC Bleeding Assessment Tool: A Standardized Questionnaire and a 
Proposal for a New Bleeding Score for Inherited Bleeding Disorders. Journal of 
thrombosis and haemostasis : JTH, 2063–2065. doi:10.1111/j.1538-7836.2010.03975.x 
Rodgers, R. P. C., & Levin, J. (1990). A Critical Reappraisal of the Bleeding Time *, 16(1), 
1–20. 
Ruiz, F. a, Lea, C. R., Oldfield, E., & Docampo, R. (2004). Human platelet dense granules 
contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular 
eukaryotes. The Journal of biological chemistry, 279(43), 44250–7. 
doi:10.1074/jbc.M406261200 
Rydz, N., & James, P. D. (2012). The Evolution and value of bleeding assessment tools. 
Journal of thrombosis and haemostasis : JTH. doi:10.1111/j.1538-7836.2012.04923.x 
Satta, N., Toti, F., Fressinaud, E., Meyer, D., & Freyssinet, J. M. (1997). Scott syndrome: an 
inherited defect of the procoagulant activity of platelets. Platelets, 8(2-3), 117–24. 
doi:10.1080/09537109709169326 
Schmitz, G., Rothe, G., Ruf, A., Barlage, S., Tschöpe, D., Clemetson, K. J., Goodall, A. H., et 
al. (1998). European Working Group on Clinical Cell Analysis: Consensus protocol for 
 121 
the flow cytometric characterisation of platelet function. Thrombosis and haemostasis, 
79(5), 885–96. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9609215 
Shenkman, B., Einav, Y., Salomon, O., Varon, D., & Savion, N. (2008). Testing agonist-
induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]. 
Platelets, 19(6), 440–446. doi:10.1080/09537100802082256 
Siddiq, S., Clark, A., & Mumford, A. (2011). A systematic review of the management and 
outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia : the official journal 
of the World Federation of Hemophilia, 17(5), e858–69. doi:10.1111/j.1365-
2516.2011.02516.x 
Smith, J. W., Steinhubl, S. R., Lincoff, a. M., Coleman, J. C., Lee, T. T., Hillman, R. S., & 
Coller, B. S. (1999). Rapid Platelet-Function Assay : An Automated and Quantitative 
Cartridge-Based Method. Circulation, 99(5), 620–625. doi:10.1161/01.CIR.99.5.620 
Solum, N. O. (1999). Procoagulant Expression in Platelets and Defects Leading to Clinical 
Disorders. Arterioscler Thromb Vasc Biol, 19(12), 2841–2846. Retrieved from 
http://atvb.ahajournals.org/cgi/content/abstract/19/12/2841 
Son, D.-J., Cho, M.-R., Jin, Y.-R., Kim, S.-Y., Park, Y.-H., Lee, S.-H., Akiba, S., et al. 
(2004). Antiplatelet effect of green tea catechins: a possible mechanism through 
arachidonic acid pathway. Prostaglandins, leukotrienes, and essential fatty acids, 71(1), 
25–31. doi:10.1016/j.plefa.2003.12.004 
Srivastava, K. C. (1989). Extracts from two frequently consumed spices — Cumin (Cuminum 
cyminum) and turmeric (Curcuma longa) — Inhibit platelet aggregation and alter 
eicosanoid biosynthesis in human blood platelets. Prostaglandins, Leukotrienes and 
Essential Fatty Acids, 37(1), 57–64. doi:10.1016/0952-3278(89)90187-7 
Toshima, H., Sugihara, H., Hamano, H., Sato, M., Yamamoto, M., Yamazaki, S., Yamada, Y., 
et al. (2008). Spontaneous platelet aggregation in normal subject assessed by a laser light 
scattering method: an attempt at standardization. Platelets, 19(4), 293–9. 
doi:10.1080/09537100701883457 
Toth, J., Kappelmayer, J., Udvardy, M. L., Szanto, T., Szarvas, M., Rejto, L., Soltesz, P., et 
al. (2009). Increased platelet glycoprotein Ib receptor number, enhanced platelet 
adhesion and severe cerebral ischaemia in a patient with polycythaemia vera. Platelets, 
20(4), 282–287. doi:10.1080/09537100902878421 
Tubman, V. N., Levine, J. E., Campagna, D. R., Monahan-Earley, R., Dvorak, A. M., 
Neufeld, E. J., & Fleming, M. D. (2007). X-linked gray platelet syndrome due to a 
GATA1 Arg216Gln mutation. Blood, 109(8), 3297–9. doi:10.1182/blood-2006-02-
004101 
Van Velzen, J. F., Laros-van Gorkom, B. a P., Pop, G. a M., & Van Heerde, W. L. (2012). 
Multicolor flow cytometry for evaluation of platelet surface antigens and activation 
markers. Thrombosis research, 130(1), 92–98. doi:10.1016/j.thromres.2012.02.041 
 122 
Varga-Szabo, D., Pleines, I., & Nieswandt, B. (2008). Cell Adhesion Mechanisms in Platelets. 
Arterioscler Thromb Vasc Biol, 28(3), 403–412. doi:10.1161/ATVBAHA.107.150474 
Varon, D., Dardik, R., Shenkman, B., Kotev-Emeth, S., Farzame, N., Tamarin, I., & Savion, 
N. (1997). A new method for quantitative analysis of whole blood platelet interaction 
with extracellular matrix under flow conditions. Thrombosis research, 85(4), 283–294. 
Vasin, S. L., Titushkin, I. a, & Sevastianov, V. I. (2003). Mathematical model of static 
platelet adhesion on a solid surface. Journal of biomedical materials research. Part A, 
67(2), 582–90. doi:10.1002/jbm.a.10112 
Violi, F., Pignatelli, P., & Basili, S. (2010). Nutrition, Supplements, and Vitamins in Platelet 
Function and Bleeding. Circulation, 121(8), 1033–1044. 
doi:10.1161/CIRCULATIONAHA.109.880211 
Vucinic, L., Singh, I., Spargo, F. J., Hawley, J. A., & Linden, M. D. (2010). Gamma 
tocopherol supplementation prevents exercise induced coagulation and platelet 
aggregation. Thrombosis research, 125(2), 196–199. doi:10.1016/j.thromres.2009.11.015 
Wagner, C. L., Mascelli, M. a, Neblock, D. S., Weisman, H. F., Coller, B. S., & Jordan, R. E. 
(1996). Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to 
human platelets. Blood, 88(3), 907–14. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8704248 
Walker, M., Payne, J., Wagner, B., & Vora, A. (2007). Hermansky-Pudlak syndrome. British 
journal of haematology, 138(6), 671. doi:10.1111/j.1365-2141.2007.06713.x 
Wallen, N. H., Ladjevardi, M., Albert, J., & Broijersen, A. (1997). Influence of different 
anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low 
molecular mass heparin and hirudin. Thrombosis research, 87(1), 151–157. Retrieved 
from http://www.sciencedirect.com/science/article/pii/S004938489700114X 
Warkentin, T. (2006). Think of HIT. Hematology / the Education Program of the American 
Society of Hematology. American Society of Hematology. Education Program, 408–14. 
doi:10.1182/asheducation-2006.1.408 
Warkentin, T. E., & Greinacher, A. (2004). Heparin-Induced Thrombocytopenia: 
Recognition, Treatment, and Prevention. Chest, 126(3 suppl), 311S–337S. 
doi:10.1378/chest.126.3_suppl.311S 
Weiss, E. J., Goldschmidt-Clermont, P. J., Grigoryev, D., Jin, Y., Kickler, T. S., & Bray, P. F. 
(1995). A monoclonal antibody (SZ21) specific for platelet GPIIIa distinguishes P1 A1 
from Pl A2. Tissue Antigens, 46(5), 374–381. doi:10.1111/j.1399-0039.1995.tb03129.x 
Weyrich, A., Lindemann, S., & Zimmerman, G. (2003). The evolving role of platelets in 
inflammation. Journal of thrombosis and haemostasis : JTH, 1(9), 1897–905. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/12941029 
Witters, P., Freson, K., Verslype, C., Peerlinck, K., Hoylaerts, M., Nevens, F., Van Geet, C., 
et al. (2008). Review article: blood platelet number and function in chronic liver disease 
 123 
and cirrhosis. Alimentary pharmacology & therapeutics, 27(11), 1017–29. 
doi:10.1111/j.1365-2036.2008.03674.x 
Yaguchi, a, Lobo, F. L. M., Vincent, J.-L., & Pradier, O. (2004). Platelet function in sepsis. 
Journal of thrombosis and haemostasis : JTH, 2(12), 2096–102. doi:10.1111/j.1538-
7836.2004.01009.x 
Yardumian, D. A., Mackie, I. J., & Machin, S. J. (1986). Laboratory investigation of platelet 
function: a review of methodology. Journal of clinical pathology, 39(7), 701–12. 
Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=500028&tool=pmcentrez&re
ndertype=abstract 
Yeaman, M. R. (2010). Platelets in defense against bacterial pathogens. Cellular and 
molecular life sciences CMLS, 67(4), 525–544. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2809947&tool=pmcentrez&r
endertype=abstract 
Zangari, M., Elice, F., Fink, L., Tricot, G., & Ph, D. (2007). Hemostatic Dysfunction in 
Paraproteinemias and Amyloidosis, 1(212), 339–349. doi:10.1055/s-2007-976169. 
Zufferey, A., Fontana, P., Reny, J., Nolli, S., & Sanchez, J.-C. (2011). Platelet proteomics. 
Mass spectrometry reviews, 31(2), 331–51. doi:10.1002/mas.20345 
 
 
 
 
 
 
 
 
 
 
 
     
  
  
    Appendices
  
 Appendix 1: Agenda for PAP User group 
 
 
  
 
Appendix 2: Presentation for PAP User group 
Minimising pre-analytical variability 
in platelet aggregation studies:
The Pre test questionnaire
David Gurney MSc CSci FIBMS
Audience Participation Questions
Do you trust your clinical team to ask the right questions?
Do you run a control with your patient?
Do you ask your control the right questions?
 
 
 
Questionnaire for all platelet aggregation patients & controls 
 
Question Response 
Are you taking?  
 Aspirin (within the last 14 days MINIMUM)  
 OTC Cold Relief Medication e.g. Lemsip  
 Ibuprofen  
On Any of the Prescription Medication below?  
COX1 inhibitors (indomethicin, sulfinpyrazone, naproxen) ADP receptor 
agonists,(ticlopidine, clopidogrel) GPIIb/IIIa agonists, (Rheopro, tirofiban, 
eptitifabatide, Intelligrin) Prostaglandins (Cliostazol), Tri-cyclic 
antidepressants (Imipramine, amitripyline) 
 
 
 
 
If the PATIENT has answered YES to the above please reschedule. 
If the CONTROL has answered YES please find another volunteer. 
 
On any other current prescription medication? Please 
circle relevant drugs. 
 Penicillin, ampicillin, propranolol, atenolol, captopril, perindopril, 
anaesthesia,  
 
 
Are you currently taking vitamin supplements? If yes 
tick or circle if listed below 
Vitamins B6, C, E all affect platelets 
 
 
 
Are you taking dietary supplements or herbal 
remedies? If yes please tick or circle if listed below: 
Starflower oil, Fish oil, Ginko Biloba and Green Tea 
all have platelet antagonistic ingredients   
 
 
 
 
 
Have you had a take-away within the last 48 hours? 
Elements in Turmeric, Cumin, Onion, Garlic, Ginger, 
Clove, black tree fungus & monosodium glutamate all 
affect platelets. 
 
Do you drink or smoke? 
Alcohol, Caffeine & Smoking have been known to 
affect platelets 
 
Was this a clean Draw?  
 
Part 1
Part 2
Part 3
Part 4
Part 1
Have you taken 
aspirin Mrs 
Jones?
 
 
Part 1
Part 2
Other anti-platelet agents
COX1 inhibitors (indomethicin, sulfinpyrazone, naproxen)
ADP receptor agonists,(ticlopidine, clopidogrel, prasagrel) 
GPIIb/IIIa agonists, (Rheopro(abiximab)), tirofiban, 
eptitifabatide, Intelligrin) 
 
 
  
Part 3
Other prescription drugs
On any other current prescription medication? 
Penicillin: Reversible prevention of GPIb/VWF 
binding 
Ampicillin Beta Lactam Antibiotics
Blocking surface receptors
Propranolol/Atenolol Beta blockers
Inhibition of secondary aggregation 
and release
Part 3
Other prescription drugs
Captopril/Perindopril ACE Inhibitors
Decrease in TxA2
Anaesthesia Halothane
Imipramine/ Amitripyline Tri-cyclic antidepressants
Inhibit aggregation responses to 
ADP, epinephrine and collagen
Prozac
 
 
Part 4
Vitamin B6 down regulates GPIIb/IIIa
Other agents affecting platelet function: Vitamins
Vitamin E interferes with Arachidonate metabolism
Part 4
Other agents affecting platelet function: Diet
Green Tea
Red WineChocolate
 
 
Part 4
Other agents affecting platelet function: Diet
Onion/Garlic inhibit collagen binding and cyclo-
oxgenase activity
Red Wine
The "Wine, Nutrition & Health" Unit of the "Office International de la Vigne et du Vin", intergovernmental organization, 
Ruf JC. Alcohol, wine and platelet function. Biol Res. 2004;37(2):209-15.
M. Ali, T. Bordia, T. Mustafa Effect of raw versus boiled aqueous extract of garlic and onion on platelet 
aggregation
Prostaglandins, Leukotrienes and Essential Fatty Acids, Volume 60, Issue 1, January 1999, Pages 43-47
“Mediterranean diet”
Part 4
Other agents affecting platelet function: Diet
Ginger: Reduction in thromboxane production
Clove: Competition for arachidonate
Turmeric/Cumin: Disruption to thromboxane 
biosynthesis
M. Thomson et al  The use of ginger (Zingiber officinale Rosc.) as a potential anti-
inflammatory and antithrombotic agent
Prostaglandins, Leukotrienes and Essential Fatty Acids, Volume 67, Issue 6, December 
2002, Pages 475-478
K. C. Srivastava  Antiplatelet principles from a food spice clove (Syzgium aromaticum L)
Prostaglandins, Leukotrienes and Essential Fatty Acids, Volume 48, Issue 5, May 1993, Pages 363-372
Shah  et al  Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and 
arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ 
signaling. Biochem Pharmacol. 1999 Oct 1;58(7):1167-72 
 
 
Part 4
Other agents affecting platelet function: Diet
Starflower oil: High in Omega 6 and Soy 
Lecithin
Green Tea: catechins inhibit collagen 
arachidonate & U46619
Dong-Ju Son et al:  Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid 
pathway.  Prostaglandins, Leukotrienes and Essential Fatty Acids Volume 71, Issue 1, July 2004, Pages 25-31 
Part 4
Other agents affecting platelet function: Diet
Daily prickly pear consumption improves platelet function 
R. Wolframa, A. Budinskyb, Y. Efthimiouc, J. Stomatopoulosc, A. Oguoghod, 1 and H. Sinzinger
Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 69, Issue 1, July 2003, Pages 61-66 
Platelet activating factor and lyso-phosphatidylcholines from 
strawberry.
Calligerou M, Siafaka-Kapadai A, Galanopoulou D, Weintraub ST, Mavri-Vavayanni M.
Phytochemistry. 1996 Jan;41(1):89-92.
Acai 
 
  
 
Part 4
Alcohol, 
Other agents affecting platelet function: Lifestyle
Smoking
Exercise
C. R. Pace-Asciak, et al. (1996). `Wines and grape juices as modulators of platelet aggregation 
in healthy human subjects'. Clinica Chimica Acta 246(1-2):163-182.
A. D. Blann, et al. (2001). `Increased platelet glycoprotein V levels in patients with 
coronary and peripheral atherosclerosis-the influence of aspirin and cigarette 
smoking.'. Thrombosis and haemostasis 86(3):777-783.
El-Sayed, Mahmoud S 1; Ali, Nagia 2; El-Sayed Ali, Zeinab (2005) Aggregation and Activation of Blood 
Platelets in Exercise and Training. Sports Medicine. 35(1):11-22,.
Part 4
Sampling
Other agents affecting platelet function
•Large gauge needle
•Discard first 1mL
•Use syringes
 
 
Overview
Patient answers yes to part 1 reschedule
Patient answers yes to part 2 assess with clinician
Patient answers yes to parts 3 and 4 check for multiple 
interactions
 
  
Appendix 2
  
Appendix 4 : Questionnaire follow up email  
From: Gurney David <David.Gurney@gsts.com> 
To: Ian Ford <Ian.Ford@uhl.nhs.uk>; "Manning, Richard A" 
<RichardA.Manning@imperial.nhs.uk>; Ann Fisher <Ann.Fisher@UHSM.NHS.UK>; Mark 
Thomas <Mark.Thomas@asph.nhs.uk>; "Ali, Iftikhar" <Iftikhar.Ali@btuh.nhs.uk>; Nick 
Dorward (ABMU NHS Trust - Haematology) <Nick.Dorward@wales.nhs.uk>; "Scott, Richard" 
<Richard.Scott@rbch.nhs.uk>; "Smith, Margaret (NHH)" 
<Margaret.Smith2@gwent.wales.nhs.uk>; "Brooks, Sarah" <Brooks@royalfree.nhs.uk>; catriona 
crow <catriona_crow@yahoo.com> 
Sent: Tuesday, 12 May, 2009 14:32:09 
Subject: Platelet Questionnaire 
Hi all 
  
At the PAP User group meeting last October you all expressed a preference in using my pre-
analytical questionnaire? I am now looking at writing up my thesis and would be grateful if you 
would answer some questions? 
     Did you find the questionnaire useful?  
     Do you use it routinely or as a guide?  
     Has it become part of your SOP?  
Any further info would be much appreciated:-)) 
Cheers  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix 5: Questions for MRCPath candiadtes 
 
This trace shows traces with various concentrations of ADP, progressing from 
high to low. Traces 1-4 are the control patient. Traces 5-8 are the patient. 
What could the diagnosis be?
What further tests would you do to confirm your diagnosis?
 
This is a trace from a different model of aggregometer. The patients traces are in red and 
the control in blue. The agonists are marked above the trace lines. 
What is the possible diagnosis?
What further tests would you do to confirm your diagnosis? 
 
 
  
This is a trace from the same model of aggregometer as above. The patients traces 
are in red and the control in blue. The agonists are marked above the trace lines. 
What is the possible diagnosis?
What further tests would you do to confirm your diagnosis?
 
  
  
Appendix 6: ‘Recent advances in platelet diagnoses’ presented at 
St Thomas’ hospital 
Recent Advances in 
Platelet Diagnostics
David Gurney MSc CSci FIBMS
Haemostasis Laboratories
Centre for Haemostasis & Thrombosis
(Haemophilia Reference Centre)
Clinical History
Family History
Medical History
Social History
Genetic Disorders
Diseases Drugs
AlcoholDiet Smoking
What do we have now?
 
 
What do we have now?
Platelet counting & sizing
Normal distribution
Distribution in a Type 2b VWD
Microscopical Platelet Size
What do we have now?
 
What do we have now?
Platelet Function Analyser-100 (PFA-100)
What do we have now?
Platelet Function Analyser-100 (PFA-100)
Measurement under sheer stress
Measurement under flow
Collagen Epinephrine Cartridge
Collagen ADP Cartridge
Good Aspirin Screen
Replaces the bleeding time
Platelet Function Analyser-100 (PFA-100)
 
  
In Vivo Haemostasis PFA-100TM
Endothelium
Collagen
vWF
Fibrinogen
Platelet
Erythrocyte
Aperture
150µm
Collagen+
EPI or ADP
vWF
Fibrinogen
Platelet
Erythrocyte
 200µm
- 40 mbar
Vasculature vs PFA. Platelet Aggregation Profiler
Born GVRF  Aggregation of blood platelets by 
ADP and its reversal 
Nature 1962; 194: 927 - 929 1
What do we have now?
 
 
Agonists
• Arachidonate Epinepherine
• Ristocetin ADP
• Collagen
How can we improve on ‘now’?
• Thrombin Receptor Agonist Peptide (TRAP)
• U44619 9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α
• A23187 Calcium Ionophore
• Convulxin specific GPVI agonist
• Collagen receptor peptides (CRP)
What do we have now? Nucleotide Analysis
What do we have now?
 
Nucleotide Analysis
Activation of Luciferin
ADP + Phospho-enol Pyruvate (PEP) ---->  ATP Pyruvate Kinase
Luciferase + Magnesium Ions
ATP + Luciferin ----> adenyl Luciferin + LIGHT
Flow Cytometry
 
Glycoprotein Analysis
• Platelet CD Reference Chart
• CD GP Integin Supplier Direct
• CD29 GPIIa Beta1 Serotec Cat No MCA1949F Y
• CD31 GPIIa/PECAM Serotec Cat No MCA1738F Y
• CD36 GPIIIa/IV Serotec Cat No MCA722F Y
• CD41 GPIIb alpha2b Serotec Cat No MCA467F Y
• CD42a GPIX Serotec Cat No MCA1227F Y
• CD42b GPIb alpha Serotec Cat No MCA740F Y
• CD42c GPIb beta
• CD42d GPV
• CD49b GPIa Serotec Cat No MCA743F Y
• CD49e GPIc alpha5 Serotec Cat No MCA698F Y
• CD49f GPIc Serotec Cat No MCA1457F Y
• CD61 GPIIIa Beta3 Serotec Cat No MCA728F Y
• CD62P P-Selectin Serotec Cat No MCA796F Y
• PAC-1 BD Bioscience Cat No 340507 (IgM) N
• PAR1 Zymed Cat No 35-2200
• GPVI Gift from Moroi N
Diamed Impact-R
How can we improve on ‘now’?
Platelet function screen
Less volume than PFA-100
Technically more demanding than PFA-100
Adjustable sheer rates
 
 
 
  
Chronolog 700
<> 
How can we improve on ‘now’?
Release studies & aggregation
Less manipulation
Involvement of other cellular 
components
Lower blood volume
Technically demanding
Haemoscope TEG
‘New for old’?
Clot properties only
Insensitive to aspirin
Global haemostatic overview
 
Haemoscope TEG Haemodyne ‘Platelet Analysis System’
Next Generation?
 
Point of Care Platelet Testing
Next Generation?
The future: proteomics and genomics?
Proteomic analysis of platelet α-granules using mass spectrometry 
Authors: MAYNARD, D. M.1; HEIJNEN, H. F. G.2; HORNE, M. K.3; WHITE, J. G.4; GAHL, 
W. A.1
Source: Journal of Thrombosis and Haemostasis, Volume 5, Number 9, September 2007 , pp. 
1945-1955(11)  
Expanding our test repertoire
• Scotts Syndrome
» Membrane disorder
• Quebec platelet disorder-
» raised uPA
» Reduced platelet FV
» Reduced multimerin
• May Hegglin Anomoly
» MYH9
• Sebastian Syndrome
» Increase in GPIIb/IIIa binding 
» Decrease in GP Ib/V/IX binding
 
 
 
 
 
  
Appendix 7: ‘Case Presentation’ presented at IBMS congress 
2005 
 
 
Case Presentation
David Gurney MSc CSci FIBMS
Haemostasis Laboratories
Centre for Haemostasis & Thrombosis
Family Tree
Unknown
DTAR
A Tale of a Maternal Bloodline AR
•Female, born 1967
•Pregnant 1999
•Noted platelet count of  < 50 x 109/L
•Assumed to be ITP
•Treated with steroid, but no improvement
•Obstetric bleed due to PPH
•Hb 3gms, ITU support and resuscitated.
 
AR
•Retrospective history– bled after dental 
extraction, menorrhagia
•Had always been iron deficient
•Family history- diagnosis of VWD/bleeding 
disorder
 
AR
•VWF:Ag 55.2 iu/dl (45-160)
•VWF: Ac 36.0 iu/dl (54-202)
•VWF: CB 28.1 u/dl (38-245)
• F VIII:C            88.0 iu/dl (65-170)
•Blood group        A Rh pos
•Platelet 117 x109/L
•PFA – 100 >300 both cartridges
Von Willebrand Disease
Overview
•Bleeding disorder
•1 in 100
•Separated into three subtypes
•Can be Autosomal dominant or recessive
 
 
  
Von Willebrand Disease
Subtypes
•Type 1
–Deficiency in Von Willebrand Factor (VWF)
•Type 2
–Qualitative abnormalities
•Type 3
–Absence of VWF
Von Willebrand Disease
Diagnostic Features
•Type I
–Prolonged APTT
–Reduced VWF:Ag, VWF:RCo, VWF:CBA
• Type III
– Very prolonged APTT
– Very Low / Undetectable VWF:Ag, VWF:RCo, 
VWF:CBA
 
Platelet Type (Pseudo) VWD
•First described by Weiss in 1982
–Weiss, H. J.; Meyer, D.; Rabinowitz, R.; Pietu, G.; Girma, J.-P.; Vicic, W. J.; Rogers, J.: 
Pseudo-von Willebrand's disease: an intrinsic platelet defect with aggregation by 
unmodified human factor VIII-von Willebrand factor and enhanced adsorption of its 
high molecular weight multimers.
New Eng. J. Med. 306: 326-333, 1982
•Moderate Bleeding
•Normal or reduced platelet count
•Gly233Val or Met239Val in GPIb
•Distinguished by mixing studies
Platelet Aggregation Profiler (PAP) 4
Born GVRF  Aggregation of blood platelets by
ADP and its reversal
Nature 1962; 194: 927 - 929 1
 
Platelet Aggregation
•Standard Platelet Rich 
Plasma (PRP)
•Low does ristocetin 
(0.5g/dl)
ET
Control
DT
AT
Platelet Mixing Studies
•Patients platelets suspended in 
control plasma
•Platelet count adjusted
•1.25g/dl Ristocetin
ET
DT
AT
 
Platelet Mixing Studies
•Patients platelets in 
control plasma
•Low dose ritocetin 
(0.5g/dl)
ET
AT
DT
AR
•Platelet aggregation by aggregometry: Normal
•Ristocetin Induced Platelet Activation (RIPA) 
positive (PRP with various doses of ristocetin)
•patients platelets/control plasma + ristocetin
•control platelets/patients plasma + ristocetin
•Platelet type VWD
•genetic test: Heterozygous for native glycine 
substituted to valine at codon 233 in GPIbα
•Pregnant again--- Management
 
 
DT Sister
•PFA Both cartridges >300
•FVIII 60 iu/dl (NR 65-170)
•VWF: Ag 38.5iu/dl (NR 45-160)
•VWF: RCo 23iu/dl (NR 54-202)
•VWF: CB 32.9 iu/dl (NR 38-245)
•Plt Count 207 x 109/l (NR 150-400)
•Multimers Normal low/intermediate
Absent high
ET (Niece)
•PFA ADP 186 sec (NR 62-
100) EPI 130 sec (NR 85-
165)
•FVIII 80.7 iu/dl (NR 65-170)
•VWF: Ag 62.5 iu/dl (NR 45-
160)
•VWF: RCo 41 iu/dl (NR 54-202)
•VWF: CB 66.7 iu/dl (NR 38-
245)
•Plt Count 285 x 109/l (NR 150-400)  
 
  
AT (Niece)
•PFA Both cartridges >300
•FVIII 70 iu/dl (NR 65-170)
•VWF: Ag 37.0 iu/dl (NR 45-
160)
•VWF: RCo 17 iu/dl (NR 54-202)
•VWF: CB 32.8 iu/dl (NR 38-
245)
•Plt Count 182 x 109/l (NR 150-400)
•Multimers Normal low/intermediate
Absent high
Platelet Sizes
Control Platelet Histogram AT Platelet Histogram
ET Platelet Histogram DT Platelet Histogram
 
 
 
 
  
  
Appendix 8 ‘Platelet case study’ presented at IBMS congress 2009 
Platelet Case Study
Presentation to:
IBMS Congress, Birmingham 2009
Presented by
David Gurney MSc CSci FIBMS
Referral from Jordan
7yr old male
history of intermittent petichiae,
previous macrothrombocytopenia ?BSS
Patient History
 
• Full Blood Count
•PFA
• Collagen Epinephrine 162 secs
• Collagen ADP 208 secs
• VWF Screen
Initial testing
•Impact-R
Initial testing
Surface coverage: 2.6 (>7.5)
Aggregate size: 32 (>25)
 
Platelet aggregation (ADP Various concentrations)
Initial testing Initial testing
Platelet aggregation (ADP low concentration)
 
Whole blood aggregation (High Dose ADP)
Further testing Further testing
Whole blood aggregation (Low Dose ADP)
 
 
 
 
 
  
Appendix 9: ‘Platelet analysis; send in the clones’ presented at 
IBMS congress 2011 
Platelet analysis: 
send in the clones
David Gurney MSc CSci FIBMS
Advanced Biomedical Scientist/Platelet Specialist
Department of Coagulation 
8th Floor, Queens Building 
Bristol Royal Infirmary 
Upper Maudlin Street
Bristol BS2 8HW 
• Does the type of clone used to 
raise a monoclonal antibody 
have a bearing on its efficacy?
Start with a question
 
 
Literature search
Pubmed search found one article comparing clones for 
flow cytometric analysis
Curvers, J. et al., 2008. Flow cytometric measurement of CD62P (P-selectin) 
expression on platelets: a multicenter optimization and standardization effort. 
Transfusion, 48(7), p.1439-46
STUDY DESIGN AND METHODS: The effects of fixation, 
source and dilution of CD62P antibody, source of
immunoglobulin G (IgG) isotypic antibody, and analysis
of results were investigated. Once the optimal variables
were defined, comparative studies were performed at
five participating centers. In the final comparative study,
eight split PLT concentrates were shipped to the
centers, where samples were stained and fixed accord-ing to the 
uniform protocol. Analyses were performed
using commercially available flow cytometers (BD Bio-sciences 
and Beckman Coulter).
RESULTS: Uniformity between centers could be
achieved by using a single clone for CD62P and IgG
monoclonal antibody. A protocol was selected using
fixation with 0.5 percent methanol-free formaldehyde.
To increase conformity between flow cytometers, in the
analysis of electronic data the thresholds of the isotypic
control were set at 0.5 percent for the BD Biosciences
and 2 percent for the Beckman Coulter flow cytometers.
In the final comparative study, the 95 percent confi-dence 
intervals (CIs) for CD62P ranged between 8 and
21 percent in fresh and 20 to 40 percent in 8-day-old
PLT concentrates.
There was considerable variation between the reported percentages of CD62P- positive PLTs.
•Establish optimal concentration of available CD61-PE 
monoclonal antibodies (mAbs) for use on platelets in citrated 
peripheral blood specimens.
•This concentration will then be used to test each mAb, 
alongside the Stago kit, on normal adult and paediatric 
citrated PB specimens.
Aim: 
 
Methods
Brief overview:
• Prepare serial dilutions of all mAbs to be tested, starting at 
30ug/ml. The final volume of antibody should be 50ul in all tubes.
•Add sample
•Incubate in the dark for 15 minutes
•Wash
•Acquire on LSR Fortessa
•Analyse
Company Clone Isotype conjugat
e
PE/Ig ratio cat no lot conc
Serotec Y2/51 IgG1 PE not stated MCA2588PE 0307 Not stated. Lyophilized. Recommend 
add 1ml, use 10ul per test. Probably 
100ug/ml
Serotec PM6/13 IgG1 PE not stated MCA728PE 0304 Not stated. Lyophilized. Recommend 
add 1ml, use 10ul per test. Probably 
100ug/ml
Coulter SZ21 IgG1 PE 0.5-1.5 PN IM3605 16 Not stated. 
20ul per test of 500,000 cells
R&D Systemts 256809 IgG2a PE not stated FAB2266P LNP02
09101
10ug/ml
Clone choices
 
Running platelets on flow
– Be aware of noise levels
Running platelets on flow
– Be aware of background fluorescence levels of the 
cells you are looking at  
 
  
Running platelets on flow
– Be aware of changes induced by processing
Clone differences – Interim data
• Median fluorescence intensity and light scatter 
parameters measured –
ul mAb
Median 
Fluoresence 
Intensities
R&D Coulter Serotec 0307 Serotec 0304
100 18855 25383 9117 15327
50 15498 24469 7163 10695
25 10671 24039 4985 6753
12.5 6144 23536 3165 3995
6.25 3313 21558 1873 2210
3.125 1752 17941 1111 1173
1.5625 884 12878 605 629
0 22 22 0 0
CD30 100ul 405
 
Results
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Results
R&D Coulter
Serotec 
0307
Serotec 
0304
100 18855 25383 9117 15327
50 15498 24469 7163 10695
25 10671 24039 4985 6753
12.5 6144 23536 3165 3995
6.25 3313 21558 1873 2210
3.125 1752 17941 1111 1173
1.5625 884 12878 605 629
0 22 22 0 0
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Clone differences: Interim data 2
• We found that one clone resulted in brighter signal than 
the others, irrespective of concentration. (Coulter)
• We found that the forward light scatter was affected by 
some clones – the effect was reduced at 12.5 ul, but the 
intensity of the signal then quite low and not suitable for 
measuring loss of an antigen.
Testing patients
• Here’s an example of the CD61 chosen together with 
CD36, used in the final assay
 
 
Testing patients
• And next, a case of Glanzmanns Thrombasthenia (GT)
Testing patients
•Current practice in many laboratories is to run a normal 
control next to a query.
•While this would certainly be adequate for finding clear-
cut GT cases, a more exact, definite value of reduction of 
antigen expression requires a reference range for normal 
and non-glanzman disease controls.
•Frequently, GT queries will be samples form children and 
an age-appropriate reference range should be aimed for. 
 
 
  
Testing patients Reference Ranges
NORMAL
 
 
Reference Ranges
• As a new assay has being developed new reference 
ranges are needed.
• 17 subjects have been recruited so far
• 10 females 5 males
• Average age 35 years old
Need more subjects to give range more power
Reference Ranges
2000
2500
3000
3500
4000
4500
5000
5500
6000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
CD42b-FITC
CD42b-FITC
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e
Participant number
Expression of CD42b (GPIb) varies in a cohort of 17 ‘normal's’ . 
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Appendix 10: Platelet disorders: Test selection, reporting and result 
interpretation SOP for St Thomas’ hospital 
  
Introduction 
Background 
Platelet disorders are notorious difficult to diagnose. Most laboratory testing is 
qualitative and although some thought has been put into quantification of these 
tests there is still a broad spread of reporting styles. (I. Jennings, et al. (2008). 
`Platelet function testing: practice among UK National External Quality 
Assessment Scheme for Blood Coagulation participants, 2006.' Journal of clinical 
pathology 61(8):950-954, K. A. Moffat, et al. (2005). `Variability in clinical 
laboratory practice in testing for disorders of platelet function: results of two 
surveys of the North American Specialized Coagulation Laboratory Association.'. 
Thrombosis and haemostasis 93(3):549-553,) This SOP is to be used to help with 
interpretation of a range of platelet assays and hopefully bring some 
standardisation to our reporting regime. 
It is not a replacement for the method SOPs. 
Guidelines 
Until very recently the last official set of guidelines for platelet testing were 
published in the Journal of Clinical Pathology in 1988 (Journal of clinical 
pathology, Vol. 41, No. 12. (December 1988), pp. 1322-1330). These had a clinical 
update in 2006 when the UKHCDO and BSHT published a joint document (British 
Journal of Haematology, Vol. 135, No. 5. (December 2006), pp. 603-633) 
Committee for Laboratory Standards Institute (CLSI) 
The CLSI of America published guidelines for aggregation in October 2008. A 
copy is available in the department. 
International Society for Thrombosis and Haemostasis (ISTH) 
At the 2009 Special Scientific Committee (SSC) meeting of the ISTH in Boston the 
minutes show that guidelines for light transmission aggregometry (LTA) were high 
on the committees’ agenda. 
British Committee for Standardisation in Haematology (BCSH) 
The BCSH guidelines were mentioned in the minutes of the ISTH SSC 2009. Dr 
Paul Harrison is involved with this and we hope to hear from him as soon as they 
are available. 
  
Testing 
Platelet Counting 
Automated Full Blood Count 
When running a full blood count (FBC) the platelet count will be shown. Some 
disorders are purely qualitative, in that the patient has insufficient platelets to 
perform their given function. This will be highlighted by a low platelet count. 
Other disorders (such as Glanzmann’s thrombasthenia) give a normal FBC platelet 
picture. Other information that can be gleaned from the FBC is the size. By looking 
at the size histogram plots (See Figs 1 & 2 below) we can see the distribution of 
platelet sizes. Some diseases such as Bernard Soulier syndrome (BSS) will have a 
macrothrombocytopaenic picture (low numbers of large platelets) 
 
 
 
Fig 1: Normal platelet histogram from a Coulter LH750 
 
 
 
Fig 2:  Abnormal platelet histogram showing various sizes and an extended ‘tail’ 
 
 
 
 
  
  
Counting chamber 
As the coulter method for counting platelets relies on size and gating, it can be 
deceived by large platelets in the red cell channel or small red cells appearing in 
the platelet channel. If this was suspected then a manual platelet count can be 
performed using an improved Neubauer counting chamber (see Fig 3 below).  
Whilst counting an assessment of the platelet sizes can also be make by an 
experienced BMS 
     
Fig 3: Improved Neubauer counting chamber and an enlarged grid section used for 
counting platelets 
 
 
Immuno-platelet count 
When platelet counts are done visually or by size, there are inherent risks in the 
procedure to be overcome. One way of doing this is to count the platelets using 
platelet specific antibody labelling. The method used in Haematology is based on 
methodology from International Council for Standardization in Haematology 
Expert Panel on Cytometry, International Society of Laboratory Hematology Task 
Force on Platelet Counting. Platelet counting by the RBC/platelet ratio method. A 
reference method. American journal of clinical pathology. 2001 March;115(3):460-
464.  While this is more accurate it is not without its pitfalls. The antibodies used 
bind to specific glycoproteins on the platelet, both of which have been well 
characterised as being deficient in some disease states (see glycoprotein analysis).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Film 
 
Fig 4: Normal romanovsky stained blood film 
  
Looking at the film should reinforce what has been seen with the platelet histogram 
data, if this is not the case further investigation is warranted. When looking at the 
platelets on the slide consider the numbers at a lower power magnification and then 
scrutinise the platelets more closely under higher power. Questions to ask are: 
 Are they all the same size- 
a. If they are all normal? Large? Small? 
b. If they are not all the same size - are there distinct populations? Various 
sizes 
 What shape are they? 
 Are they stained adequately? 
a. If the rest of the film is stained adequately and the platelets are not it could 
be a granule deficiency such a grey platelet syndrome (- granule deficiency) 
  
 
PFA-100 (Platelet Function Analyser) 
 
Originally described in Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, 
Ostgaard RA. Description of an in vitro platelet function analyzer-PFA-100. 
Seminars in thrombosis and hemostasis. 1995;21 Suppl 2:106-112  the platelet 
function analyser (PFA-100) has come to replace the bleeding time in many 
laboratories. This analyser uses pressure to recreate the shear forces mimicking 
movement through the vasculature. To simulate a break in the vasculature collagen 
is used with either ADP or epinephrine as a stimulate agonist. The time taken for 
the platelets to form a thrombus and block the capillary, creating and equal 
opposite pressure to the shear forces is called the ‘closure time’. Much was claimed 
of the PFA-100 when it was introduced over a decade ago. There is no benefit 
doing a PFA-100 if a collagen/vasculature based bleeding disorder, such as 
hereditary telangiectasia, is suspected. 
 
However it is now best used as a screening test and regardless of whether it is 
prolonged or not, if there if sufficient clinical evidence to go onto to perform 
platelet aggregation, then this is what should be done. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5: Cut away of a PFA-100 cartridge and sample being loaded into the analyser. 
Images courtesy of Sysmex UK 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 Collagen ADP 
Cartridge Closure 
time 
(seconds) 
Collagen 
Epinephrine 
Cartridge 
Closure time 
(seconds) 
Normal Range 62 - 100 85 - 165 
COX deficiency N P 
Aspirin Ingestion N P 
Glanzmann’s  
Thrombasthenia 
P P 
Thromboxane 
receptor  
defects 
N P 
P2Y12 receptor 
defects  
(Clopidogrel 
resistance) 
N/P N/P 
VWD P P 
*Due to the Hb and PCV constraints of this assay Bernard Soulier Syndrome,  
the MYH9 disorders & grey platelet syndrome cannot be diagnosed by 
PFA as these are macrothrombocytopenias and the platelet count will be too low. 
 
Table 6: PFA100 results. Normal ranges and some  responses in common platelet defects.  
N= Normal  P = Prolonged 
Modified from: Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function 
analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. 
Journal of Thrombosis and Haemostasis. 2006 February;4(2):312-319.  
 
~However it is now best used as a screening test and regardless of whether it is 
prolonged or not, if there if sufficient clinical evidence to go onto to perform 
platelet aggregation, then this is what should be done.~ 
  
Platelet aggregation (PA): (HSP-002) 
Platelet aggregation (PA): PRP, sometimes known as Born aggregometry (after its 
inventor Born GVR. Aggregation of Blood Platelets by Adenosine Diphosphate and 
its Reversal. Nature. 1962 June;194(4832):927-929.) or light transmission 
aggregometry (LTA, after the technique used) 
 
Gustav Born 
 
Fig 7: Platelet activation pathways:  courtesy of Labmedics/Chronolog 
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Normal aggregation traces: ADP 
 
ADP is essential for platelet aggregation. It is stored in the delta (δ) or dense 
granules. When released into the bloodstream it reacts with receptors on the 
platelet surface. These receptors are named P2Y1, P2Y12 and PX1. P2Y1 in the 
above diagram is the ADP receptor activating phospholipase C, the process which 
eventually leads to shape change. P2Y12 interacts with phospholipase A2  
 
 
 
Fig 8: ADP 10μM platelet aggregation trace as displayed on the BioData PAP-8E 
 
 
 
  
Fig 9: ADP 5μM platelet aggregation trace as displayed on the BioData PAP-8E 
  
 
 
 
 
Fig 10: ADP 2μM platelet aggregation traces as displayed on the BioData PAP-8E, 
showing the variation in the ‘biphasic’ response 
 
 
 
 
Fig 11: ADP 1μM platelet aggregation traces as displayed on the BioData PAP-8E, 
showing the variation in the ‘biphasic’ and ‘flat-line’ response 
 
Normal aggregation: Collagen 
 
  
 
 
 
Fig 12: Collagen 20g/L platelet aggregation traces as displayed on the BioData 
PAP-8E 
 
 
 
 
Fig 13: Collagen 5g/L platelet aggregation traces as displayed on the BioData PAP-
8E 
  
 
 
Fig 14: Collagen 1g/L platelet aggregation traces as displayed on the BioData PAP-
8E 
 
 
Normal aggregation: Epinephrine 
 
 
 
Fig 15: Epinephrine 20μM platelet aggregation traces as displayed on the BioData 
PAP-8E. 
Note the variability of the traces 
 
 
  
 
 
Fig 16: Epinephrine 2μM platelet aggregation traces as displayed on the BioData 
PAP-8E. 
Note the variability of the traces 
 
Normal aggregation: Arachidonate 
 
 
Fig 17: Arachidonate, also known as aracidonic acid platelet aggregation traces as 
displayed on the BioData PAP-8E. 
 
Normal aggregation: Ristocetin 
 
 
  
 
 
Fig 18: Ristocetin 1.25g/L platelet aggregation traces as displayed on the BioData 
PAP-8E 
 
Normal aggregation: Thrombin receptor agonist peptide (TRAP) 
 
 
Fig 19: Thrombin receptor agonist peptide (TRAP) 20μM platelet aggregation 
traces as displayed on the BioData PAP-8E 
 
 
  
 
 
Fig 20: Thrombin receptor agonist peptide (TRAP) 10μM platelet aggregation 
traces as displayed on the BioData PAP-8E 
 
 
Fig 21: Thrombin receptor agonist peptide (TRAP) 1μM platelet aggregation traces 
as displayed on the BioData PAP-8E 
 
Normal aggregation: U46619 
 
  
 
 
Fig 22: U46619 (9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α) 100μM 
platelet aggregation traces as displayed on the BioData PAP-8E 
 
 
 
 
 
 
 
Fig 23: U46619 (9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α) 50μM 
platelet aggregation traces as displayed on the BioData PAP-8E 
 
 
  
 
 
Fig 24: U46619 (9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α) 25μM 
platelet aggregation traces as displayed on the BioData PAP-8E 
 
 
 
 
 
Fig 25: U46619 (9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α) 5μM 
platelet aggregation traces as displayed on the BioData PAP-8E, showing variation 
in response at this dosage of the agonist 
 
 
  
 
 
Fig 26: U46619 (9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α) 500nM 
(0.5μM) platelet aggregation traces as displayed on the BioData PAP-8E 
 
 
 
Interpretation 
When looking at platelet traces there are a number of characteristics to consider: 
 Agonist response 
a. If it responds rapidly at low doses, dilute until a biphasic response is seen 
b. If it does not respond increase agonist concentrations until one is observed 
 Slope. The slope of the traced line indicates how quickly the platelets are 
reacting to a given stimulus. A shallow slope is a slow reaction and could indicate a 
breakdown in the mechanisms of the platelet response. 
 Maximum aggregation.  
a. How far down does the slope go?  
b. How far should it go?  
c. How does it compare to the control? A reduced maximum aggregation 
indicates a reduction in the platelets response to an agonist. 
 Pattern.  
a. Is there a biphasic response?  
b. Is it stepped and proceeds to full aggregation?  
c. Alternatively does is the trace indicate that the platelet responds then 
reverses back?  
 How far does it reverse? Completely? Partially? 
  
 
 
 
Many primary haemostatic or platelet disorders present with distinct aggregation 
patterns. Delta storage pool disorder, which is a lack of delta or dense granules, 
exhibits a biphasic response with ADP, the stronger doses of agonist giving a 
stepped style of responses (See Fig 27) where as the lower doses give what we 
refer to as ‘ a biphasic response with full or partial reversal’ (See Fig 27 for 
examples). 
 
 
Drugs such as aspirin, clopidogrel (Plavix
©
), and Prasugrel affect platelet function. 
Aspirin is an irreversible cyclooxygenase isomer 1 (COX1) inhibitor. In platelet 
aggregation testing this will manifest as a reduction or absence of response to ADP 
and Arachidonate, but is restored when U46619 is used. This pattern will also be 
observed if there is an enzyme problem, often called ‘aspirin like’ deficiency. If 
neither arachidonate nor U46619 work, the defect is likely to be in the 
thromboxane receptor. 
 
Fig27: Example of ADP traces showing possible storage pool disorder.  
Control traces 1 - 4 (10μM, 5μM, 2μM & 1μM) Patient 5 – 8 (10μM, 5μM, 2μM & 1μM) 
 
  
 
 
Fig 28: Showing an abnormal arachidonate trace (Line 1 in red) with a normal 
series of U46619 (9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α) traces 
(Lines 2-5) The possible diagnosis is an enzyme deficiency (either acquired or 
genetic) 
 
 
Clopidogrel and Prasugrel, bind to the P2Y12 receptor so will blunt the ADP 
response.  
 
Receptor disorders especially glycoprotein (GP) based diseases give a distinct 
‘combination’ pattern. Glanzmann’s thrombasthenia, which involves the GPIIb/IIIa 
receptor is reduced or absent with ADP, collagen, epinephrine, but not with 
ristocetin. Bernard Soulier syndrome is only reduced with ristocetin, but has other 
distinguishing characteristics such as macrothrombocytopaenia. If the patient has 
macrothrombocytopaenia, but responds to ristocetin then an MYH9 disorders such 
as May-Hegglin, Fechner or Sebastian syndrome would be suspected.  
 
  
 
 
Fig 29: ADP traces showing control (Lines 1-4 10μM, 5μM, 2μM & 1μM) and a 
patient with possible Ehlers danlos syndrome (Lines 5-8 10μM, 5μM, 2μM & 
1μM) 
 
 Example of a subjective written report for the above traces (Fig 29):- 
 Control 
 Line 1 (Red):  Full aggregation (81%) 
 Line 2 (Yellow): Full aggregation (78%) 
 Line 3 (Green): Full aggregation (73%) 
 Line 4 (Cyan): Biphasic aggregation with 18% first phase with partial 
reversal    10% 
 Patient 
 Line 5 (Black): First phase aggregation (52%) with no second phase 
 Line 6 (Purple): First phase (42%) with reversal (21%) 
 Line 7 (Silver): First phase (19%) with full reversal 
 Line 8 (Grey):  First phase (5%) with full reversal 
 
Depending on the results of the aggregation, this will dictate the direction of 
further testing. As above the presence of a first phase with reversal with ADP as an 
agonist further testing would lean toward granular disorder testing such as 
nucleotides. 
 
 
 
 
  
 
Platelet aggregation (Whole blood): sometimes known as impedance 
aggregometry, after the technique used. (Cardinal DC, Flower RJ. The 
electronic aggregometer: a novel device for assessing platelet behaviour in blood. 
Journal of pharmacological methods. 1980 February;3(2):135-158.) 
 
 
 
Fig 30: Trace showing Chronolog whole blood aggregation (top) and 
release reaction (bottom) to collagen, ADP and Arachidonate. 
 
Whole blood aggregometry is normally performed in conjunction with 
luminescence studies. The luminescence component of the assay will provide ‘real 
time’ information on the platelets release of ADP. If this is reduced (as in the 
examples below) then there are two possible pathologies. One diagnosis could be 
that the enzyme signalling cascade causing the release mechanism is at fault; the 
other is that the granule contents (or granules themselves) are absent. To 
distinguish between these platelet nucleotide analysis must be performed (HSP-004 
next section) If the nucleotides are present then the former diagnosis is the most 
likely, if not the second is. 
 
 
 
Aggregation traces 
 
Release traces 
Collagen 
ADP 
Arachidonate 
  
 
 
 
 
Figs 31 & 32: Above are examples of suspected storage pool disorder 
patients analysed with lumi-aggregometry. Note the reduction in the 
release curves. 
In Figs 31 and 32 there is a marked reduction in the release curves 
when compared to those in Fig 30. In Fig 32 the green lines show the 
aggregation (dark green) and release (light green) of the normal 
control to arachidonic acid. In comparison the patients’ aggregation 
(purple) and release (orange) are reduced indicating reduced release. 
This could be because the granule products are not being released 
(enzyme defect) or there is none to release (dense granule defect). 
  
 
Platelet nucleotides will distinguish between these. 
 
2.2 Platelet nucleotides. (HSP-004) 
Depending on the aggregation results, as mentioned above, will inform the 
direction of further testing. One of the most common primary specific platelet 
disorders is delta storage pool disorder. This will be characterised by a biphasic 
response to ADP at high concentrations and first phase with reversal at lower 
concentrations in LTA and weak release and response in WBA. To separate delta 
storage pool disorder from the rarer enzyme disorder platelet nucleotide analysis is 
done. This measures the ATP and ADP in the delta (dense) storage granules in the 
platelet. There are 5-6 dense granules per platelet and they also contain: 
 
GPIb  GPIIb-IIIa  LAMP2 
CD-63 5-HT   Calcium Ions   
CD-62P Histamine  GTP/GDP 
Magnesium Ions 
 
If the platelet nucleotides levels and the ratio is outside the reference range this is 
indicative of a storage pool disorder. 
If the nucleotides are normal then this could indicate a release disorder. If platelet 
nucleotides are being released re-assay the patient. However if the patient does not 
release the nucleotides in the whole blood assay this indicates that the mechanism 
for releasing the granules into the environment is at fault. 
 
2.3 Platelet Lysates (HSP-009) 
 Platelets also have larger more common granules (approximately 40/platelet) 
known as alpha granules. These are the granules which stain giving platelets on a 
blood film their granular appearance. Hence when they are absent the disease is 
referred to as ‘grey platelet syndrome’. Laboratory diagnosis of this disorder is 
based around analysis the contents of these granules, and electron microscopy. The 
easiest of the alpha granule content to analyse is fibrinogen and VWF (other 
contents are shown in the list below) 
 
 
  P-Selectin (CD-62P) GP IIb-IIIa GPIb-IX  
Fibronectin  PECAM beta-Thromboglobulin 
Vitronectin  PF-4  GPIV 
Thrombospondin VWF  PDGF  EDGF 
Fibrinogen  Kininogen Protein S VEGF  
Factors V, VIII, XI, & XIII  Plasminogen 
 
  
 
Platelet glycoproteins (HSP-005) 
Analysis of the surface receptors is diagnostic in diseases such a GT and BSS. 
GT Type I  0-5% functioning GPIIb/IIIa 
 Type II 6-20% functioning GPIIb/IIIa 
 Variant 21-100% with variable fibrinogen binding 
 
BSS 
 
 
 
Fig 33; CD41 (GPIIb/IIIa) FACS results, normal control histogram on the left and 
a Glanzmann’s patient on the right 
 
As this test is specific, quantitative test there is no information that can be ‘infered’ 
from the results. The patient either has a deficiency or they have normal levels of 
glycoprotein. 
 
 
 
 
Ristocetin induced platelet aggregation 
Type IIb von Willebrand’s disease is characterised by the absence of large VWF 
multimers from plasma, and induction of platelet aggregation in platelet rich 
plasma (PRP) at concentrations of ristocetin lower than required for normal 
individuals. The high molecular weight (HMW) multimers are absent from the 
plasma due to a mutation that causes the VWF to have an increased affinity with 
GPIb-IX receptor.  This can lead to thrombocytopenia due to platelet aggregates 
being removed from the circulation. 
Thus, this technique, in combination with VWF multimer analysis, supports the 
diagnosis of Type IIb von Willebrand’s disease.  Additionally, pseudo-VWD (or 
platelet type VWD), that has a similar pathology, is hyper-responsive to ristocetin 
due to a mutation causing an increased sensitivity of the patients GPIb to normal 
VWF.  
  
 
 
These diseases give a ‘gain of function’ in that the platelets over react to ristocetin. 
Therefore the assay uses dilutions of ristocetin to establish that this is the case. 
Once this is confirmed the use of ‘mixing studies’ is used to determine which of 
these diseases it is. Mixing studies is the process of washing the patient and control 
platelets and resuspending them in their opposite plasma. Patients’ platelets in 
control plasma and control platelets in patients’ plasma, then the RIPA is performed 
again. If the over reaction is in the sample with patients platelets it is Pseudo 
(platelet type) VWD and if its patients plasma then is VWD Type 2b. 
 
Fig 34: Platelet aggregation with 0.5g/L Ristocetin (normal screening concentration 
1.25g/L) showing control, unaffected family member and two affected family 
members 
 
Control 
Unaffected family 
member 
Affected family 
member 
Affected family 
member 
 
  
 
 
Fig 35: Mixing studies showing above family platelets suspended in control plasma 
stimulated with 1.25g/L Ristocetin (normal) Notice all patients respond. 
 
Fig 36: Mixing studies showing above family platelets suspended in control plasma 
stimulated with 0.5g/L Ristocetin (low dose)  
Unaffected family 
member 
Affected family 
member 
 
Affected family 
member 
 
Affected family 
member 
 
Affected family 
member 
 
Unaffected family 
member 
  
 
Heparin Induced Thrombocytopenia (HIT) 
 
Guidance for HIT diagnosis 
From http://www.cap.org/apps/docs/cap_today/images/maycoag2.jpg 
 
Patients receiving heparin treatment for at least a week may develop 
thrombocytopenia. In some cases the platelet levels reduce moderately and return 
to normal even when heparin treatment is continued. This type of 
thrombocytopenia is termed Type I heparin-induced thrombocytopenia (HIT) and 
is not antibody mediated. In other patients thrombocytopenia is more severe and is 
antibody mediated. This condition is termed Type II HIT. It is known that 
antibodies associated with Type II HIT recognise sites on a platelet protein ‘platelet 
factor 4’ (PF4) that are created when PF4 is complexes with heparin.  Two types of 
assay are available to diagnose type II HIT: functional and antigenic assays.  No 
one type of assay is 100% reliable for the diagnosis of HIT. 
 
Serotonin Release Assay (SRA) Not done at GSTS. 
The serotonin release assay is the ‘gold standard’ for diagnosing HIT. In this test, 
normal platelets obtained from a donor previously shown to be reactive to a panel 
of heparin-PF4 antibodies, are incubated with radio-labelled serotonin. The 
labelled platelets are then incubated with the patient's serum in the absence and 
presence of heparin (in therapeutic and supratherapeutic concentrations). Platelet 
activation is measured by the release of radioisotope from the platelets. 
 
Heparin Induced Platelet Aggregation (HIPA) (HSP-007) 
Platelet aggregation for HIT testing follows similar principles as the SRA. Donor 
platelets are exposed to patients’ plasma in the presence of two different 
concentrations of heparin. In this case the end point is measured via platelet 
  
 
aggregation. A positive result is noted when the low dose of heparin (0.5IU) causes 
aggregation but the high dose (1000IU) does not. The high dose causes an increase 
in the negative charge present in the solution interfering with the IgG PF4 antibody 
complex and they cannot react with the platelets Fc receptor. 
 
 
Fig 37: Positive HIT aggregation performed on a PAP-4D 
 
HIT ELISA (HSP-008) 
The GTI ELISA is a commercial ELISA kit that measures antibodies to the 
HeparinPF4 complexes. There are two variations of the kit, one that measures all 
antibodies (IgG, IgM and IgA) and one that measures IgG alone. The IgG 
antibodies have been found to be the major causative subtype and most guidelines 
state that it is only necessary to measure IgG (see Keeling D, Davidson S, Watson 
H, Haemostasis and Thrombosis Task Force of the British Committee for Standards 
in Haematology. The management of heparin-induced thrombocytopenia. British 
journal of haematology. 2006 May;133(3):259-269 for example) 
 
 
 
  
 
 
Fig 38: Appropriate use of laboratory HIT assays. 
From http://www.aacc.org/publications/cln/2009/May/Pages/series0509.aspx 
 
Interpretation of HIT results.  
HIT ELISA assays have a high sensitivity but a poor specificity. That is that they 
can detect the antibodies, but these antibodies don’t always cause HIT. If the 
patient has a low clinical probability (4T score - Warkentin TE. Platelet count 
monitoring and laboratory testing for heparin-induced thrombocytopenia. Archives 
of pathology & laboratory medicine. 2002 November;126 (11):1415-1423 ) and a 
negative ELISA then the probability of HIT is very low. Alternatively, if the 4T 
score indicates a high probability and the ELISA optical density (OD) is high (as in 
on a par with the positive control) then the probability of HIT is high. If neither of 
these criteria is met then the diagnosis is somewhat more complicated.  If the 
ELISA is not ‘clear cut’ then a qualitative assay should be performed. Qualitative 
assays include the SRA and the HIPA. These tests measure the ability of the anti-
platelet complexes to activate control platelets. 
 
The paper below gives further guidance 
Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced 
thrombocytopenia. Current hematology reports. 2003 March;2(2):148-157. 
 
Bleeding time (not done at GSTS) 
The bleeding time measures the time taken to stop a specific sized wound to stop 
bleeding. It has largely been superseded by the PFA-100 and genetic analysis. It 
has recently become discredited for the variability of the results, but is the only 
‘rapid’ method to measure the part played by the vasculature in the healing process. 
It has however been discredited in a number of guidelines and papers such as those 
below: 
  
 
Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA, et al. The 
Preoperative Bleeding Time Test Lacks Clinical Benefit: College of American 
Pathologists' and American Society of Clinical Pathologists' Position Article. Arch 
Surg. 1998 February;133(2):134-139. 
 
Lind SE. The bleeding time does not predict surgical bleeding [see comments]. 
Blood. 1991 June;77(12):2547-2552 
 
Impact-R 
The impact R is the commercialisation of a technique first described as the ‘cone 
and plate(let)’ method (Kenet G, Lubetsky A, Shenkman B, Tamarin I, Dardik R, 
Rechavi G, et al. Cone and platelet analyser (CPA): a new test for the prediction of 
bleeding among thrombocytopenic patients. British journal of haematology. 1998 
May;101(2):255-259) and is a screening tool is a similar vein to the PFA-100. It 
has advantages over the PFA in that it takes a lower volume of blood, but needs 
greater operator intervention.  
 
 
 
 
 
 
 
 
 
 
 
 
 
6.0 Thromboelastogram (TEG) 
Thromboelastography or rotational thromboelastographic mapping (ROTEM) work 
on similar principles and are further attempts to introduce whole blood haemostatic 
measurements. Both methods rely on the torsion increase in a wire as a clot is 
formed. TEG rotates a pin attached to the wire and ROTEM rotates the cuvette 
Fig 39: Impact R results 
from a ‘normal’ patient 
Fig 40: Impact R results for a 
Glanzmanns Thrombasthenia patient 
  
 
 
with the sample in. The manufacturers of these instruments claim a vast amount of 
diagnostic information can be gleaned from the traces.  
 
 
 
   
Fig 41: Normal TEG trace 
 
6.1 Genetics 
There are many diseases whereby a genetic diagnosis is easier to obtain than a 
phenotypic one. Among these are the collagen defects such as telangiectasia. More 
common diseases can be easily subtyped by knowing the specific genetic defect, 
von Willebrand disease for example. 
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1. THE APPLICANT 
 
1.1 Surname   GURNEY 
 
1.2 Forenames   David Andrew 
 
1.3 Title (Mr, Mrs, Ms etc)  Mr. 
 
1.4 Qualifications  MSc  Biomedical Science 
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1.5 Full address of place of employment 
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  E-mail  davidagurney@yahoo.co.uk 
 
2. PROGRAMME OF PROFESSIONAL RESEARCH AND DEVELOPMENT 
 
2.1 Title 
 
 A strategy to extend the scope of platelet function testing will enhance the diagnosis of 
 primary haemostatic disorders and impact patient care. 
 
2.2 Aims of the programme 
 
To improve and enhance detection of primary haemostatic disorders, with particular emphasis 
on platelet disorders in the clinical haemostasis laboratory by: 
 
  
 
 Critically reviewing current methodologies for platelet function testing and develop methods of 
 minimising pre-assay variability. 
 
Extension of the most commonly used assay, platelet aggregation, to include additional 
agonists designed to reduce the frequency of equivocal/borderline result interpretations 
thereby increasing diagnostic precision. 
 
To evaluate and test a new research analyser, the Diamed Impact-R based on the cone and 
plate(let) methodology, having the ability to adjust shear rates. 
 
To implement and extend the reference ranges for all the platelet assays based in the 
laboratory. 
 
To convert the platelet glycoprotein assays from a qualitative measurement to a quantitative 
measurement and investigate the change in numbers of glycoprotein receptors on the surface 
membrane in response to common antiplatelet agents such as aspirin. 
 
Considering the impact of enhanced diagnostic strategies on patient care and factors 
influencing implementation and dissemination of these strategies. 
 
Exploring the implications for professional practice upon adoption of new and modified 
diagnostic approaches.  
 
 
2.3 Proposed plan of work (This must be contained within three pages and should include: 
background, stages of the proposed programme of research, outline methodology and key 
references) 
 
Background 
 
Platelets play an integral role in maintaining normal haemostasis, acting as delivery 
vehicles and reaction support in addition to their traditional role of ‘plugging’ the break 
in the vasculature.  More recently the study of platelets and detection of clinically 
significant abnormalities has developed beyond basic aggregometry utilizing 
fluorescent conjugated monoclonal antibodies and luminescence reagents. These 
diagnostic strategies have lead to the requirement of expansion of the present 
specialist platelet facilities in order to accommodate the equipment and reagents and 
utilisation of expertise. 
 
Research plan 
Phase 1a: Development of existing repertoire. 
Time scale: Now - 6months 
1. Using thrombin receptor agonist peptide (TRAP), a thromboxane analogue (U-44167) and 
a calcium ionophore (A23167) as additional agonists the repertoire for platelet aggregation 
has been expanded significantly. The development and refinement of this procedure will be 
ongoing.  
2. Standardisation of the procedure for producing washed platelets for analysis by Ristocetin 
Induced Platelet Aggregation (RIPA) has been accomplished. This was implemented as the 
technique was used rarely and needed updating. It is crucial for detecting and distinguishing 
between VWD Type IIb and Pseudo VWD, an essential part of a reference centres repertoire 
3. The luminometer that is used to analyse platelet nucleotides is being replaced, the 
analysers from Thermo Life Sciences and Berthold Industries having been evaluated, the 
Berthold analyser has been purchased and now needs assimilation into laboratory procedure 
including writing of standard operating procedures, generating reference ranges and staff 
training. This will lead to a direct improvement in assay quality and turn around time. 
4. The development and standardisation of the platelet glycoprotein method using FACScan 
analysis is on-going.  Microspheres of a known size coated with relevant antibodies to 
produce a standard curve of fluorescence. This graph is then used to quantify fluorescence on 
  
 
the platelet membrane surface. 
  5. The implementation of a pre-analytical questionnaire for platelet aggregation has  
  reduced the reporting of false positives and minimised inappropriate testing due to the patient 
  taking medications known to affect platelet aggregation 
 
Phase 1b: Development of new reference ranges for existing repertoire 
  Time Scale Concurrent with Phase 1a 
The development of platelet aggregation reference ranges for all the new agonists in 
the aggregation repertoire and reaffirmation of the ranges for the established agonists. 
Nucleotide reference ranges are to be re-established at the same time 
 
Phase 2: Development of Glycoprotein Reference Ranges. 
Time Scale: Concurrent with Phase 3 (Three years) 
Development of antibodies to a range of glycoproteins and flow cytometric counting 
technology has led to being able to count the number of glycoprotein sites that have bound 
the fluorescent antibodies. Whereas this has aided diagnosis and discovery of abnormal 
states, there has not been an establishment of a reference range. Addressing the 
development of a reference range for the standard platelet glycoproteins would be a priority of 
the new laboratory. This would entail development of the counting technology on the current 
BD FACScan analysers, involving the calibration of Calibrite beads, and establishing the 
antibodies to be used for further investigation. Assessment of the Quantum Simply Cellular 
Bead system and implementation for routine glycoprotein assays is also planned. 
The minimum number of samples for establishing a range is normally accepted as twenty. For 
this to be able to stand as a standard then at least double that number need to be recruited 
and ideally one hundred normal volunteers recruited. These volunteers need to be strictly 
monitored for dietary/pharmaceutical agonists such as aspirin, anti-depressants, green tea, 
smoking and vitamin B6. These patients will have a glycoprotein panel run and data analysis 
completed. 
 
Phase 3a: Monitoring patients against the new reference ranges. 
Time Scale: Concurrent with Phase 3b (Three years) 
Every patient that comes in for platelet function analysis will have flow cytometric analysis of 
the glycoprotein receptor numbers.   Past patients that have had ambiguous platelet results 
would be reinvestigated within the context of the new normal ranges to determine whether 
these patients have significant variation from the numbers of platelet glycoprotein sites 
available and whether these results contribute to their pathology. 
 
Phase 3b: Monitoring effects of external agents on normal range 
  Time Scale: Concurrent with Phase 3a 
Investigation into whether drugs and dietary supplements, such as those mentioned above, 
which are known to affect platelet function, also affect glycoprotein receptor numbers. 
Volunteers (that are known to be taking certain drugs/dietary supplements) would be 
monitored over a period of three months to determine basal levels and to establish whether 
the products reduce the receptor numbers. 
 
Stage 4. Professional dimensions 
 
 4.1 Dissemination of research findings 
 
If the research findings are to have more than a local impact, they must be disseminated in 
such a way as to reach as wider audience as possible.  Implementation will include seminars 
within the department, revision of SOPs and publication in trade and peer reviewed journals. 
 
4.2 Local and wider implementation new methodologies 
 
All reference ranges, new technologies and new assays will be implemented within the 
department. The objective is to make the department a centre for excellence in platelet 
  
 
diagnostics.  To enhance this reputation methodologies and modifications will be published in 
trade and peer reviewed journals. 
 
4.3 Impact on patient care of adoption of new methodologies 
 
40% of all primary haemostatic disorders remain without a sufficient diagnosis. The aim of the 
centre of excellence is to increase this diagnostic ‘hit rate’ 
 
4.4 Personal reflection 
 
Reflection will be undertaken covering the personal development achieved as a result 
of undertaking the research and having contributed to departmental research output 
from a diagnostic laboratory.  
  
References 
 
  
 
2.4 Facilities in the Department/Faculty/University which will be used in support of the 
programme 
 
All research will be accommodated in the workplace. University staff will be closely involved in 
guidance (i.e. Dr David McLellan, Dr Graham Mills). 
 
 
2.5 Facilities in the Workplace which will be used in support of the programme 
 
(i) Establishment/Individual(s):  
 
Key members of staff: Dr S Rangarajan Consultant Haematologist 
   Dr GW Moore  Head Biomedical Scientist 
 
Other staff:  Biomedical Scientist colleagues in the Haemostasis Laboratories 
 
 
(ii) Facilities available: 
  
 Use of laboratory facilities, bench space and basic equipment.  
  
 Reagents and consumables 
 
 Analytical equipment: PFA-100 platelet function analyser 
    PAP-4 Platelet aggregometer 
    Chronolog Whole blood aggregometer 
    BD FACScan 
    Berthold Lumat LB9507 Luminometer 
    Diamed Impact R 
  
 IT hardware and software 
 
2.6 Details of collaboration required for programme  
 
 None 
 
2.7 Has ethical approval been applied for or obtained at your place of work/employer? 
Note: All research subsequently undertaken for this unit must conform to the 
principles embodied within the Declaration of Helsinki (October 2000) (Give full details of the 
application, reference number and dates. If ethical approval will not be sought, please justify why this should not be 
the case). Ethical Committee decisions must be obtained before the commencement of any research work; and 
copies of these decisions where already available should be appended to this form. In addition, your proposal may be 
presented to the University of Portsmouth’s Ethical Committee for further approval. 
  
 Ethical approval has been given for platelet glycoprotein analysis for a previous project. This 
 project is building on that data and the same approval holds.                                     
 
Ethical approval has not been sought for the following reasons: 
 
1. The samples that are taken for routine platelet analysis are consented as a matter of course. 
 Part of the project involves assessment of additional platelet diagnostic assays, thus implied 
 consent has been given
1
 
 
2 As no additional blood samples are taken and results generated are within the remit of 
platelet  diagnostics this represents no additional risk to the patient.
2
 
 
3. The department has a consent process in place for donation of blood samples for reference 
 ranges and normal controls. 
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3. COST OF THE PROGRAMME OF WORK 
  
FINANCIAL DETAILS OF SUPPORT REQUIRED: 
 
1. Associated Staff Year 1 Year 2 TOTAL 
 
Grade 
 
% FT 
 
Salary 
 
Employer Contribution 
Some results from initial 
diagnostic investigations 
have been generated by 
incumbent Biomedical 
Scientists. 
 
No additional costs  
Some results from 
initial diagnostic 
investigations have 
been generated by 
incumbent Biomedical 
Scientists. 
No additional costs 
 
Subtotal    
2. Materials and Consumables    
 
Platelet aggregation agonists 
 
PFA Cartridges 
 
Impact R Reagents 
 
Glycoprotein antibodies & kit 
 
Buffers for FACS analyser 
 
Laboratory consumables – pipette 
tips, cuvettes etc 
 
 
 
£1000 
 
£100 
 
£200 
 
£600 
 
£25 
 
£100 
 
 
£300 
 
£1000 
 
£100 
 
£200 
 
£600 
 
£25 
 
£200 
 
 
Subtotal £2025 £2125 £4250 
3. Equipment    
 
PFA-100 
PAP-4 PRP aggregometer 
Chronolog Whole blood 
aggregometer 
BD FACScan 
Berthold Lumat LB9507 
Luminometer 
Diamed Impact R 
 
IT hardware & software 
 
 
All equipment part of 
establishment – no 
additional costs 
 
All equipment part of 
establishment – no 
additional costs 
 
Subtotal    
4. Travel    
 
Visits to the university 
 
£100 
 
£150 
 
  
 
 
Subtotal £100 £150 £250 
5. Other e.g. animals    
 
N/A 
 
   
Subtotal    
 
               Total costs £4500 
Reasons for support required: 
Please justify a) staff, b) material and consumables, c) equipment and d) animals required. (Continue on an additional page) 
 
 Staff 
 The Biomedical Scientist staff involved have generated any results used as part of their normal duties. These results 
constitute those necessary for initial diagnosis to confirm the presence of disease states relevant to the project. All other 
investigations, modifications, development and assessment have, or will, be performed by the applicant. 
 
 Materials & consumables 
  
 PFA/Aggregation 
 The PFA-100 uses a cartridge based system to process samples. This analyser is in routine use in the department and 
consequently consumable cost will be absorbed into the normal department routine. The reagent panel for platelet aggregation 
is being extended and as a consequence additional reagents are being ordered. This increases the consumables being used with 
the test. Once this is a proven technique it will be incorporated into the departments’ repertoire and funded accordingly. 
 
 Flow Cytometry 
 Flow cytometry is in routine use within the department, this is just an extension of this method. Additional antibodies will 
be purchased for the project using different antigenic targets on the platelet surface using known fluorochromes. Using 
supplementary reagents these fluorescence levels can be calculated to express numbers of surface glycoproteins. A company has 
provided the project with a discount code for ordering these antibodies and reagents. Once this is a proven technique it will be 
incorporated into the departments’ repertoire and funded accordingly. 
 
 Diamed Impact-R 
 The Diamed Impact-R is a relatively new analyser that the department is evaluating with a view to purchasing to widen 
its diagnostic range. This evaluation procedure would have been undertaken by the department for any new procurement of 
equipment. It is therefore of no additional cost both in terms of instrument (as it is on loan for the trial) or reagents, as they 
would have been evaluated as a matter of course.  
  
 Luminometry 
 The departments’ luminometer had come to the end of its working life and it was established that the results it produced 
were integral to our diagnostic service. The department is evaluating with a view to purchasing this replacement. This 
evaluation procedure would have been undertaken by the department for any new procurement of equipment. It is therefore of 
no additional cost both in terms of instrument (as it is on loan for the trial) or reagents, as they would have been evaluated as a 
matter of course.  
 
 Travelling 
 It will be necessary to visit the university for meetings and tutorials with supervisors. Travelling to conferences and 
meetings may be necessary as part of the dissemination process. 
 
 
Please give any details/dates of external funding obtained to conduct this investigation. Has external funding been sought? 
 
 No external funding has, or will, be sought. 
  
 
 
How will the financial costs be met? (Give details of how the project will be funded) 
 
 The project will be funded entirely by the department; however we have managed to secure discounts on reagents from 
some manufacturers 
 
 
3.1 Associated Staff 
 
  Within current staffing budget.   
 
 
 
3.2 Consumables and Materials 
 
  Within reagent budget for the Diagnostic Haemostasis Laboratories. 
 
 
3.3 Equipment 
 
  All necessary equipment is available within the department.  
 
 
3.4 Travel 
 
  Within departmental expenses budget. 
 
 
3.5 Other e.g. animals 
 
  N/A
  
 
4. EXPLOITATION AND DISSEMINATION OF RESULTS 
 
 
1. If the proposed research is likely to give rise to a commercially viable discovery please give 
details, including an indication of the likely route for transferring technology to the market 
place. 
 
This is a proposed evaluation of change and extension of practice. New technology/ 
developments are unlikely to arise. 
 
2. If no immediate commercial benefit is foreseen, applicants should give details of how the 
knowledge gained from the project will be passed to the public domain. 
 
It is intended that all the work will be presented for publication in appropriate medical / 
biomedical science journals. The work will also be summarised and presented for publication 
in the professional gazette of the IBMS and may be included as required reading for specified 
CPD activities. Presentations at scientific meetings are planned and also an approach to a 
scientific standardisation committee for inclusion in future guidelines.  
 
 
  
 
5. STATEMENT BY APPLICANT 
 
I wish to apply for registration for a programme of professional research/development leading 
to a Professional Doctorate; the proposed start date is 01/07/00 
 
I confirm that the particulars given at Section 1 are correct. I understand that all research work 
undertaken must confirm the ethical principles embodied within the Declaration of Helsinki 2000. I 
understand that, except with the specific permission of the University, I must prepare and defend my 
portfolio/thesis in English. 
 
 
Signature of Applicant ................................................................................ Date ....................  
  
 
6. RECOMMENDATION BY SUPERVISORS 
 
We support this application and believe that Mr. David Andrew Gurney has the potential to 
complete successfully the programme of work proposed.  We recommend that this applicant 
be registered for the University's Professional Doctorate degree. 
 
Signature     Date:                                   
 
Signature     Date:                                   
 
Signature     Date:                                   
 
Signature     Date:                                   
 
Signature     Date:                                   
 
Comments: 
 
7. SUPERVISORS 
 
  
 
7.1 Director of Studies 
 
Name:  Dr David McLellan 
 
Qualifications: PhD MSc FIBMS MIBiol 
 
Current post/where held: Honorary Lecturer, University of Portsmouth 
 
I am currently supervising: 2  student(s) as Director of Studies, and no student(s)  as an 
Additional Supervisor. 
 
Previously supervised & completed: MPhil - 2 PhD -  2 PD -  2 
 
7.2 University Supervisors (with area of expertise/responsibility) 
 
Name:   Dr Graham Mills    
 
Area of Expertise Professional Doctorates   
 
Area of Responsibility Course Manager for DBMS programme     
 
Qualifications: 
 
BSc(Eng) BA(Ed) CertEd MA(Ed) PhD CChem FRSC CEng MinstE AMI Chem E  
   
Current post/where held  Principal Lecturer, University of Portsmouth   
Telephone No: 02392 842115       
 
Current Supervision: 2 x PhD, 1x PD     
 
Previously supervised/completed:    
 
MPhil -  0 PhD -    3 PD -   1     
 
7.3 Workplace Supervisors/Advisors (with area of expertise/responsibility) 
 
Name: Dr Gary Moore    Name: Dr Savita Rangarajan 
 
Area of Expertise    Haemostasis  Area of Expertise Haematology 
 
Area of Responsibility Supervisor  Area of Responsibility    Advisor 
 
Qualifications: BSc DBMS CSci FIBMS CBiol Qualifications: MRCP MRCPath 
                                                  MIBiol CertMHS 
 
Current post/where held    Current post/where held 
 Principle Biomedical Scientist   Consultant Haematologist 
 Haemophilia Reference Centre   Haemophilia Reference Centre 
 Centre for Haemostasis & Thrombosis  Centre for Haemostasis & Thrombosis 
 St. Thomas’ Hospital, London, SE1 7EH  St Thomas’ Hospital, London SE1 7EH 
 
Telephone No: 020 7188 2797   Telephone No:   020 7188 2806 
 
Current Supervision:    Current Supervision: 
 
Previously supervised/completed:  Previously supervised/completed: 
 
MPhil -  1 MSc - 4 PD -   0  MPhil -     0   PhD -   0     PD –   0  
     
 
 
  
 
7.4 Advisors 
 
Name: 
 
Qualifications: 
 
Current Post: 
 
  
 
 
8. HEAD OF SCHOOL/DEPARTMENT 
 
I have accepted this student in the department and confirm that the facilities, details given in 
Section 2.3, will be provided. 
  
 Name:………………………………………………………………. 
 
Signed:....................................................................................... Date ......................... 
  
 
 
9. HEAD OF EMPLOYING ESTABLISHMENT 
 
I confirm that the facilities, details given in Section 2.5, will be provided. I confirm that ethical 
clearance has been sought/approved to undertake the proposed work within the 
establishment. 
  
 Name: Dr Savita Rangarajan 
 
 Signed:.....................................................................…................ Date ......................... 
 
  
 
 
 
10. ASSESSOR(S) NOMINATED BY DIRECTOR OF STUDIES 
 
 
 
Assessor: 
 
Department: 
 
Telephone No: 
 
 
 
Assessor: 
 
Department: 
 
Telephone No: 
  
 
11. ASSESSOR NOMINATED BY THE FACULTY RESEARCH COMMITTEE 
 
 
Assessor: 
 
  
 
Department:  
 
Telephone No: 
 
 
12. APPROVAL OF REGISTRATION 
 
I confirm that the candidate was registered for the degree of Professional Doctorate with effect from:  
 
 
 
 
Signature: ............................................................................................................................... Date:                               
(Chair/Secretary of Research Degrees Committee) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
